

# CITATION REPORT

List of articles citing

**Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials**

**DOI: 10.1016/s0140-6736(10)61350-5**  
**Lancet, The, 2010, 376, 1670-81.**

**Source:** <https://exaly.com/paper-pdf/49637228/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2208	Meta-analysis and Pedagogy. 77-100		
2207	Selective release of newly synthesised and newly captured GABA from synaptosomes by potassium depolarisation. <b>1975</b> , 258, 254-6		37
2206	Management of Neurological Disorders. <b>1996</b> , 61, 658-658		
2205	Sequential proteome alterations during genesis and progression of colon cancer. <b>2004</b> , 61, 1246-55		65
2204	Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase. <b>2005</b> , 62, 599-605		13
2203	Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1658-69	40	416
2202	10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1074-84	40	606
2201	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <b>2011</b> , 32, 1345-61		793
2200	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. <b>2011</b> , 43, 167-71		30
2199	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. <b>2011</b> , 124, 2458-73		1087
2198	Statins: adherence and side-effects. <b>2011</b> , 53, 205-215		
2197	Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. <b>2011</b> , 32, 1409-15		106
2196	¿Se estã alcanzando las metas en el perfil lipídico de personas con enfermedad coronaria previa?. <b>2011</b> , 18, 262-267		2
2195	Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. <b>2011</b> , 11, 93-107		18
2194	La diŕtigue conserve-t-elle encore une place ^lãŕe des statines?. <b>2011</b> , 5, 263-268		
2193	Les inhibiteurs de la CETP : lâŕeure dâŕn nouveau dŕpart?. <b>2011</b> , 5, 9		
2192	El tratamiento intensivo con estatinas no reduce significativamente los episodios vasculares mayores y aumenta la incidencia de miopatã. <b>2011</b> , 9, 96-97		

2191	Opening a new lipid "apo-theary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. <b>2011</b> , 86, 762-80	25
2190	Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. <b>2011</b> , 57, 1455-64	115
2189	Apolipoprotein A-I therapy promise, challenges, and disappointment. <b>2011</b> , 57, 1120-1	9
2188	No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. <b>2011</b> , 57, 2000-7	54
2187	Reply. <b>2011</b> , 58, 1081-1083	
2186	The year in atherothrombosis. <b>2011</b> , 58, 779-91	7
2185	Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. <b>2011</b> , 58, 457-63	118
2184	How much statin intervention is enough?. <b>2011</b> , 58, 1672-3	4
2183	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <b>2011</b> , 58, 2550-2583	99
2182	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <b>2011</b> , 58, e44-122	1703
2181	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. <b>2011</b> , 58, 2584-2614	59
2180	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. <b>2011</b> , 58, e123-210	531
2179	On-clopidogrel platelet reactivity: a target in sight?. <b>2011</b> , 58, 1955-7	
2178	AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. <b>2011</b> , 58, e432-416	574
2177	Potential effects on clinical management of treatment algorithms on the basis of apolipoprotein-B/A-1 and total/high-density lipoprotein-cholesterol ratios. <b>2011</b> , 5, 159-165	4
2176	Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. <b>2011</b> , 5, 124-132	3
2175	Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <b>2011</b> , 5, S18-29	90
2174	Statins and myocardial remodelling: cell and molecular pathways. <b>2011</b> , 13, e22	40

2173	Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study. <b>2011</b> , 64, 393-6	5
2172	Effect of two intensive statin regimens on progression of coronary disease. <b>2011</b> , 365, 2078-87	574
2171	Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. <b>2011</b> , 9, 1383-90	4
2170	Medical management of the patient with intermittent claudication. <b>2011</b> , 29, 363-79	10
2169	Statins, inflammation and kidney disease. <b>2011</b> , 7, 385-97	52
2168	Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. <b>2011</b> , 27, 635-62	135
2167	Current developments in lipid-lowering therapy for the patient with chronic kidney disease. <b>2011</b> , 6, 693-702	
2166	Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol. <b>2011</b> , 149, 267-269	
2165	Statins discontinuation in compliant chronic users induces atherothrombotic profile despite baseline clinical setting and treatments. <b>2011</b> , 153, 328-9	8
2164	Invited commentary: outcome of carotid artery interventions among female patients, 2004 to 2005. <b>2011</b> , 53, 1464-5	1
2163	Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?. <b>2011</b> , 32, 694-9	23
2162	[ESC/EAS Guidelines for the management of dyslipidaemias]. <b>2011</b> , 64, 1168.e1-1168.e60	37
2161	[Comments on the ESC/EAS guidelines for the management of dyslipidaemias 2011. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology]. <b>2011</b> , 64, 1090-5	15
2160	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <b>2011</b> , 32, 1769-818	2020
2159	Surrogates under scrutiny: fallible correlations, fatal consequences. <b>2011</b> , 343, d5160	27
2158	Statins for the primary prevention of cardiovascular disease. <b>2011</b> , CD004816	178
2157	Dementia and Alzheimer's disease: a new direction. The 2010 Jay L. Foster Memorial Lecture. <b>2011</b> , 7, 540-50	21
2156	Generic-to-branded drug switch-back patterns: exploratory analysis and insights from the statin class. <b>2011</b> , 2, 217-226	4

2155	Update on the medical treatment of stable angina. <b>2011</b> , 104, 536-44		19
2154	Comments on the 2011 ESC/EAS guidelines for the management of dyslipidemias. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. <b>2011</b> , 64, 1090-1095		
2153	Effects of ezetimibe on atherosclerosis in preclinical models. <b>2011</b> , 215, 266-78		30
2152	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <b>2011</b> , 217 Suppl 1, S1-44		152
2151	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <b>2011</b> , 217, 3-46		459
2150	Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. <b>2011</b> , 219, 907-12		23
2149	Familial hypercholesterolaemia: a model of care for Australasia. <b>2011</b> , 12, 221-63		153
2148	C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. <i>Lancet, The</i> , <b>2011</b> , 377, 469-76	40	132
2147	Best medical treatment for a symptomatic carotid artery stenosis –Authors' reply. <i>Lancet, The</i> , <b>2011</b> , 377, 123-124	40	0
2146	Efficacy and safety of more intensive lowering of LDL cholesterol. <i>Lancet, The</i> , <b>2011</b> , 377, 715; author reply 715-6	40	8
2145	Efficacy and safety of more intensive lowering of LDL cholesterol. <i>Lancet, The</i> , <b>2011</b> , 377, 715; author reply 715-6	40	3
2144	Efficacy and safety of more intensive lowering of LDL cholesterol –Authors' reply. <i>Lancet, The</i> , <b>2011</b> , 377, 715-716	40	3
2143	Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. <i>Lancet, The</i> , <b>2011</b> , 377, 1681-92	40	128
2142	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2011</b> , 377, 2181-92	40	1627
2141	C-reactive protein in the Heart Protection Study –Authors' reply. <i>Lancet, The</i> , <b>2011</b> , 377, 1918-1919	40	5
2140	SHARP: a stab in the right direction in chronic kidney disease. <i>Lancet, The</i> , <b>2011</b> , 377, 2153-4	40	12
2139	Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. <i>Lancet, The</i> , <b>2011</b> , 378, 2013-2020	40	193
2138	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. <i>Lancet, The</i> , <b>2011</b> , 378, 1231-43	40	627

2137	Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. <i>Lancet, The</i> , <b>2011</b> , 378, 1547-59	40	407
2136	Statins and safety: can we finally be reassured?. <i>Lancet, The</i> , <b>2011</b> , 378, 1980-1981	40	9
2135	Benefits of lowering cholesterol in chronic kidney disease – Authors' reply. <i>Lancet, The</i> , <b>2011</b> , 378, 1377-1378	1	
2134	Focus on Type 2 Diabetes Comorbidities: Using Incretin-Based Therapies in Patients With Renal, Cardiovascular, and Hepatic Insufficiencies. <b>2011</b> , 17, 1-4		
2133	Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study. <b>2011</b> , 2011, 830434		4
2132	The status of statins. <b>2011</b> , 9, 581-581		
2131	Statins for primary prevention of cardiovascular disease Taylor F, Ward K, Moore THM, Burke M, Davey Smith G, Casas J-P, Ebrahim S (2011) Statins for the primary prevention of cardiovascular disease. <i>Cochrane Database Syst Rev</i> 2011(Issue 1): CD004816.. <b>2011</b> , 6, 296-297		
2130	Statinunverträglichkeit und Statinrisiken. <b>2011</b> , 11, 52-55		
2129	Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. <b>2011</b> , 5, 283-97		9
2128	Statins: the high risks of discontinuation and large benefits of continuation. <b>2011</b> , 7, 931-2		2
2127	A common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: two meta-analyses and a meta-regression analysis. <b>2011</b> , 6, e28834		23
2126	?????????????. <b>2011</b> , 20, 47-58		
2125	Statin/ezetimibe combination therapy: emerging evidence. <b>2011</b> , 22, 146-7		1
2124	Susceptibility of LDL and its subfractions to glycation. <b>2011</b> , 22, 254-61		57
2123	Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches. <b>2011</b> , 22, 324-5		1
2122	Ideal lipid profile and genes for an extended life span. <b>2011</b> , 26, 348-55		11
2121	Are statins diabetogenic?. <b>2011</b> , 26, 342-7		77
2120	Current world literature. <b>2011</b> , 26, 356-61		

2119	Combination therapy for dyslipidemia. <b>2011</b> , 26, 420-3	6
2118	Current world literature. <b>2011</b> , 26, 457-61	
2117	Antisense oligonucleotides for the treatment of dyslipidemia. <b>2011</b> , 17, 950-60	15
2116	Lipid management for the prevention of cardiovascular disease. <b>2011</b> , 17, 852-60	22
2115	Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. <b>2011</b> , 2011, 239-241	
2114	Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries. <b>2011</b> , 2011, 236-239	
2113	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <b>2011</b> , 2011, 190-193	26
2112	Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. <b>2011</b> , 2011, 359-360	1
2111	Is there a future for CETP-inhibitor therapy?. <b>2011</b> , 1, 367-370	
2110	Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients. <b>2011</b> , 75, 2062-70	4
2109	New considerations in the design of clinical trials for anti-atherosclerotic drugs. <b>2011</b> , 1, 795-803	1
2108	Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?. <b>2011</b> , 75, 1326-7	2
2107	Statin wars: efficacy vs. cost. <b>2011</b> , 65, 108-11	
2106	Niacin: the only vitamin that reduces cardiovascular events. <b>2011</b> , 65, 379-85	21
2105	LDL-C et morbi-mortalit'cardiovasculaire : avantage aux statines. <b>2011</b> , 2011, 30	
2104	Neonatal trials need thousands, not hundreds, to change global practice. <b>2011</b> , 100, 330-3	9
2103	Introducci3n: estatinas y salud cardiovascular. <b>2011</b> , 11, 1-2	
2102	Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. <b>2011</b> , 92, 1284-90; discussion 1290-1	62

2101	Miscellaneous non-inflammatory musculoskeletal conditions. Rare thesaurismosis and xanthomatosis. <b>2011</b> , 25, 683-701	10
2100	Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. <b>2011</b> , 365, 2255-67	2046
2099	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <b>2013</b> , 82, E266-355	81
2098	Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?. <b>2011</b> , 27, 1551-62	41
2097	Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. <b>2011</b> , 124, 2233-42	117
2096	Lipids: how low should we go?. <b>2011</b> , 22, 8-10	
2095	Concise guide to recommended lipid-lowering drug treatment. <b>2011</b> , 22, 18-32	
2094	Genomic markers to tailor treatments: waiting or initiating?. <b>2011</b> , 130, 15-8	9
2093	Lipid lowering therapy in type 2 diabetes. <b>2011</b> , 161, 289-96	8
2092	[Optimal lipid treatment: possibilities and current limitations]. <b>2011</b> , 52, 328-35	6
2091	[Cardiovascular risk in type 2 diabetes. ACCORD study (Action to Control Cardiovascular Risk in Diabetes)]. <b>2011</b> , 52, 601-4	0
2090	Suboptimal use of statins at treatment initiation. <b>2011</b> , 67, 971-3	7
2089	Should There Be a Different Cardiovascular Prevention Polypill Strategy for Women and Men?. <b>2011</b> , 5, 280-286	
2088	Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. <b>2011</b> , 28, 811-23	28
2087	Treatment of risk factors to prevent stroke. <b>2011</b> , 8, 463-74	13
2086	Drug targets beyond HMG-CoA reductase: Why venture beyond the statins?. <b>2011</b> , 6, 197-205	5
2085	What intervention trials don't tell us: the residual risk in primary prevention. <b>2011</b> , 6 Suppl 1, 53-60	2
2084	Residual cardiovascular risk in secondary prevention. <b>2011</b> , 6 Suppl 1, 61-8	5



2083	Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. <b>2011</b> , 13, 266-76	38
2082	Blood lipids and stroke: what more can we do besides reducing low-density lipoprotein cholesterol?. <b>2011</b> , 13, 306-13	2
2081	The JUPITER trial: myth or reality?. <b>2011</b> , 13, 413-21	7
2080	Familial hypercholesterolemia: present and future management. <b>2011</b> , 13, 527-36	35
2079	The role of soluble fiber intake in patients under highly effective lipid-lowering therapy. <b>2011</b> , 10, 80	23
2078	Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. <b>2011</b> , 10, 146	17
2077	Sortilin: an unusual suspect in cholesterol metabolism: from GWAS identification to in vivo biochemical analyses, sortilin has been identified as a novel mediator of human lipoprotein metabolism. <b>2011</b> , 33, 430-7	32
2076	Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. <b>2011</b> , 12, 1481-9	11
2075	Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. <b>2011</b> , 7, 137-44	5
2074	Lipid modification in the elderly using the combination of a statin and a cholesterol absorption inhibitor. <b>2011</b> , 12, 675-8	1
2073	Clinical trials of lipid-modifying agents: design considerations. <b>2011</b> , 6, 109-116	
2072	Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy. <b>2011</b> , 12, 137-9	3
2071	Primary prevention of cardiovascular disease. <b>2011</b> , 342, d201	2
2070	Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. <b>2011</b> , 103, 1461-8	257
2069	Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia. <b>2011</b> ,	1
2068	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. <b>2011</b> , 12, 1429-38	15
2067	The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient. <b>2011</b> , 27, 1959-60; author reply 1961	4
2066	Combination lipid therapy in type 2 diabetes mellitus. <b>2011</b> , 12, 1393-403	1

2065	Statins and the risk of new-onset diabetes: a review of recent evidence. <b>2011</b> , 22, 460-6	76
2064	Intestinal sterol transporters and cholesterol absorption inhibition. <b>2011</b> , 22, 467-78	20
2063	Lipid-lowering drug therapy in elderly patients. <b>2011</b> , 17, 877-93	18
2062	Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. <b>2011</b> , 305, 2556-64	944
2061	The fourth dimension: associations of change in albuminuria over time. <b>2011</b> , 22, 1186-8	2
2060	Sunrise of statins after AURORA and 4D?. <b>2011</b> , 22, 1184-6	6
2059	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2011</b> , 124, e652-735	487
2058	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <b>2011</b> , 124, 2574-609	389
2057	High-density lipoprotein cholesterol as the Holy Grail. <b>2011</b> , 306, 2153-5	16
2056	Effective Lipid-lowering Therapy in High-risk Patients. <b>2011</b> , 1,	
2055	The ezetimibe controversy: implications for clinical practice. <b>2011</b> , 5, 199-208	12
2054	Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus. <b>2011</b> , 34, 209-17	12
2053	Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. <b>2011</b> , 124, 2202-7	235
2052	Treatment strategies for chronic stable angina. <b>2011</b> , 12, 2833-44	4
2051	Significance of LDL-C lowering therapy in diabetic patients. <b>2011</b> , 6, 389-399	2
2050	Racial and geographic differences in prevalence, awareness, treatment and control of dyslipidemia: the reasons for geographic and racial differences in stroke (REGARDS) study. <b>2011</b> , 37, 39-44	26
2049	Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. <b>2011</b> , 6, 131-136	4
2048	The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. <b>2011</b> , 1, e000363	25

2047	Dyslipidemias in the older subject: features, significance and treatment dilemmas. <b>2011</b> , 6, 339-350	2
2046	Commentary: the death of clinical freedom. <b>2011</b> , 40, 859-61	3
2045	Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia. <b>2011</b> , 6, 675-692	9
2044	The facts behind niacin. <b>2011</b> , 5, 227-40	16
2043	Using nonfasting lipids--hemodilution or convenience?. <b>2011</b> , 57, 1336-8; author reply 1338-40	6
2042	Statin use in outpatients with obstructive coronary artery disease. <b>2011</b> , 124, 2405-10	51
2041	Do statins reduce the incidence of stroke in familial hypercholesterolemia?. <b>2011</b> , 9, 349-53	3
2040	Treatment of lipid disorders in obesity. <b>2011</b> , 9, 1069-80	32
2039	4th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 12-14, 2011, Budapest, Hungary. <b>2011</b> , 13, 1161-76	2
2038	New clinical concepts after the ONTARGET trial. <b>2011</b> , 9, 685-9	9
2037	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <b>2011</b> , 124, e574-651	1039
2036	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2011</b> , 124, 2610-42	345
2035	Medical angioplasty - hope and expectations: an optimistic overview. <b>2011</b> , 18, 101-10	
2034	Mechanism of beneficial effects of physical activity on atherosclerosis and coronary heart disease. <b>2011</b> , 111, 308-10	38
2033	Climacteric commentaries. Possible net harms of breast cancer screening. <b>2012</b> , 15, 398-9	
2032	Reducing residual risk in secondary prevention of cardiovascular disease. <b>2012</b> , 125, 1958-60	14
2031	Vascular risk factors and cardiovascular outcomes in the Alzheimer's disease neuroimaging initiative. <b>2012</b> , 27, 275-9	4
2030	Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. <b>2012</b> , 9, e1001310	67

2029	Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. <b>2012</b> , 53, 1755-66	115
2028	Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. <b>2012</b> , 2012, 861924	42
2027	MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE <sup>-/-</sup> mice. <b>2012</b> , 1, e003376	167
2026	Current world literature. <b>2012</b> , 27, 441-54	
2025	What works and in whom? A simple, easily applied, evidence-based approach to guidelines for statin therapy. <b>2012</b> , 5, 592-3	7
2024	Triglycerides: a case for treatment?. <b>2012</b> , 27, 398-404	24
2023	Statins and noncardiac vascular disease. <b>2012</b> , 27, 392-7	17
2022	Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentile. <b>2012</b> , 27, 405-11	15
2021	Body mass index and mortality in China: a 15-year prospective study of 220 000 men. <b>2012</b> , 41, 472-81	84
2020	The fats of life in diabetes. <b>2012</b> , 12, 216-220	3
2019	Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. <b>2012</b> , 308, 804-11	99
2018	Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. <b>2012</b> , 5, 257-64	200
2017	Statin use and intracerebral hemorrhage: evidence for safety in recurrent stroke prevention?. <b>2012</b> , 69, 13-6	9
2016	Learning from hackers: open-source clinical trials. <b>2012</b> , 4, 132cm5	6
2015	The cardiovascular polypill in high-risk patients. <b>2012</b> , 19, 1234-42	20
2014	Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. <b>2012</b> , 125, 1979-87	114
2013	Lipid-related markers and cardiovascular disease prediction. <b>2012</b> , 307, 2499-506	271
2012	Cardiovascular disease prevention and the rise in dementia. <b>2012</b> , 105, 93-7	1

2011	The statin-low cholesterol-cancer conundrum. <b>2012</b> , 105, 383-8	55
2010	Lipid lowering agents and the endothelium: an update after 4 years. <b>2012</b> , 10, 33-41	16
2009	Diabetes: Should we use fibrates in patients with diabetes and mild CKD?. <b>2012</b> , 8, 201-2	4
2008	Pharmacotherapy: Statins and new-onset diabetes--the important questions. <b>2012</b> , 9, 190-2	18
2007	Novel strategies for managing dyslipidemia: treatment beyond statins. <b>2012</b> , 124, 43-54	12
2006	Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. <b>2012</b> , 28, 1447-54	7
2005	Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized trials. <b>2012</b> , 17, 357-65	17
2004	Statins in the management of dyslipidemia associated with chronic kidney disease. <b>2012</b> , 8, 214-23	38
2003	Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study. <b>2012</b> , 63, 528-34	6
2002	Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates. <b>2012</b> , 7, 737-743	6
2001	CVD screening in low-risk, asymptomatic adults: clinical trials needed. <b>2012</b> , 9, 599-604	29
2000	The rise of cardiovascular medicine. <b>2012</b> , 33, 838-45, 845a	34
1999	New lipid and lipoprotein targets for the treatment of cardiometabolic diseases. <b>2012</b> , 53, 1719-21	5
1998	Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. <b>2012</b> , 33, 393-407	75
1997	Letter by goldstein regarding article, "statins and intracerebral hemorrhage". <b>2012</b> , 125, e1015	
1996	Is prolactin involved in the evolution of atherothrombotic disease?. <b>2012</b> , 7, 345-361	3
1995	Statins and intracerebral hemorrhage: a retrospective cohort study. <b>2012</b> , 69, 39-45	43
1994	The case for more intensive use of statins. <b>2012</b> , 3, 201-10	2

1993	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <b>2012</b> , 5, 463-71	268
1992	Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. <b>2012</b> , 5, 463-71	58
1991	Statins work just as well in women as in men. <b>2012</b> , 172, 919-20	9
1990	Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. <b>2012</b> , 2012, 927352	8
1989	Cholesterol: its regulation and role in central nervous system disorders. <b>2012</b> , 2012, 292598	174
1988	The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. <b>2012</b> , 31, 2276-85	33
1987	The lights went out. <b>2012</b> , 41, 1213-7	
1986	Will New Lipid Guidelines Abandon LDL Treatment Targets?. <b>2012</b> , 38, 4-6	
1985	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <b>2012</b> , 172, 919-20	537
1984	Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. <b>2012</b> , 2,	8
1983	Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. <b>2012</b> , 43, 2149-56	205
1982	A new approach to managing the 'statin-intolerant' patient?. <b>2012</b> , 33, 1040-3	5
1981	Comment on 'The great cholesterol myth: unfortunate consequences of Brown and Goldstein's mistake'. <b>2012</b> , 105, 291-2; author reply 292	
1980	Endobronchial ultrasound guided transbronchial needle aspiration: a novel way to diagnose metastatic urological cancer. <b>2012</b> , 105, 292-4	
1979	The great cholesterol myth; unfortunate consequences of Brown and Goldstein's mistake. <b>2012</b> , 105, 292-292	
1978	Role of p67phox in salt-sensitive hypertension. <b>2012</b> , 8, 193-193	
1977	Screening for familial hypercholesterolaemia. <b>2012</b> , 44, 122-8	23
1976	Special Articles: 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2012</b> , 114, 11-45	30

1975	Should patients with high cardiovascular risk and an LDL-C concentration below 70 mg/dl be treated with aggressive statin therapy?. <b>2012</b> , 7, 1-4		
1974	Plaquetfuhe als Pridiktor fur das kardiovaskulure Risiko. <b>2012</b> , 12, 47-50		
1973	Advancing cardiovascular research. <b>2012</b> , 141, 500-505		20
1972	Weniger Herzerkrankungen, aber mehr Diabetesfulle?. <b>2012</b> , 12, 48-51		
1971	Einfache Therapie fordert die Compliance. <b>2012</b> , 12, 52-53		
1970	Module 15. Statins and their role in the prevention of cardiovascular disease. <b>2012</b> , 10, 1-11		
1969	Nonalcoholic fatty liver disease and lipids. <b>2012</b> , 23, 345-52		42
1968	Rate of change in carotid intima-media thickness and vascular events: meta-analyses can not solve all the issues. A point of view. <b>2012</b> , 30, 1690-6		12
1967	Prevention secondaire chez le coronarien. <b>2012</b> , 7, 1-8		
1966	Hyperlipoproteines : diagnostic et traitement. <b>2012</b> , 7, 1-4		
1965	Response to Hoenselaar from Pedersen et al.. <b>2012</b> , 107, 452-454		2
1964	Which statin is the ideal statin for polymedicated patients?. <b>2012</b> , 7, 11-16		1
1963	Modifiable factors for reducing the gender difference in lipid control. <b>2012</b> , 7, 379-387		
1962	Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. <b>2012</b> , 76, 729-36		49
1961	Malondialdehyde-modified low-density lipoprotein is a useful marker to identify patients with vulnerable plaque. <b>2012</b> , 76, 2211-7		21
1960	The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. <i>Lancet, The</i> , <b>2012</b> , 380, 581-90	40	1716
1959	Epidemiology of venous thromboembolism: the need for large (including prospective) studies and meta-analyses. <b>2012</b> , 10, 2186-8		4
1958	Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. <b>2012</b> , 10, 211-21		22

1957	Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk. <b>2012</b> , 110, 530-3		6
1956	Statin use and reduced cancer-related mortality. <b>2012</b> , 367, 1792-802		669
1955	Emphasizing statin safety in the hospitalized patient: a review. <b>2012</b> , 125, 845-53		16
1954	Lipid disorders in uremia and dialysis. <b>2012</b> , 178, 100-105		20
1953	Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. <b>2012</b> , 14, 721-31		18
1952	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the		139
1951	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American		1138
1950	College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <b>2012</b> , 60, e44-e164		71
1949	Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. <b>2012</b> , 221, 471-7		12
1948	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , <b>2012</b> , 380, 1995-2006	40	276
1947	Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. <b>2012</b> , 60, 747-69		73
1946	Efficacy and Safety of Statins in Older Adults. <b>2012</b> , 6, 372-379		2
1945	The controversies of statin therapy: weighing the evidence. <b>2012</b> , 60, 875-81		114
1944	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. <i>Lancet, The</i> , <b>2012</b> , 380, 2007-17	40	327
1943	Into the future: diversifying lipid management. <i>Lancet, The</i> , <b>2012</b> , 380, 1971-4	40	6
1942	Statin pleiotropy in acute myocardial infarction--is it about timing?. <b>2012</b> , 80, 766-7		
1941	The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data. <b>2012</b> , 35, 714-7		8
1940	Inhibition of cholesterol absorption: targeting the intestine. <b>2012</b> , 29, 3235-50		14



1939	CETP inhibition in perspective. <b>2012</b> , 220, 325-8	2
1938	Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. <b>2012</b> , 223, 251-61	152
1937	Identical LDL-cholesterol lowering but non-identical effects on NF- $\kappa$ B activity: High dose simvastatin vs combination therapy with ezetimibe. <b>2012</b> , 223, 190-6	18
1936	Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. <b>2012</b> , 223, 197-203	39
1935	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <b>2012</b> , 223, 1-68	286
1934	A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. <b>2012</b> , 224, 150-3	29
1933	A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. <b>2012</b> , 225, 208-15	42
1932	Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication. <b>2012</b> , 6, 312-7	8
1931	Authors' reply to commentary entitled "EPA and DHA: Distinct yet essential n-3 fatty acids" <b>2012</b> , 6, 477-479	2
1930	Statin treatment in patients with elevated liver enzymes: pitch to proceed. <b>2012</b> , 6, 310-1	2
1929	Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. <b>2012</b> , 6, 303-9	35
1928	[The long haul to achieve the objectives in the treatment of dyslipidaemias]. <b>2012</b> , 212, 488-90	0
1927	[Statins, diabetes risk and the treatment of hypercholesterolemia in elderly people]. <b>2012</b> , 47, 243-4	2
1926	Medical options to fight mortality in end-stage renal disease: a review of the literature. <b>2012</b> , 27, 4298-307	20
1925	Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. <b>2012</b> , 60, 383-8	8
1924	Les statines diminuent-elles le risque septique chez les patients de ranimation ?. <b>2012</b> , 16, 296-307	
1923	[Preventive cardiovascular recommendations]. <b>2012</b> , 44 Suppl 1, 3-15	12
1922	Estatinas en pacientes sin enfermedad cardiovascular: una revisi3n crtica. <b>2012</b> , 10, 36-43	0

1921	LDL-cholesterol target values and actual values in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic monotherapy: the lipid results of the French ESCALADE survey. <b>2012</b> , 73, 503-9	
1920	Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis. <b>2012</b> , 28, 687-92	1
1919	Tratamiento lipídico en la guía europea de dislipemias. <b>2012</b> , 12, 19-25	
1918	Tratamiento de las dislipemias en situaciones especiales. <b>2012</b> , 12, 26-32	
1917	Progress and prospective of plant sterol and plant stanol research: report of the Maastricht meeting. <b>2012</b> , 225, 521-33	50
1916	Les inhibiteurs de la CETP: CETP inhibitors. <b>2012</b> , 6, 43-48	
1915	Eficacia bioquímica y beneficio clínico de la doble inhibición con ezetimiba y simvastatina. <b>2012</b> , 12, 2-7	
1914	Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study: Ahern TP, Pedersen L, Tarp M, et al (Brigham and Women's Hosp and Harvard Med School, Boston, MA; Aarhus Univ Hosp, Denmark; et al) J Natl Cancer Inst 103:1461-1468, 2011. <b>2012</b> , 23, 228-229	
1913	Estatinas: perspectiva actual. <b>2012</b> , 47, 151-153	1
1912	Triglycerides: how much credit do they deserve?. <b>2012</b> , 96, 39-55	14
1911	Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. <b>2012</b> , 10, 19-28	4
1910	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <b>2012</b> , 23, 1665-701	2797
1909	Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. <b>2012</b> , 8, 745-58	7
1908	Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study. <b>2012</b> , 10, 955-63	16
1907	Food combinations for cholesterol lowering. <b>2012</b> , 25, 249-66	24
1906	Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. <b>2012</b> , 28, 371-8	37
1905	Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia. <b>2012</b> , 28, 5-9	
1904	Statin therapy for the octogenarian?. <b>2012</b> , 17, 37-42	1

1903	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <b>2012</b> , 19, 585-667	233
1902	Safety of statins: an update. <b>2012</b> , 3, 133-44	55
1901	Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients. <b>2012</b> , 7, 943-8	34
1900	Epidemiology and prevention of stroke: a worldwide perspective. <b>2012</b> , 12, 199-208	78
1899	Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?. <b>2012</b> , 33, 2258-64	12
1898	Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. <b>2012</b> , 175, 250-62	157
1897	Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals. <b>2012</b> , 337, 1482-7	149
1896	Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. <b>2012</b> , 163, 515-21, 521.e1-3	45
1895	Statin therapy and new-onset diabetes: a cause for concern?. <b>2012</b> , 72, 95-6	2
1894	Caveats to aggressive lowering of lipids by specific statins. <b>2012</b> , 154, 97-101	19
1893	Effectiveness of statin therapy for elderly acute myocardial infarction patients with normal levels of low-density lipoprotein cholesterol. <b>2012</b> , 158, 139-43	3
1892	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. <b>2012</b> , 6, 180-91	16
1891	JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. <b>2012</b> , 56, 2163-71	100
1890	The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population. <b>2012</b> , 12, 712	9
1889	Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. <b>2012</b> , 11, 29	23
1888	What is the role of advanced lipoprotein analysis in practice?. <b>2012</b> , 60, 2607-15	16
1887	Dyslipidemia: management using optimal lipid-lowering therapy. <b>2012</b> , 46, 1368-81	26
1886	Statin Therapy in Patients with Diabetic Nephropathy. <b>2012</b> , 101-115	

1885	Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. <b>2012</b> , 72, 565-84	22
1884	LDL cholesterol: the lower the better. <b>2012</b> , 96, 13-26	62
1883	Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. <b>2012</b> , 21, 667-76	30
1882	Statin use and the risk of incident diabetes mellitus: a review of the literature. <b>2012</b> , 28, 581-9	22
1881	Developing a yeast cell factory for the production of terpenoids. <b>2012</b> , 3, e201210006	45
1880	Lipid-lowering therapy in individuals with CKD: lessons learned from SHARP. <b>2012</b> , 59, 170-3	4
1879	Severe familial hypercholesterolaemia: current and future management. <b>2012</b> , 105, 656-65	18
1878	Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods. <b>2012</b> , 6, 241-246	12
1877	Meta-analysis of statin effects in women versus men. <b>2012</b> , 59, 572-82	175
1876	On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). <b>2012</b> , 59, 1521-8	72
1875	The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial: to believe or not to believe?. <b>2012</b> , 59, 2065-7	18
1874	Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. <b>2012</b> , 59, 2344-53	415
1873	Statins, risk of diabetes, and implications on outcomes in the general population. <b>2012</b> , 60, 1231-8	99
1872	Coronary artery calcium scanning should be used for primary prevention: pros and cons. <b>2012</b> , 5, 111-8	16
1871	Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. <b>2012</b> , 110, 1468-76	86
1870	Tratamiento de las hiperlipidemias. <b>2012</b> , 11, 1145-1152	
1869	Paciente varón de 56 años con múltiples factores de riesgo cardiovascular. <b>2012</b> , 11, 1186.e1-1186.e5	
1868	Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. <b>2012</b> , 22, 697-703	12

1867	Dyslipidemias in the prevention of cardiovascular disease: risks and causality. <b>2012</b> , 14, 709-20	71
1866	Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. <b>2012</b> , 367, 1891-900	375
1865	Current concept of reverse cholesterol transport and novel strategy for atheroprotection. <b>2012</b> , 60, 339-43	37
1864	Management of cardiovascular disease risk factors in individuals with chronic spinal cord injury: an evidence-based review. <b>2012</b> , 29, 1999-2012	38
1863	Klinische Befunde und rationelle Differenzialdiagnostik der diabetischen Dyslipidämie. <b>2012</b> , 8, 536-543	
1862	Kardiovaskuläres Risiko und medikamentöse Lipidtherapie. <b>2012</b> , 8, 568-572	
1861	Neue Entwicklungen in der Lipidtherapie. <b>2012</b> , 8, 573-578	
1860	Ernährung bei diabetischer Dyslipidämie. <b>2012</b> , 8, 556-561	
1859	Cholesterinrücktransport und HDL-Funktion. <b>2012</b> , 6, 329-336	
1858	European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <b>2012</b> , 19, 403-88	196
1857	Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. <b>2012</b> , 60, 2631-9	493
1856	Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). <b>2012</b> , 65, 937.e1-937.e66	7
1855	Dislipemia aterogénica. <b>2012</b> , 24, 3-7	1
1854	Exercise Cardiopulmonary Function in Cardiac Patients. <b>2012</b> ,	8
1853	Treatment targets in the management of dyslipidemias: which targets in whom?. <b>2012</b> , 14, 692-700	3
1852	Update on guidelines for management of hypercholesterolemia. <b>2012</b> , 10, 1239-49	3
1851	Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. <b>2012</b> , 72, 2314-26	171
1850	HDL-cholesterol: perfection is the enemy of good?. <b>2012</b> , 96, 27-37	3

1849	Statin drug interactions and related adverse reactions. <b>2012</b> , 11, 933-46	67
1848	Statin-Induced Muscle Toxicity. <b>2012</b> , 945-954	
1847	Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence. <b>2012</b> , 11, 140	29
1846	Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. <b>2012</b> , 11, 123	60
1845	Differences in statin usage and target-goal achievement between departments at the same hospital. <b>2012</b> , 7, e50466	
1844	Disorders of Lipid Metabolism. <b>2012</b> , 1346-1354	0
1843	Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review. <b>2012</b> , 5, 165-9	
1842	A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates. <b>2012</b> , 2012, 392734	3
1841	Lipoproteins Impact Increasing Cardiovascular Mortality. <b>2012</b> ,	
1840	Screening for lipid disorders. <b>2012</b> , 44, 115-21	2
1839	Blood cholesterol level and risk of stroke in community-based or worksite cohort studies: a review of Japanese cohort studies in the past 20 years. <b>2012</b> , 61, 79-88	16
1838	Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly. <b>2012</b> , 9, 83-90	4
1837	Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications. <b>2012</b> , 9, 82-93	73
1836	The role of statin therapy in patients with lower vascular risk. <b>2012</b> , 197, 130-1	
1835	Was bei Diabetikern unbedingt zur Routinediagnostik gehört. <b>2012</b> , 154, 95-99	
1834	How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines?. <b>2012</b> , 8, 608-13	9
1833	Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies. <b>2012</b> , 45, 1095-101	10
1832	SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE. <b>2012</b> , 8, 788-797	

1831	Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. <b>2012</b> , 4, 1-11	16
1830	Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. <b>2012</b> , 4, 367-83	34
1829	Hypercholesterolaemia: what to do when first-line treatment fails. <b>2012</b> , 23, 28-33	
1828	HDL cholesterol: the importance of targeting low plasma levels. <b>2012</b> , 23, 23-28	
1827	Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. <b>2012</b> , 125, 1905-19	614
1826	Pharmacological actions of statins: a critical appraisal in the management of cancer. <b>2012</b> , 64, 102-46	303
1825	Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. <b>2012</b> , 125, 2469-78	154
1824	Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. <b>2012</b> , 9, 232-46	22
1823	The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?. <b>2012</b> , 13, 1469-80	9
1822	Effects of plant sterols and stanols on intestinal cholesterol metabolism: suggested mechanisms from past to present. <b>2012</b> , 56, 1058-72	186
1821	Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. <b>2012</b> , 21, 485-93	26
1820	Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. <b>2012</b> , 4, 251-68	146
1819	Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice. <b>2012</b> , 32, 631-41	12
1818	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <b>2012</b> , 79, 453-95	121
1817	Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. <b>2012</b> , 35, 385-91	37
1816	A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology. <b>2012</b> , 35, 404-9	12
1815	Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. <b>2012</b> , 35, 722-9	14
1814	Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. <b>2012</b> , 7, 29-38	26

1813	Niacin in cardiovascular disease: recent preclinical and clinical developments. <b>2012</b> , 32, 582-8	39
1812	LDL cholesterol targets--how low to go?. <b>2012</b> , 23, 265-70	4
1811	Statin use and risk of pancreatic cancer: a meta-analysis. <b>2012</b> , 23, 1099-111	59
1810	ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. <b>2012</b> , 26, 181-7	67
1809	Acute myocardial infarction in New York State: 1996-2008. <b>2012</b> , 37, 473-9	7
1808	Evacetrapib. <b>2012</b> , 14, 245-50	13
1807	Metformin use among individuals at risk for type 2 diabetes. <b>2012</b> , 12, 265-73	3
1806	Evidence-based medicine and the selection of lipid-lowering therapy in type 2 diabetes. <b>2012</b> , 12, 221-3	1
1805	Identification and Treatment of Women with Familial Hypercholesterolemia. <b>2012</b> , 6, 196-204	
1804	Kommentar zu den neuen Leitlinien (2011) der Europäischen Gesellschaft für Kardiologie zum Management von Dyslipidämien. <b>2012</b> , 6, 210-216	4
1803	Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. <b>2012</b> , 110, 307-13	32
1802	Management of cardiovascular risk: the importance of meeting lipid targets. <b>2012</b> , 110, 3A-14A	56
1801	Recent clinical studies of the effects of lipid-modifying therapies. <b>2012</b> , 110, 15A-26A	30
1800	Modern management of acute myocardial infarction. <b>2012</b> , 37, 237-310	12
1799	Dyslipidemia and its therapeutic challenges in renal transplantation. <b>2012</b> , 12, 1975-82	55
1798	Diabetes mellitus and the heart. <b>2012</b> , 66, 640-7	24
1797	Optimal lipid targets for the new era of cardiovascular prevention. <b>2012</b> , 1254, 106-14	2
1796	Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?. <b>2012</b> , 38, 138-46	4



1795	2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2012</b> , 143, 4-34	187
1794	[Update on ischemic heart disease]. <b>2012</b> , 65 Suppl 1, 42-9	4
1793	Non-obstructive low attenuation coronary plaque predicts three-year acute coronary syndrome events in patients with hypertension: multidetector computed tomographic study. <b>2012</b> , 59, 167-75	19
1792	Therapeutic strategies to deplete macrophages in atherosclerotic plaques. <b>2012</b> , 74, 246-63	20
1791	Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. <b>2012</b> , 14, 1-10	215
1790	Initiation of statin therapy: are there age limits?. <b>2012</b> , 14, 17-25	7
1789	Do persons with diabetes benefit from combination statin and fibrate therapy?. <b>2012</b> , 14, 112-24	18
1788	[HDL level or HDL function as the primary target in preventive cardiology]. <b>2012</b> , 37, 51-5	4
1787	Report of the JDS/JCA Joint Committee on Diabetes and Cancer. <b>2013</b> , 4, 81-96	26
1786	Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. <b>2013</b> , 2, 22	18
1785	Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. <b>2012</b> , 18 Suppl 3, 6-26; quiz 27-8	6
1784	Intolerance to statins: mechanisms and management. <b>2013</b> , 36 Suppl 2, S325-30	98
1783	Statins in the primary prevention of cardiovascular disease. <b>2013</b> , 10, 453-64	119
1782	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2013</b> , 61, 485-510	433
1781	The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. <b>2013</b> , 166, 282-289.e1 <sup>38</sup>	
1780	Do statins lower testosterone and does it matter?. <b>2013</b> , 11, 58	4
1779	Selective peroxisome proliferator-activated receptor $\beta$ modulators (SPPARM $\beta$ ) the next generation of peroxisome proliferator-activated receptor $\beta$ agonists. <b>2013</b> , 12, 82	117
1778	Statins in cardiometabolic disease: what makes pitavastatin different?. <b>2013</b> , 12 Suppl 1, S1	13

1777	Statin diabetogenicity: guidance for clinicians. <b>2013</b> , 12 Suppl 1, S3	25
1776	Medical management of stable coronary atherosclerosis. <b>2013</b> , 15, 313	5
1775	The role of early LDL lowering to prevent the onset of atherosclerotic disease. <b>2013</b> , 15, 312	28
1774	Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. <b>2013</b> , 15, 397	25
1773	Cardiac Rehabilitation for Women. <b>2013</b> , 7, 203-211	4
1772	Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. <b>2013</b> , 7, 141-156	
1771	Lipoprotein and Lipid Metabolism. <b>2013</b> , 1-33	2
1770	Common sources and composition of phytosterols and their estimated intake by the population in the city of São Paulo, Brazil. <b>2013</b> , 29, 865-71	24
1769	Statin therapy in patients with atypical chest pain and mild-to-moderate coronary stenosis on 64-slice multidetector coronary computed tomography; a retrospective propensity score matching analysis. <b>2013</b> , 23, 2954-60	2
1768	The lipid story in chronic kidney disease: a long story with a happy end?. <b>2013</b> , 45, 1273-87	4
1767	Statin use and cataract surgery: a nationwide retrospective cohort study in elderly ethnic Chinese patients. <b>2013</b> , 36, 1017-24	31
1766	Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database. <b>2013</b> , 36, 779-87	14
1765	LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?. <b>2013</b> , 73, 293-301	16
1764	Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. <b>2013</b> , 31, 377-91	13
1763	High-density lipoproteins: a consensus statement from the National Lipid Association. <b>2013</b> , 7, 484-525	215
1762	Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. <b>2013</b> , 62, 2090-9	141
1761	Pharmacotherapies for lipid modification: beyond the statins. <b>2013</b> , 10, 560-70	29
1760	Can the development of cardiac dysfunction in patients with liver cirrhosis and portal hypertension be predicted?. <b>2013</b> , 168, 1528-30	0

1759 Prevenci3 secundaria en el paciente coronario. **2013**, 17, 1-8

1758 Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials. **2013**, 7, 546-60 24

1757 Plaque regression measured by intravascular ultrasound and reduction of cardiovascular events: not yet the case, commentary on the study of D'Ascenzo et al. **2013**, 226, 45-6

1756 All at sea: new lipid-lowering drug trials continue to disappoint. **2013**, 67, 595-8 2

1755 The beneficial effects of statins in patients undergoing hemodialysis. **2013**, 168, 4155-9 7

1754 Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. **2013**, 231, 300-7 49

1753 [Therapeutic Strategies. Cardiovascular risk and dyslipidemia in elderly and women]. **2013**, 25, 146-50

1752 Gu3 de pr3tica cl3nica de la ESH/ESC para el manejo de la hipertensi3 arterial (2013). **2013**, 30, 4-91 7

1751 Real-life effectiveness of statins in the prevention of first acute coronary syndrome in France: a prospective observational study. **2013**, 169, 271-5 6

1750 The influence of consuming an egg or an egg-yolk buttermilk drink for 12 wk on serum lipids, inflammation, and liver function markers in human volunteers. **2013**, 29, 1237-44 31

1749 American Association of Clinical EndocrinologistsâComprehensive Diabetes Management Algorithm 2013 Consensus Statement. **2013**, 19, 1-48 102

1748 Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. **2013**, 310, 2061-8 342

1747 Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice. **2013**, 27, 3805-17 27

1746 Exercise is the real polypill. **2013**, 28, 330-58 323

1745 Accumulating evidence for statins in primary prevention. **2013**, 310, 2405-6 12

1744 Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. **2013**, 20, 641-57 136

1743 Lipid-lowering agents. **2013**, 18, 401-11 23

1742 Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. **2013**, 29, 1553-68 126

1741	Meta-analyses of statin trials: clear benefit for primary prevention in the elderly. <b>2013</b> , 62, 2100-1	2
1740	Dyslipidemia. <b>2013</b> , 37 Suppl 1, S110-6	13
1739	[Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)]. <b>2013</b> , 42, 930-50	19
1738	New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. <b>2013</b> , 35, 1082-98	94
1737	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <b>2013</b> , 34, 2025-87	1444
1736	RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. <b>2013</b> , 12, 142	3
1735	Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. <b>2013</b> , 44, 1833-9	180
1734	Dyslipidmie. <b>2013</b> , 37, S484-S491	1
1733	Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. <b>2013</b> , 48, 477-83	91
1732	Human genetics as a foundation for innovative drug development. <b>2013</b> , 31, 975-8	34
1731	Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study. <b>2013</b> , 38, 365-409	18
1730	Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. <b>2013</b> , 29, 181-8	4
1729	Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer. <b>2013</b> , 104, 965-76	56
1728	Low-density lipoprotein cholesterol: how low can we go?. <b>2013</b> , 13, 225-32	8
1727	UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. <b>2013</b> , 17, 233-7	15
1726	Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. <b>2013</b> , 27, 211-9	8
1725	Are there differences in LDL-C target value attainment in Austrian federal states? Yes!. <b>2013</b> , 163, 528-35	1
1724	First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients. <b>2013</b> , 12, 170	10

1723	Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. <b>2013</b> , 69, 2001-9	33
1722	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. <b>2013</b> , 8, 329-344	2
1721	Evidence that periodontal treatment improves biomarkers and CVD outcomes. <b>2013</b> , 84, S85-S105	62
1720	Role of enterocytes in dyslipidemia of insulin-resistant states. <b>2013</b> , 60, 179-189	1
1719	Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010). <b>2013</b> , 112, 1126-32	49
1718	Lipid-lowering pharmacogenomics in Chinese patients. <b>2013</b> , 11, 985-97	2
1717	Coronary Heart Disease in Women & Men: Similar and Different. <b>2013</b> , 7, 423-424	
1716	[Update: clinical lipidology]. <b>2013</b> , 155, 49-52; quiz 53-4	1
1715	Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis. <b>2013</b> , 33, 233-41	9
1714	Strategies to lower low-density lipoprotein cholesterol in metabolic syndrome: averting the diabetes risk. <b>2013</b> , 11, 149-51	3
1713	Evidence that periodontal treatment improves biomarkers and CVD outcomes. <b>2013</b> , 40 Suppl 14, S85-105	90
1712	Taking small steps towards targets - perspectives for clinical practice in diabetes, cardiometabolic disorders and beyond. <b>2013</b> , 67, 322-32	21
1711	Stable angina: current guidelines and advances in management. <b>2013</b> , 24, 35-44	
1710	Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. <b>2013</b> , 31, 172-80	32
1709	Antagonist molecules in the treatment of angina. <b>2013</b> , 14, 2323-42	9
1708	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <b>2013</b> , 20, 678-85	47
1707	In search of the right word: a statement of the HEART Group on scientific language. <b>2013</b> , 34, 7-9	12
1706	Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. <b>2013</b> , 167, 2482-9	29

1705	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2013</b> , 61, e78-e140	2122
1704	Transcriptome analysis in patients with progressive coronary artery disease: identification of differential gene expression in peripheral blood. <b>2013</b> , 6, 81-93	17
1703	Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy. <b>2013</b> , 27, 49-60	8
1702	Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients. <b>2013</b> , 166, 431-9	23
1701	The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. <b>2013</b> , 228, 18-28	102
1700	[Therapeutic strategies. Evolution and current status of the European Guidelines on Cardiovascular disease prevention]. <b>2013</b> , 25, 92-7	1
1699	How will new medications affect the lipoprotein apheresis situation in Germany?. <b>2013</b> , 14, 71-2	6
1698	Recomendações da ESC/EAS para a abordagem clínica das dislipidemias. <b>2013</b> , 32, 81.e1-81.e50	
1697	Recomendações Europeias para a prevenção da doença cardiovascular na prática clínica (versão de 2012). <b>2013</b> , 32, 553.e1-553.e77	4
1696	Long-term use of opioids for complex chronic pain. <b>2013</b> , 27, 663-72	34
1695	Emerging clinical challenges in the use of statins. <b>2013</b> , 126, 663-4	1
1694	High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. <b>2013</b> , 227, 118-24	28
1693	Discordance: can we capitalize on it to better personalize atherosclerosis treatment?. <b>2013</b> , 229, 504-6	6
1692	Determinants of cardiovascular mortality in a cohort of primary care patients with chronic ischemic heart disease. BARBANZA Ischemic Heart Disease (BARIHD) study. <b>2013</b> , 167, 442-50	17
1691	Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. <b>2013</b> , 230, 322-9	33
1690	The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naive patients undergoing primary percutaneous coronary intervention. <b>2013</b> , 167, 458-63	19
1689	American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. <b>2013</b> , 19, 536-57	196
1688	Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies. <b>2013</b> , 18, 199-210	1

1687	Gender medicine: a task for the third millennium. <b>2013</b> , 51, 713-27	101
1686	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. <b>2013</b> , 7, 292-303	13
1685	[Which vaccination and cardiovascular prevention in elderly?]. <b>2013</b> , 42, 202-8	0
1684	Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: a cost-effectiveness analysis. <b>2013</b> , 7, 642-52	12
1683	Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. <b>2013</b> , 226, 161-4	33
1682	Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). <b>2013</b> , 62, 1826-33	65
1681	Guà de pràctica clínic de la ESH/ESC para el manejo de la hipertensiã arterial (2013). <b>2013</b> , 66, 880.e1-880.e64	13
1680	The necessity for clinical reasoning in the era of evidence-based medicine. <b>2013</b> , 88, 1108-14	53
1679	The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. <b>2013</b> , 61, 440-446	142
1678	Tratamento com estatina no diabético tipo 2. <b>2013</b> , 8, 50-54	
1677	Los fibratos en el control del sîndrome metabólico. <b>2013</b> , 30, 39-44	0
1676	Histoire des statines. <b>2013</b> , 7, 407-412	0
1675	Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. <b>2013</b> , 7, 399-407	18
1674	High dose atorvastatin therapy and QTc interval in patients treated with coronary bypass surgery. <b>2013</b> , 168, 1526-8	1
1673	Point: why statins have failed to reduce mortality in just about anybody. <b>2013</b> , 7, 222-4	8
1672	[Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society]. <b>2013</b> , 25, 155-63	16
1671	Long-term clinical course of acute pulmonary embolism. <b>2013</b> , 27, 185-92	21
1670	Role of enterocytes in dyslipidemia of insulin-resistant states. <b>2013</b> , 60, 179-89	2

1669	Lipid control in patients with coronary heart disease treated in primary care or cardiology clinics. <b>2013</b> , 7, 637-41	2
1668	Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. <b>2013</b> , 29, 915-9	9
1667	Treatment with statins improves long-term survival in individuals with carotid artery stenosis. <b>2013</b> , 168, 624-6	4
1666	Lomitapide for homozygous familial hypercholesterolaemia. <i>Lancet, The</i> , <b>2013</b> , 381, 7-8	40 22
1665	Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. <b>2013</b> , 167, 1696-702	24
1664	How do we improve patient compliance and adherence to long-term statin therapy?. <b>2013</b> , 15, 291	118
1663	Does the benefit from statin therapy extend beyond 5 years?. <b>2013</b> , 15, 297	8
1662	The evolution or revolution of statin therapy in primary prevention: where do we go from here?. <b>2013</b> , 15, 298	4
1661	Is the future of statins aligned with new novel lipid modulation therapies?. <b>2013</b> , 15, 300	5
1660	LDL Lowering After Acute Coronary Syndrome: Is Lower Better?. <b>2013</b> , 15, 33-40	5
1659	PCSK9 Inhibitors: potential in cardiovascular therapeutics. <b>2013</b> , 15, 345	27
1658	Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either . <b>2013</b> , 228, 265-9	19
1657	Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. <b>2013</b> , 111, 1221-9	29
1656	HDL cholesterol and cardiovascular outcomes: what is the evidence?. <b>2013</b> , 15, 349	13
1655	Exploring the ticagrelor-statin interplay in the PLATO trial. <b>2013</b> , 124, 105-7	14
1654	Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. <b>2013</b> , 346, f880	166
1653	Statins for the primary prevention of cardiovascular disease. <b>2013</b> , CD004816	490
1652	Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. <b>2013</b> , 61, 148-52	130



1651	Triglyceride levels, pancreatitis and choice of lipid-modifying therapy. <b>2013</b> , 7, 193-5		5
1650	Dyslipidaemia: Failure to THRIVE: the end for niacin?. <b>2013</b> , 10, 246-7		3
1649	2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. <b>2013</b> , 29, 151-67		545
1648	The Role of Statins in the Metabolic Syndrome. <b>2013</b> , 147-153		
1647	The Metabolic Syndrome and Cancer. <b>2013</b> , 55-61		1
1646	Pharmacogenomics of lipid-lowering therapies. <b>2013</b> , 14, 981-95		18
1645	A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. <b>2013</b> , 73, 1025-54		18
1644	Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels. <b>2013</b> , 9, 76-8		8
1643	LDL cholesterol in CKD--to treat or not to treat?. <b>2013</b> , 84, 451-6		29
1642	Simvastatin impairs exercise training adaptations. <b>2013</b> , 62, 709-14		171
1641	Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. <i>Lancet, The</i> , <b>2013</b> , 382, 769-79	40	1078
1640	Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care. <b>2013</b> , 29, 751-60		3
1639	Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. <b>2013</b> , 92, 845-51		15
1638	Effects of pitavastatin on HDL metabolism. <b>2013</b> , 8, 55-68		2
1637	Risk Factors and Prevention, Including Hyperlipidemia. <b>2013</b> , 405-418		
1636	Lipids in Women. <b>2013</b> , 965-974		
1635	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. <b>2013</b> , 22, 193-278		286
1634	The need for combination drug therapies in patients with complex dyslipidemia. <b>2013</b> , 15, 391		7

1633	Dietary lipid modification for mild and severe dyslipidaemias. <b>2013</b> , 72, 337-41	11
1632	When choosing statin therapy: the case for generics. <b>2013</b> , 173, 229-32	14
1631	Coronary Heart Disease and Stroke. <b>2013</b> , 85-103	
1630	Statins and the risk of developing diabetes. <b>2013</b> , 346, f3156	6
1629	Risk of incident diabetes among patients treated with statins: population based study. <b>2013</b> , 346, f2610	270
1628	Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?. <b>2013</b> , 8, 273-277	2
1627	Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. <b>2013</b> , 165, 26-33.e3	19
1626	ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management. <b>2013</b> , 50, 163-71	14
1625	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <b>2013</b> , 34, 2159-219	3400
1624	Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. <b>2013</b> , 12, 166	21
1623	Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. <b>2013</b> , 16, 367-71	12
1622	Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering. <b>2013</b> , 33, 447-60	4
1621	Atherosclerosis: dyslipidemia, inflammation and lipoapoptosis. <b>2013</b> , 6-17	
1620	Kommentar zu den neuen Leitlinien (2012) der Europäischen Gesellschaft für Kardiologie zur kardiovaskulären Prävention. <b>2013</b> , 7, 251-260	2
1619	Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus ezetimibe on pro- and anti-inflammatory markers. <b>2013</b> , 8, 151-157	2
1618	Lipid management: maximising reduction of cardiac risk. <b>2013</b> , 13, 618-20	1
1617	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. <b>2013</b> , 34, 3478-90a	1551
1616	[Lipid lowering therapy in geriatric patients]. <b>2013</b> , 46, 577-85; quiz 586-7	

1615	Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. <b>2013</b> , 50, 79-89	12
1614	Factors underlying regression of coronary atheroma with potent statin therapy. <b>2013</b> , 34, 1818-25	49
1613	Fat-free mass and fasting glucose values in patients with and without statin therapy assigned to age groups between 75 years. <b>2013</b> , 6, 9-16	9
1612	Medical management and strategies to prevent coronary artery disease in patients with type 2 diabetes mellitus. <b>2013</b> , 125, 17-33	10
1611	[Secondary prevention of ischemic stroke--part 2]. <b>2013</b> , 81, 44-53; quiz 54-5	
1610	When is evidence sufficient for decision-making? A framework for understanding the pace of evidence adoption. <b>2013</b> , 2, 383-91	8
1609	Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. <b>2013</b> , 44, 2688-93	23
1608	Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. <b>2013</b> , 34, 1292-7	43
1607	Lipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk. <b>2013</b> , 8, 195-203	2
1606	Fettstoffwechselstörungen. <b>2013</b> , 09, 55-66	
1605	HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. <b>2013</b> , 34, 1279-91	480
1604	Frail HDLs and stiff arteries in type 2 diabetes in juveniles. <b>2013</b> , 62, 2662-4	2
1603	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. <b>2013</b> , 34, 3182-90	69
1602	Imaging coronary atherosclerosis: is there space for magnetic resonance imaging?. <b>2013</b> , 11, 383-5	1
1601	References. <b>2013</b> , 3, 303-305	1
1600	Chapter 5: Triglyceride-lowering treatment in adults. <b>2013</b> , 3, 284-285	2
1599	Lipid disorders. <b>2013</b> , 68-77	1
1598	Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies. <b>2013</b> , 346, e8539	243

1597	Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. <b>2013</b> , 34, 972-81	28
1596	Lipoprotein(a): a promising marker for residual cardiovascular risk assessment. <b>2013</b> , 35, 551-9	30
1595	Tackling non-communicable diseases in low- and middle-income countries: is the evidence from high-income countries all we need?. <b>2013</b> , 10, e1001377	105
1594	Diagnosis and treatment of familial hypercholesterolaemia. <b>2013</b> , 34, 962-71	187
1593	Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV. <b>2013</b> , 17, 628-35	20
1592	Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement. <b>2013</b> , 35, 857-62	16
1591	Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people. <b>2013</b> , 36 Suppl 2, S292-300	4
1590	Effects of atorvastatin on systemic and renal nitric oxide in healthy man. <b>2013</b> , 35, 148-57	7
1589	Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. <b>2013</b> , 2, e000028	92
1588	Dyslipidemia: current management and the challenge of residual cardiovascular risk reduction. <b>2013</b> , 110-122	
1587	Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. <b>2013</b> , 2, e000037	12
1586	Commentary: Last and Icebergs - spotting the iceberg doesn't predict its scale, even after 50 years. <b>2013</b> , 42, 1615-7	
1585	Schwere, asymptomatische Hypercholesterinämie im jungen Lebensalter. <b>2013</b> , 13, 39-44	
1584	Plant sterols and atherosclerosis. <b>2013</b> , 24, 12-7	28
1583	High-density lipoprotein cholesterol raising: does it matter?. <b>2013</b> , 28, 464-74	17
1582	Update on the detection and treatment of atherogenic low-density lipoproteins. <b>2013</b> , 20, 140-7	10
1581	Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <b>2013</b> , 10, 99-114	5
1580	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <b>2013</b> , 31, 1281-357	3363

1579	Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. <b>2013</b> , 23, 518-25	19
1578	Is mipomersen ready for clinical implementation? A transatlantic dilemma. <b>2013</b> , 24, 301-6	18
1577	Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. <b>2013</b> , 20, 1080-7	14
1576	Beyond LDL cholesterol in assessing cardiovascular risk: apo B or LDL-P?. <b>2013</b> , 59, 723-5	15
1575	Most important outcomes research papers on treatment of stable coronary artery disease. <b>2013</b> , 6, e17-25	2
1574	Limit to benefits of large reductions in low-density lipoprotein cholesterol levels: use of fractional polynomials to assess the effect of low-density lipoprotein cholesterol level reduction in metaregression of large statin randomized trials. <b>2013</b> , 173, 1028-9	7
1573	Mayo Clinic: management of patients with statin intolerance. <b>2013</b> , 8, 541-549	1
1572	The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. <b>2013</b> , 7, 1135-48	29
1571	Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. <b>2013</b> , 28, 49-58	13
1570	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <b>2013</b> , 8, 13-41	21
1569	Drugs for Elevated Low-Density Lipoprotein Cholesterol. <b>2013</b> , 421-433	
1568	Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides. <b>2013</b> , 434-441	
1567	Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis. <b>2013</b> , 6, 63-72	32
1566	Niacin, an old drug with a new twist. <b>2013</b> , 54, 2586-94	34
1565	Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. <b>2013</b> , 173, 1491-2	14
1564	Midlife characteristics of older men using statins. <b>2013</b> , 61, 831-2	2
1563	A review of statin use in patients with acute coronary syndrome in Western and Japanese populations. <b>2013</b> , 41, 523-36	10
1562	Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. <b>2013</b> , 14, 25-34	15

1561	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2013</b> , 127, 529-55	1686
1560	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2013</b> , 127, e362-425	1252
1559	The spectrum of statin myopathy. <b>2013</b> , 25, 747-52	44
1558	New therapies to reduce low-density lipoprotein cholesterol. <b>2013</b> , 28, 452-7	19
1557	Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. <b>2013</b> , 34, 982-92	78
1556	Reappraisal of SFA and cardiovascular risk. <b>2013</b> , 72, 390-8	13
1555	Lipid goal attainment and prescription behavior in asian patients with acute coronary syndromes: experience from a tertiary hospital. <b>2013</b> , 7, 51-7	14
1554	Outcome and safety of colonoscopy in minorities aged 85 and older. <b>2013</b> , 61, 832-4	1
1553	HDL, Atherosclerosis, and Emerging Therapies. <b>2013</b> , 2013, 891403	59
1552	Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study. <b>2013</b> , 67, 1228-37	9
1551	Risk-benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes. <b>2013</b> , 4, 344-6	1
1550	Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. <b>2013</b> , 43, 698-707	11
1549	Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. <b>2013</b> , 21, 944-50	42
1548	Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. <b>2013</b> , 40, 219-26	13
1547	The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin. <b>2013</b> , 34, 1254-7	14
1546	Thought for food: Clinical evidence for the dietary prevention strategy in cardiovascular disease. <b>2013</b> , 11, 330-6	6
1545	Incident diabetes and statins: the blemish of an undisputed heavy weight champion?. <b>2013</b> , 75, 955-8	4
1544	Beyond statins: what to expect from add-on lipid regulating therapy?. <b>2013</b> , 34, 2660-5	18

1543	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. <b>2013</b> , 22, 1411-23	18
1542	High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. <b>2013</b> , 128, 1189-97	163
1541	Management of the patient with diabetes and coronary artery disease: a contemporary review. <b>2013</b> , 9, 387-403	7
1540	Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. <b>2013</b> , 6, 390-9	191
1539	C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. <b>2013</b> , 128, 2395-403	88
1538	High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. <b>2013</b> , 127, 2485-93	34
1537	The Role of Statins in Diabetes Treatment. <b>2013</b> , 26, 156-164	6
1536	Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. <b>2013</b> , 128, 2422-46	130
1535	PCSK9 inhibition: drug development for low-density lipoprotein lowering. <b>2013</b> , 42-57	
1534	Imaging progression of coronary atherosclerosis. <b>2013</b> , 77, 3-10	5
1533	Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial. <b>2013</b> , 77, 1791-8	19
1532	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. <b>2013</b> , 8, 243-256	2
1531	Familial hypercholesterolemia: bridging and minding the gap in healthcare. <b>2013</b> , 18-41	1
1530	Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice. <b>2013</b> , 6, 1365-77	13
1529	Stable Angina Pectoris: Current Medical Treatment. <b>2013</b> , 19, 1569-1580	6
1528	Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis. <b>2013</b> , 10, 157-70	8
1527	[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment topics: I. Pathophysiology, diagnosis and treatment: 9. Dyslipidemia]. <b>2013</b> , 102, 890-4	4
1526	[Universal health coverage and accomplishment of secondary prevention goals among patients with acute myocardial infarction]. <b>2013</b> , 141, 977-86	5

1525	High density lipoprotein cholesterol in coronary artery disease: when higher means later. <b>2013</b> , 20, 23-31	5
1524	Transitioning from population to individualized preventive cardiology. <b>2013</b> , 55	1
1523	Familial hypercholesterolemia and the atherosclerotic disease. <b>2013</b> , 43, 363-7	10
1522	[Management of dyslipidemia in the elderly]. <b>2013</b> , 50, 619-21	
1521	Persistence with statin therapy in Hungary. <b>2013</b> , 9, 409-17	12
1520	Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. <b>2013</b> , 54, 33-9	22
1519	Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys. <b>2013</b> , 8, e59309	16
1518	Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an asian country. <b>2013</b> , 8, e71817	25
1517	Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). <b>2013</b> , 8, e72642	37
1516	Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. <b>2013</b> , 8, e77049	25
1515	RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. <b>2013</b> , 8, e83190	135
1514	Anti-hyperlipidemic effects and potential mechanisms of action of the caffeoylquinic acid-rich Pandanus tectorius fruit extract in hamsters fed a high fat-diet. <b>2013</b> , 8, e61922	63
1513	Deep sea water modulates blood pressure and exhibits hypolipidemic effects via the AMPK-ACC pathway: an in vivo study. <b>2013</b> , 11, 2183-202	32
1512	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. <b>2013</b> , 9, 719-27	24
1511	Fluvastatin influences hair color in C57BL/6 mice. <b>2013</b> , 14, 14333-45	3
1510	Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. <b>2013</b> , 20, 708-16	46
1509	Lowering cholesterol naturally alongside prescribed medication. <b>2013</b> , 11, 609-614	1
1508	EFFECT OF CHOLESTEROL BLOOD LEVEL REDUCTION BEGINNING EARLY IN LIFE ON THE RISK OF ISCHEMIC HEART DISEASE. <b>2013</b> , 9, 203-204	



1507	EFFECT OF LONG-TERM EXPOSURE TO LOWER LOW-DENSITY LIPOPROTEIN CHOLESTEROL BEGINNING EARLY IN LIFE ON THE RISK OF CORONARY HEART DISEASE. A MENDELIAN RANDOMIZATION ANALYSIS. <b>2013</b> , 9, 90-98	4
1506	STATINS IN PREVENTION OF ISCHEMIC STROKE. <b>2013</b> , 9, 409-416	1
1505	Lipids and disorders of lipoprotein metabolism. <b>2014</b> , 702-736	8
1504	The association between low-density lipoprotein cholesterol goal attainment, physician and patient attitudes and perceptions, and healthcare policy. <b>2014</b> , 21, 1044-54	2
1503	The pharmacoconomics of routine postoperative troponin surveillance to prevent and treat myocardial infarction after non-cardiac surgery. <b>2014</b> , 104, 619-23	20
1502	Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. <b>2014</b> , 9, e111247	32
1501	Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. <b>2014</b> , 9, e96929	15
1500	Utilization of statins: guiding principles and the new United States guidelines. <b>2014</b> , 128, 41-2	2
1499	The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in Taiwan. <b>2014</b> , 11, 381-8	10
1498	Management of acute coronary syndrome in special subgroups: female, older, diabetic and Indigenous patients. <b>2014</b> , 201, S91-6	1
1497	Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?. <b>2014</b> , 5, 444-70	375
1496	Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. <b>2014</b> , 10, 237-46	9
1495	Optimal treatment of chronic angina in patients with type 2 diabetes mellitus. <b>2014</b> , 155	
1494	Are high coronary risk patients missing out on lipid-lowering drugs in Australia?. <b>2014</b> , 201, 213-6	8
1493	Posicionamiento del Comitè Español Interdisciplinario de Prevenciñ Cardiovascular y la Sociedad Española de Cardiologã en el tratamiento de las dislipemias: divergencia entre las guãs europea y estadounidense. <b>2014</b> , 16, e161-e172	
1492	Combinaton or Individual Lipid-Lowering Therapy-What Is The Right Direction?. <b>2014</b> , 02,	
1491	STATINS IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES: REPETITION OF THE PAST AND OPTIMISM FOR THE FUTURE. <b>2014</b> , 10, 513-524	5
1490	The Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment. <b>2014</b> , 03,	

1489	Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged?. <b>2014</b> , 67, 246-9	3
1488	Prescribing statins: the real issues. <b>2014</b> , 200, 440-1	2
1487	Secondary Prevention as Integral Part of Stroke Rehabilitation. <b>2014</b> , 7, 86	
1486	Antioxidant effects of statins in the management of cardiometabolic disorders. <b>2014</b> , 21, 997-1010	28
1485	Effect of CPAP treatment for obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. <b>2014</b> , 10, 1295-302	43
1484	Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis. <b>2014</b> , 21, 739-54	5
1483	Eight challenges faced by general practitioners caring for patients after an acute coronary syndrome. <b>2014</b> , 201, S110-4	1
1482	Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy. <b>2014</b> , 47, 432-7	24
1481	[Management of dyslipidemia in elderly patients]. <b>2014</b> , 51, 214-7	
1480	Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. <b>2014</b> , 10, 475-89	83
1479	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. <b>2014</b> , 35, 2249-59	106
1478	Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. <b>2014</b> , 45, 315-53	496
1477	Are add-on agents to statin therapy necessary in hypercholesterolemia?. <b>2014</b> , 9, 695-707	
1476	Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database. <b>2014</b> , 30, 655-65	6
1475	Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies. <b>2014</b> , 51, 321-31	0
1474	Stärken und Grenzen randomisierter Studien zur Lipidtherapie. <b>2014</b> , 14, 45-50	
1473	Unanswered clinical questions in the management of cardiometabolic risk in the elderly: a statement of the Spanish Society of Internal Medicine. <b>2014</b> , 14, 193	8
1472	Perspektiven zu cholesterinwirksamer Behandlung 2014. <b>2014</b> , 14, 50-60	1

1471	Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation. <b>2014</b> , 15, 460	23
1470	Examining controversies and new frontiers in lipid management. <b>2014</b> , 9, 587-595	
1469	Genealogical analysis as a new approach for the investigation of drug intolerance heritability. <b>2014</b> , 22, 916-22	3
1468	A dysglycaemic effect of statins in diabetes: relevance to clinical practice?. <b>2014</b> , 57, 2433-5	16
1467	LDL cholesterol: should guidelines include targets?. <b>2014</b> , 12, 285-90	0
1466	Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. <b>2014</b> , 12, 1045-54	5
1465	How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?. <b>2014</b> , 29, 972-80	12
1464	Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins. <b>2014</b> , 15, 250-8	30
1463	Dyslipidaemia: what's around the corner?. <b>2014</b> , 14 Suppl 6, s41-4	3
1462	Cholesterol-lowering statin therapy to prevent atherosclerotic cardiovascular disease - is the new guideline based on best evidence?. <b>2014</b> , 69, 317-8	
1461	Lipoprotein and Lipid Metabolism. <b>2014</b> ,	
1460	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <b>2014</b> , 5, 5068	160
1459	Statins after acute coronary syndrome: a missed opportunity. <b>2014</b> , 100, 752-3	0
1458	Nonfatal outcomes in the primary prevention of atherosclerotic cardiovascular disease: is all-cause mortality really all that matters?. <b>2014</b> , 7, 481-5	3
1457	Harveian Oration 2012: Halving premature death. <b>2014</b> , 14, 643-57	3
1456	Molecular mechanisms underlying the effects of statins in the central nervous system. <b>2014</b> , 15, 20607-37	94
1455	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. <b>2014</b> , 715-746	
1454	Determinants of high cardiovascular risk in relation to plaque-composition of a non-culprit coronary segment visualized by near-infrared spectroscopy in patients undergoing percutaneous coronary intervention. <b>2014</b> , 35, 282-9	16

1453	Statins, percutaneous coronary intervention and myocardial infarction. <b>2014</b> , 30, 387-9	2
1452	Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CENtralized Pan-Levant survey on tHE Undertreatment of hypercholesterolemia (CEPHEUS) study. <b>2014</b> , 30, 1957-65	4
1451	[Familial combined hyperlipidemia: consensus document]. <b>2014</b> , 46, 440-6	8
1450	Niacin for reduction of cardiovascular risk. <b>2014</b> , 371, 1943-4	6
1449	Clinical utility gene card for: hyperlipoproteinemia, TYPE II. <b>2014</b> , 22,	7
1448	Response by Michael W. Rich. <b>2014</b> , 62, 948-9	
1447	2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <b>2014</b> , 46, 517-92	588
1446	Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. <b>2014</b> , 16, 810-9	47
1445	Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. <b>2014</b> , 129, 1022-32	181
1444	Self-reported adherence by MARS-CZ reflects LDL cholesterol goal achievement among statin users: validation study in the Czech Republic. <b>2014</b> , 20, 671-7	7
1443	New therapies for reducing low-density lipoprotein cholesterol. <b>2014</b> , 43, 1007-33	31
1442	A method to identify and validate mitochondrial modulators using mammalian cells and the worm <i>C. elegans</i> . <b>2014</b> , 4, 5285	39
1441	The 2013 American College of Cardiology/American Heart Association guidelines on treating blood cholesterol and assessing cardiovascular risk: a busy practitioner's guide. <b>2014</b> , 43, 869-92	4
1440	No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction. <b>2014</b> , 15, 1471-7	8
1439	Aggressive lipid management in very elderly adults: less is more. <b>2014</b> , 62, 945-7	19
1438	Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice. <b>2014</b> , 37, 119-25	48
1437	Combination therapy with statins: who benefits?. <b>2014</b> , 43, 993-1006	1
1436	Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials. <b>2014</b> , 34, 452-63	5

1435	Statin use and survival following glioblastoma multiforme. <b>2014</b> , 38, 722-7	49
1434	A bloody maze: acquired hemophilia A manifesting as a spontaneous intramuscular hematoma. <b>2014</b> , 62, 205-6	
1433	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. <b>2014</b> , CD007784	66
1432	Response letter to Dr. Timo Strandberg. <b>2014</b> , 62, 206-7	
1431	Alice in lipidland: the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol. <b>2014</b> , 64, 2193-5	2
1430	Response by Neil J. Stone, Sunny Intwala, and Dan Katz. <b>2014</b> , 62, 947-8	1
1429	Statin-induced insulin resistance through inflammasome activation: sailing between Scylla and Charybdis. <b>2014</b> , 63, 3569-71	24
1428	Pharmacogenomics in the development and characterization of atheroprotective drugs. <b>2014</b> , 1175, 259-300	4
1427	Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. A case-control study. <b>2014</b> , 68, 1001-9	4
1426	Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. <b>2014</b> , 37, 195-203	10
1425	Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial. <b>2014</b> , 30, 1627-32	1
1424	National Lipid Association Annual Summary of Clinical Lipidology 2015. <b>2014</b> , 8, S1-36	56
1423	Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United States. <b>2014</b> , 30, 1613-9	33
1422	Statins and the risk of liver injury: a population-based case-control study. <b>2014</b> , 23, 719-25	15
1421	Safe use of statins in elderly people. <b>2014</b> , 44, 138-142	4
1420	Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?. <b>2014</b> , 68, 144-51	1
1419	Differences in lipid profiles in two Hispanic ischemic stroke populations. <b>2014</b> , 9, 394-9	5
1418	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <b>2014</b> , 130, e344-426	754

1417	Statins in very elderly adults (debate). <b>2014</b> , 62, 943-5	21
1416	Anticoagulant effects of statins and their clinical implications. <b>2014</b> , 111, 392-400	79
1415	Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. <b>2014</b> , 312, 1136-44	82
1414	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. <b>2014</b> , 168, 682-9	303
1413	Canadian Cardiovascular Society position statement on familial hypercholesterolemia. <b>2014</b> , 30, 1471-81	71
1412	Effects of lowering LDL cholesterol on progression of kidney disease. <b>2014</b> , 25, 1825-33	108
1411	Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. <b>2014</b> , 3, e001363	75
1410	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. <b>2014</b> , 14, 121	40
1409	Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice. <b>2014</b> , 14, 145	6
1408	Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study. <b>2014</b> , 13, 133	3
1407	Critical review of high-sensitivity C-reactive protein and coronary artery calcium for the guidance of statin allocation: head-to-head comparison of the JUPITER and St. Francis Heart Trials. <b>2014</b> , 7, 315-22	10
1406	Comparison of therapeutic lipid target achievements among high-risk patients in Oman. <b>2014</b> , 65, 430-5	3
1405	Efficacy and safety of ezetimibe plus atorvastatin therapy. <b>2014</b> , 9, 441-470	5
1404	Geographic variation in statin use for complex acute myocardial infarction patients: evidence of effective care?. <b>2014</b> , 52 Suppl 3, S37-44	20
1403	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. <b>2014</b> , 32, 1741-50	31
1402	The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. <b>2014</b> , 25, 239-46	8
1401	Statin therapy in women. <b>2014</b> , 21, 896-8	4
1400	Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. <b>2014</b> , 130, 1110-30	208

1399	Diagnosis and treatment of diabetic kidney disease. <b>2014</b> , 347, 406-13	24
1398	Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia. <b>2014</b> , 25, 353-9	8
1397	Nonpharmacological approaches for reducing serum low-density lipoprotein cholesterol. <b>2014</b> , 29, 360-5	8
1396	Pharmacogenomics of statin therapy: any new insights in efficacy or safety?. <b>2014</b> , 25, 438-45	11
1395	Statin use and risk of liver cancer: an update meta-analysis. <b>2014</b> , 4, e005399	41
1394	An update on the benefits and risks of rosuvastatin therapy. <b>2014</b> , 126, 7-17	14
1393	A comparative analysis of risk factors for stroke in blacks and whites: the Atherosclerosis Risk in Communities study. <b>2014</b> , 19, 601-16	12
1392	Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. <b>2014</b> , 3, e000759	74
1391	The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: what clinicians need to know. <b>2014</b> , 126, 35-44	26
1390	ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. <b>2014</b> , 11, 133-73	137
1389	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <b>2014</b> , 130, 2354-94	696
1388	Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. <b>2014</b> , 25, 16-23	24
1387	Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. <b>2014</b> , 311, 1870-82	347
1386	Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands. <b>2014</b> , 21, 377-83	22
1385	Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. <b>2014</b> , 9, e99070	78
1384	Imaging Coronary Atherosclerosis. <b>2014</b> ,	
1383	Preventing Diabetes Complications: Non-glucose Interventions. <b>2014</b> , 21-42	
1382	Randomized trial of telephone outreach to improve medication adherence and metabolic control in adults with diabetes. <b>2014</b> , 37, 3317-24	32

1381	A comparison of live counseling with a web-based lifestyle and medication intervention to reduce coronary heart disease risk: a randomized clinical trial. <b>2014</b> , 174, 1144-57	57
1380	Effects of simvastatin on glucose metabolism in mouse MIN6 cells. <b>2014</b> , 2014, 376570	22
1379	Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol. <b>2014</b> , 6, 191-8	18
1378	GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. <b>2014</b> , 2014, 360-6	7
1377	Recent advances in physiological lipoprotein metabolism. <b>2014</b> , 52, 1695-727	116
1376	Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. <b>2014</b> , 14, 19	22
1375	Improving lipid control following myocardial infarction. <b>2014</b> , 29, 454-66	4
1374	HDL cholesterol: all hope is not lost after the torcetrapib setback--emerging therapeutic strategies on the horizon. <b>2014</b> , 21, 222-32	6
1373	Register-based predictors of adherence among new statin users in Finland. <b>2014</b> , 8, 117-25	21
1372	The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cholesterol management and for cardiovascular risk stratification: a reappraisal. <b>2014</b> , 66, 1-4	3
1371	Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. <b>2014</b> , 63, 2541-2548	398
1370	Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study. <b>2014</b> , 232, 31-9	16
1369	Toward individualized cholesterol-lowering treatment in end-stage renal disease. <b>2014</b> , 24, 65-71	5
1368	Screening lipids in children. <b>2014</b> , 8, 233-4	1
1367	LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy. <b>2014</b> , 36, 792-9	3
1366	Merits and potential downsides of the 2013 ACC/AHA cholesterol management guidelines. <b>2014</b> , 24, 573-6	7
1365	Effect of combination of ezetimibe and a statin on coronary plaque regression in patients with acute coronary syndrome: ZEUS trial (eZETimibe Ultrasound Study). <b>2014</b> , 3, 8-13	17
1364	The association between statin medication and progression after surgery for localized renal cell carcinoma. <b>2014</b> , 191, 914-9	27



1363	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <b>2014</b> , 8, 148-72	79
1362	High-potency statins increase the risk of acute kidney injury: evidence from a large population-based study. <b>2014</b> , 234, 224-9	15
1361	Curing atherosclerosis should be the next major cardiovascular prevention goal. <b>2014</b> , 63, 2779-85	62
1360	Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. <b>2014</b> , 113, 76-83	69
1359	Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: the di@bet.es study. <b>2014</b> , 26, 107-14	7
1358	Reversing social disadvantage in secondary prevention of coronary heart disease. <b>2014</b> , 171, 346-50	8
1357	Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. <b>2014</b> , 171, 580-94	127
1356	Differential metabolic actions of specific statins: clinical and therapeutic considerations. <b>2014</b> , 20, 1286-99	18
1355	Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk. <b>2014</b> , 57, 1-17	38
1354	Impacts of age on coronary atherosclerosis and vascular response to statin therapy. <b>2014</b> , 29, 456-63	23
1353	The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?. <b>2014</b> , 16, 380	11
1352	Kidney Transplantation. <b>2014</b> ,	2
1351	Novel therapies focused on the high-density lipoprotein particle. <b>2014</b> , 114, 193-204	25
1350	What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. <b>2014</b> , 21, 464-74	130
1349	Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. <b>2014</b> , 35, 353-64	57
1348	Clinical evidence of statin therapy in non-dyslipidemic disorders. <b>2014</b> , 88, 20-30	16
1347	Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. <b>2014</b> , 23, 700-13	950
1346	The role of advanced lipid testing in the prediction of cardiovascular disease. <b>2014</b> , 16, 394	13

1345	Update in therapeutic approaches to plaque stabilization. <b>2014</b> , 16, 392	2
1344	ST elevation acute myocardial infarction accelerates non-culprit coronary lesion atherosclerosis. <b>2014</b> , 30, 253-61	31
1343	[Differential therapy in coronary heart disease]. <b>2014</b> , 39, 178-85	0
1342	[Treatment of lipid disorders]. <b>2014</b> , 39, 119-28; quiz 129-30	
1341	Trends in statin therapy initiation during the period 2000-2010 in Israel. <b>2014</b> , 70, 557-64	3
1340	Prognostic impact of lipid contents on the target lesion in patients with drug eluting stent implantation. <b>2014</b> , 29, 761-8	9
1339	[PCSK9 as new target in hyperlipidemia treatment]. <b>2014</b> , 39, 466-9	4
1338	Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus. <b>2014</b> , 231-238	
1337	About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus. <b>2014</b> , 329-346	
1336	Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. <b>2014</b> , 373-398	
1335	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. <b>2014</b> , 435-453	
1334	Long-term efficacy and safety of statin treatment beyond six years: a meta-analysis of randomized controlled trials with extended follow-up. <b>2014</b> , 81, 64-73	21
1333	Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). <b>2014</b> , 100 Suppl 2, ii1-ii67	34 <sup>0</sup>
1332	Clinical practice guidelines for chronic cardiovascular disorders: a roadmap for the future. <b>2014</b> , 311, 1195-6	7
1331	An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. <b>2014</b> , 8, 29-60	246
1330	2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better. <b>2014</b> , 63, 2674-8	47
1329	New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. <b>2014</b> , 126, 169-75	14
1328	Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010. <b>2014</b> , 38, 42-7	37

1327	An assessment by the Statin Diabetes Safety Task Force: 2014 update. <b>2014</b> , 8, S17-29	79
1326	Lipids and lipid management in diabetes. <b>2014</b> , 28, 325-38	45
1325	Lipid-lowering guidelines and statin use in CKD: a time for change. <b>2014</b> , 63, 736-8	1
1324	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <b>2014</b> , 67, 136.e1-136.e56	8
1323	Simvastatin dose and risk of rhabdomyolysis: nested case-control study based on national health and drug dispensing data. <b>2014</b> , 174, 83-9	7
1322	Addressing statin adverse effects in the clinic: the 5 Ms. <b>2014</b> , 19, 533-42	19
1321	2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <b>2014</b> , 63, 2889-934	2794
1320	Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. <b>2014</b> , 107, 188-200	13
1319	Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. <b>2014</b> , 44, 211-21	312
1318	Statins in heart failure--With preserved and reduced ejection fraction. An update. <b>2014</b> , 141, 79-91	26
1317	Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy. <b>2014</b> , 113, 631-6	30
1316	Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in sweden. <b>2014</b> , 113, 17-22	7
1315	Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. <b>2014</b> , 2, 116-24	131
1314	Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. <b>2014</b> , 20, 1268-85	67
1313	Association between statin use and intracerebral hemorrhage: a systematic review and meta-analysis. <b>2014</b> , 21, 192-8	30
1312	Statins: protectors or pretenders in prostate cancer?. <b>2014</b> , 25, 188-96	31
1311	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. <b>2014</b> , 15, 380-8	111
1310	Recent findings on certain bioactive components in whole grain wheat and rye. <b>2014</b> , 59, 294-311	92

1309	Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. <b>2014</b> , 129, 77-86		172
1308	Secondary stroke prevention. <b>2014</b> , 13, 178-94		146
1307	Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. <i>Lancet, The</i> , <b>2014</b> , 383, 970-83	40	613
1306	The Year in Cardiology 2013: cardiovascular disease prevention. <b>2014</b> , 35, 307-12		38
1305	Unlocking the door to new therapies in cardiovascular disease: microRNAs hold the key. <b>2014</b> , 16, 539		8
1304	Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. <b>2014</b> , 78, 498-508		21
1303	Atherogenic dyslipidemia: A condition that should not be overlooked. <b>2014</b> , 214, 513-4		
1302	Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia. <b>2014</b> , 5, 48-57		5
1301	Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. <b>2014</b> , 237, 829-37		19
1300	Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. <b>2014</b> , 37, 131-9		22
1299	Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS). <b>2014</b> , 68, 180-7		12
1298	Hormone replacement therapy does not replace statins in women. <b>2014</b> , 62, 206		
1297	Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. <b>2014</b> , 23, 240-50		22
1296	Mechanisms and assessment of statin-related muscular adverse effects. <b>2014</b> , 78, 454-66		73
1295	Inactivating mutations in NPC1L1 and protection from coronary heart disease. <b>2014</b> , 371, 2072-82		307
1294	PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. <b>2014</b> , 55, 2370-9		46
1293	Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. <b>2014</b> , 74, 285-95		8
1292	Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. <b>2014</b> , 34, 1069-77		270

1291	Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. <b>2014</b> , 114, 1465-72	37
1290	The effect of infrequent low-dose rosuvastatin on the lipid profile. <b>2014</b> , 30, 1392-5	
1289	Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines. <b>2014</b> , 67, 913-9	1
1288	Contemporary evidence-based guidelines: practice based on the strongest evidence. <b>2014</b> , 89, 1176-82	3
1287	Is Lp(a) ready for prime time?. <b>2014</b> , 64, 861-2	1
1286	Starting primary prevention earlier with statins. <b>2014</b> , 114, 1437-42	22
1285	Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. <b>2014</b> , 129, 1303-9	50
1284	The therapeutic role of niacin in dyslipidemia management. <b>2014</b> , 19, 141-58	41
1283	Nutraceuticals for the treatment of hypercholesterolemia. <b>2014</b> , 25, 592-9	55
1282	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <b>2014</b> , 8, 594-605	11
1281	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <b>2014</b> , 64, 2645-2687	132
1280	Freeze-dried strawberries lower serum cholesterol and lipid peroxidation in adults with abdominal adiposity and elevated serum lipids. <b>2014</b> , 144, 830-7	91
1279	[Familial combined hyperlipidemia: consensus document]. <b>2014</b> , 40, 374-80	5
1278	Epidemiological studies of CHD and the evolution of preventive cardiology. <b>2014</b> , 11, 276-89	367
1277	Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias. Divergencia entre las guías europea y estadounidense. <b>2014</b> , 67, 913-919	19
1276	Statins for acute coronary syndrome. <b>2014</b> , CD006870	18
1275	[Cardiovascular preventive recommendations]. <b>2014</b> , 46 Suppl 4, 3-15	4
1274	[Treatment of older patients with dyslipidemia]. <b>2014</b> , 40 Suppl 1, 17-21	0

1273	[LDL cholesterol control in patients with very high cardiovascular risk. A simplified algorithm for achieving LDL cholesterol goals "in two steps"]. <b>2014</b> , 26, 242-52		
1272	How to balance cardiorenometabolic benefits and risks of statins. <b>2014</b> , 235, 644-8		19
1271	Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. <b>2014</b> , 10, 51-65		22
1270	Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. <b>2014</b> , 349, g4356		177
1269	Induction of hepatic apolipoprotein A-I gene expression by the isoflavones quercetin and isoquercetrin. <b>2014</b> , 110, 8-14		9
1268	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. <b>2014</b> , 64, 485-94		372
1267	Antibodies in Phase III Studies for Immunological Disorders. <b>2014</b> , 851-926		
1266	Lipid pharmacotherapy for treatment of atherosclerosis. <b>2014</b> , 15, 1119-25		12
1265	Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. <b>2014</b> , 19, 54-66		18
1264	Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. <b>2014</b> , 37, 2843-63		216
1263	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <b>2014</b> , 35, 2541-619		3467
1262	Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism. <b>2014</b> , 236, 312-20		28
1261	2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. <b>2014</b> , 64, 601-12		50
1260	Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. <b>2014</b> , 65, 417-31		69
1259	LDL cholesterol: controversies and future therapeutic directions. <i>Lancet, The</i> , <b>2014</b> , 384, 607-617	40	181
1258	Dyslipidaemia in perspective. <i>Lancet, The</i> , <b>2014</b> , 384, 566-568	40	3
1257	Triglycerides and cardiovascular disease. <i>Lancet, The</i> , <b>2014</b> , 384, 626-635	40	698
1256	High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. <b>2014</b> , 37, 3114-20		45

1255	[Atherosclerosis in systemic lupus erythematosus]. <b>2014</b> , 43, 1034-47	9
1254	Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs. <b>2014</b> , 7, 787-92	23
1253	Combination therapy in dyslipidemia: where are we now?. <b>2014</b> , 237, 319-35	34
1252	Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. <b>2014</b> , 7, 1013-22	40
1251	Women are from SATURN and men are from an ASTEROID: deciphering the REVERSAL of coronary atheroma. <b>2014</b> , 7, 1023-4	1
1250	Principles of Primary and Secondary Prevention of Cardiovascular Disease. <b>2014</b> , 1-44	
1249	Non-cardiovascular effects associated with statins. <b>2014</b> , 349, g3743	121
1248	¿Es necesario reducir aún más el colesterol-LDL en prevención secundaria?. <b>2014</b> , 21, 471-474	
1247	Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes?. <b>2014</b> , 74, 1841-1848	23
1246	Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice research datalink. <b>2014</b> , 14, 85	45
1245	Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: a pilot prospective clinical trial. <b>2014</b> , 12, 65	24
1244	Personalized approach to primary and secondary prevention of ischemic stroke. <b>2014</b> , 5, 9	7
1243	Statin use and risk of hepatocellular carcinoma in a U.S. population. <b>2014</b> , 38, 523-7	38
1242	Clinical Strategies for Managing Dyslipidemias. <b>2014</b> , 8, 216-230	1
1241	Outcome quality of in-patient cardiac rehabilitation in elderly patients--identification of relevant parameters. <b>2014</b> , 21, 172-80	15
1240	Statins and breast cancer prognosis: evidence and opportunities. <b>2014</b> , 15, e461-8	128
1239	Consuming a buttermilk drink containing lutein-enriched egg yolk daily for 1 year increased plasma lutein but did not affect serum lipid or lipoprotein concentrations in adults with early signs of age-related macular degeneration. <b>2014</b> , 144, 1370-7	15
1238	Promotion of Long-Term Adherence to a Healthy Lifestyle. <b>2014</b> , 8, 239-241	

1237	Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations. <b>2014</b> , 41, 351-62	5
1236	A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. <b>2014</b> , 89, 1257-78	29
1235	Statins, glycemia, and diabetes mellitus: another point of view. <b>2014</b> , 16, 458	4
1234	National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. <b>2014</b> , 8, 473-88	323
1233	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <b>2014</b> , 64, e139-e228	1822
1232	[New pharmaceuticals in cardiology. Heart failure, anticoagulation, dyslipidemia]. <b>2014</b> , 55, 382-9	1
1231	[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the DÄÄÄCH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology]. <b>2014</b> , 55, 601-6	5
1230	Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study. <b>2014</b> , 70, 99-108	10
1229	Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. <b>2014</b> , 28, 361-77	29
1228	Effects of extended-release niacin with laropiprant in high-risk patients. <b>2014</b> , 371, 203-12	1073
1227	Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society. <b>2014</b> , 6, 58	14
1226	From the "Ivory Tower" to the trenches: A practical approach to the 2013 ACC/AHA Cholesterol and Risk Assessment Guidelines. <b>2014</b> , 8, 231-3	1
1225	Lipid-lowering therapy and mortality post-MI: is it just about the LDL?. <b>2014</b> , 100, 825-6	
1224	LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. <b>2014</b> , 21, 1420-8	22
1223	The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future. <b>2014</b> , 96, 64-73	12
1222	MicroRNA-management of lipoprotein homeostasis. <b>2014</b> , 115, 2-6	14
1221	Primary prevention of cardiovascular disease with statins in the elderly. <b>2014</b> , 16, 420	20
1220	Emerging therapeutic approaches to treat dyslipidemia. <b>2014</b> , 16, 506	4



1219	Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. <b>2014</b> , 70, 687-96	18
1218	Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. <b>2014</b> , 14, 367-76	28
1217	Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. <b>2014</b> , 37, 481-500	4
1216	A comparison of risk factors for mortality from heart failure in Asian and non-Asian populations: an overview of individual participant data from 32 prospective cohorts from the Asia-Pacific Region. <b>2014</b> , 14, 61	21
1215	Marital status shows a strong protective effect on long-term mortality among first acute myocardial infarction-survivors with diagnosed hyperlipidemia--findings from the MONICA/KORA myocardial infarction registry. <b>2014</b> , 14, 98	22
1214	Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. <b>2014</b> , 12, 51	113
1213	An overview of the new frontiers in the treatment of atherogenic dyslipidemias. <b>2014</b> , 96, 57-63	29
1212	The 2013 ACC/AHA guidelines on the treatment of blood cholesterol: questions, questions, questions. <b>2014</b> , 114, 761-4	15
1211	2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <b>2014</b> , 129, S1-45	2786
1210	Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. <b>2014</b> , 35, 1996-2000	25
1209	Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. <b>2014</b> , 10, 183-99	34
1208	Lxr-driven enterocyte lipid droplet formation delays transport of ingested lipids. <b>2014</b> , 55, 1944-58	38
1207	An assessment by the Statin Muscle Safety Task Force: 2014 update. <b>2014</b> , 8, S58-71	300
1206	Use of expert consensus to improve atherogenic dyslipidemia management. <b>2014</b> , 67, 36-44	2
1205	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. <b>2014</b> , 168, 205-12.e1	83
1204	NLA Task Force on Statin Safety--2014 update. <b>2014</b> , 8, S1-4	101
1203	Use and misuse of ezetimibe: analysis of use and cost in Saskatchewan, a Canadian jurisdiction with broad access. <b>2014</b> , 30, 237-43	3
1202	Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica. <b>2014</b> , 67, 36-44	22

1201	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. <b>2014</b> , 8, 107-16	26
1200	Are investments in disease prevention complements? The case of statins and health behaviors. <b>2014</b> , 36, 151-63	20
1199	Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). <b>2014</b> , 113, 1593-8	22
1198	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <b>2014</b> , 171, 309-25	251
1197	Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. <b>2014</b> , 28, 423-37	34
1196	Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. <b>2014</b> , 172, 88-95	41
1195	Risque cardiovasculaire de la polyarthrite rhumatoïde. <b>2014</b> , 81, 281-285	1
1194	Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey. <b>2014</b> , 77, 61-7	8
1193	Running interference to lower cholesterol. <i>Lancet, The</i> , <b>2014</b> , 383, 10-12	40 7
1192	Tragopogon porrifolius improves serum lipid profile and increases short-term satiety in rats. <b>2014</b> , 72, 1-7	9
1191	Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. <b>2014</b> , 129, 234-43	180
1190	Dizziness & Stroke. <b>2014</b> , 2, 4-6	
1189	[A history and review of cholesterol ester transfer protein inhibitors and their contribution to the understanding of the physiology and pathophysiology of high density lipoprotein]. <b>2014</b> , 26, 78-84	
1188	Cardiovascular risk in rheumatoid arthritis. <b>2014</b> , 81, 298-302	40
1187	Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. <b>2014</b> , 4, e005402	17
1186	Genetically low triglycerides and mortality: further support for "the earlier the better"?. <b>2014</b> , 60, 705-7	3
1185	[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. <b>2014</b> , 155, 62-8	
1184	Novel concepts in lipoprotein particle metabolism and regulation. <b>2014</b> , 63, 1-4	2

1183	[Management of vascular risk factors in patients older than 80]. <b>2014</b> , 143, 134.e1-11	8
1182	Coronary artery disease and diabetes mellitus. <b>2014</b> , 32, 439-55	92
1181	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. <b>2014</b> , 15, 1-15	62
1180	Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. <b>2014</b> , 29, 313-9	11
1179	[Neurological common diseases in the super-elder society. Topics: II. Stroke: 1. Risk factor control for preventing stroke]. <b>2014</b> , 103, 1772-82	
1178	Treatment of dyslipidemia. <b>2014</b> , 6, 17	7
1177	2014 Meet-The-Professor: Endocrine Case Management. <b>2014</b> ,	
1176	Characterization of statin dose response in electronic medical records. <b>2014</b> , 95, 331-8	28
1175	ACP Journal Club. In 85-year-old adults, MMSE predicted 5-year risk for first stroke better than Framingham score. <b>2014</b> , 160, JC13	
1174	Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. <b>2014</b> , 78, 1073-82	87
1173	Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?. <b>2015</b> , 79, 49-50	
1172	Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. <b>2014</b> , 160, 468-76	44
1171	Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. <b>2014</b> , 37, 653-9	48
1170	[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial]. <b>2014</b> , 155, 669-75	
1169	The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. <b>2014</b> , 9, 914-9	12
1168	Pharmacological lipid lowering for prevention of cardiovascular disease in older adults. <b>2014</b> , 11, 49-58	1
1167	HMG CoA reductase inhibitors (statins) for kidney transplant recipients. <b>2014</b> , CD005019	33
1166	Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain. <b>2015</b> , 32, 944-61	24

- 1165 Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target. **2015**, 145, 67-69
- 1164 The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Trial: Where to Now?. **2015**, 2, 1008-9
- 1163 Comment on "Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus". **2015**, 34, 435-8
- 1162 Epidemiologã de la prevenciã secundaria en Espaã: hechos y cifras. **2015**, 15, 2-6
- 1161 Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. **2015**, 9, 758-769 306
- 1160 Posicionamiento del Comit'Españ Interdisciplinario de Prevenciã Cardiovascular y la Sociedad Espaõla de Cardiologã en el tratamiento de las dislipemias. Divergencia entre las guã europea y estadounidense. **2015**, 67, 488-496
- 1159 Statins Provide Less Benefit in Populations with High Noncardiovascular Mortality Risk: Meta-Regression of Randomized Controlled Trials. **2015**, 63, 1413-9 4
- 1158 Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. **2015**, 38, 763-9 7
- 1157 Lipid lowering in patients with kidney disease - is it really that hard?. **2015**, 79, 976-7
- 1156 Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. **2015**, 163, 291-7 71
- 1155 Potential drug interactions with statins: Estonian register-based study. **2015**, 10, 254-260 2
- 1154 Dyslipidaemia and the military patient. **2015**, 161, 206-10
- 1153 American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan ã2015. **2015**, 21, 1-87 390
- 1152 2015 Meet-The-Professor: Endocrine Case Management. **2015**,
- 1151 Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease: Grand Rounds Discussion From the Beth Israel Deaconess Medical Center. **2015**, 163, 280-90 2
- 1150 The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. **2015**, 2015, 59 2
- 1149 Enteral siRNA delivery technique for therapeutic gene silencing in the liver via the lymphatic route. **2015**, 5, 17035 25
- 1148 Something important is missing in the ACC/AHA cholesterol treatment guidelines. **2015**, 55, 324-9 2

1147	Statins for Primary Prevention in Adults Aged 75 Years or Older. <b>2015</b> , 163, 481	
1146	Wie kriegt man das Gefäßisiko in den Griff?. <b>2015</b> , 9, 34-45	
1145	Development and Content Validity Testing of a Patient-Reported Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection. <b>2015</b> , 18, 1000-7	8
1144	Comentário a «Associação entre a hipercolesterolemia familiar e a prevalência de diabetes mellitus». <b>2015</b> , 34, 435-438	
1143	Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. <b>2015</b> , 14, 57	18
1142	Does statin use have a disease modifying effect in symptomatic knee osteoarthritis? Study protocol for a randomised controlled trial. <b>2015</b> , 16, 584	15
1141	Effective risk stratification in patients with moderate cardiovascular risk using albuminuria and atherosclerotic plaques in the carotid arteries. <b>2015</b> , 33, 1563-70	9
1140	Improving the odds: ezetimibe and cardiovascular disease. <b>2015</b> , 69, 390-5	2
1139	RNY-derived small RNAs as a signature of coronary artery disease. <b>2015</b> , 13, 259	29
1138	PCSK9 inhibition: the way forward in the treatment of dyslipidemia. <b>2015</b> , 13, 258	27
1137	Prevention of cardiovascular diseases. <b>2015</b> , 13, 261	5
1136	Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia. <b>2015</b> , 14, 107	3
1135	The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. <b>2015</b> , 80, 473-9	15
1134	Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database. <b>2015</b> , 5, e007954	10
1133	'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. <b>2015</b> , 26, 169-78	93
1132	Hyperlipidemia and cardiovascular disease: reinforcement for 'lower is better'. <b>2015</b> , 26, 468-9	5
1131	Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. <b>2015</b> , 35, 771-9	4
1130	New worldwide lipid guidelines. <b>2015</b> , 30, 447-53	2

1129	Long-term follow-up of lipid-lowering trials. <b>2015</b> , 26, 572-9	14
1128	Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies. <b>2015</b> , 35, 1189-203	14
1127	Biomarkers, Risk Factors, and Risk: Clarifying the Controversy About Surrogate End Points and Clinical Outcomes. <b>2015</b> , 8, 457-9	8
1126	Prioritizing health outcomes in a limited world: writing lipid guidelines. <b>2015</b> , 26, 188-94	1
1125	Acute high-density lipoprotein therapies. <b>2015</b> , 26, 521-5	2
1124	Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. <b>2015</b> , 26, 566-71	34
1123	8.5 Ratschlage zur Abklung und Betreuung von Patienten mit chronischer Nierenerkrankung. <b>2015</b> ,	
1122	Quality of Healthcare Provided to Elderly with Type 2 Diabetes: Data from the AMD* Annals Initiative. <b>2015</b> , 06,	
1121	Palm oil and the heart: A review. <b>2015</b> , 7, 144-9	52
1120	Single-nucleotide polymorphisms: a perspective of cardiovascular prevention. <b>2015</b> , 61, 458-68	1
1119	Comparative efficacy of pitavastatin and simvastatin in patients with hypercholesterolemia: a meta-analysis of randomized controlled clinical trials. <b>2015</b> , 9, 1859-64	1
1118	Application of New Cholesterol Guidelines to the Korean Adult Diabetic Patients. <b>2015</b> , 30, 1612-7	5
1117	The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine. <b>2015</b> , 16, 12230-42	16
1116	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <b>2015</b> , 21, 6820-34	91
1115	Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel. <b>2015</b> , 13, 759-70	18
1114	Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?. <b>2015</b> , 11, 203-9	5
1113	Adherence to statin treatment following a myocardial infarction: an Italian population-based survey. <b>2015</b> , 7, 273-80	4
1112	TREATMENT OF PATIENTS WITH SEVERE DYSLIPIDEMIA IN REAL CLINICAL PRACTICE. <b>2015</b> , 11, 380-384	2

1111	Combination pharmacotherapy in lipid management. <b>2015</b> , 58, 745	
1110	Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes. <b>2015</b> , 22, 676-84	9
1109	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. <b>2015</b> , 21, 1403-14	20
1108	Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. <b>2015</b> , 16, 17245-72	7
1107	Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. <b>2015</b> , 56, 278-85	38
1106	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. <b>2015</b> , 14, 45	11
1105	Impact of cholesterol on disease progression. <b>2015</b> , 5, 7	27
1104	Use of statins and the incidence of type 2 diabetes mellitus. <b>2015</b> , 61, 375-80	3
1103	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <b>2015</b> , 21, 7860-8	97
1102	Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials. <b>2015</b> , 7, 555-65	6
1101	Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease. <b>2015</b> , 10, e0123367	25
1100	Lipid-lowering therapy in older persons. <b>2015</b> , 11, 43-56	14
1099	Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study. <b>2015</b> , 10, e0127835	8
1098	Salvia Miltiorrhiza Root Water-Extract (Danshen) Has No Beneficial Effect on Cardiovascular Risk Factors. A Randomized Double-Blind Cross-Over Trial. <b>2015</b> , 10, e0128695	9
1097	Statin-Associated Adverse Events. <b>2015</b> , 7, CMT.S18865	2
1096	Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation. <b>2015</b> , 2015, 179434	5
1095	Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography. <b>2015</b> , 2015, 235742	5
1094	Serum cholesterol reduction efficacy of biscuits with added plant stanol ester. <b>2015</b> , 2015, 353164	12

1093	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <b>2015</b> , 11, 1-23	252
1092	Impact of predictors upon the reduction of lipid parameters in family medicine practice. <b>2015</b> , 133, 428-34	
1091	Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients. <b>2015</b> , 128, 259-66	16
1090	Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis. <b>2015</b> , 11, 459-463	1
1089	Knowledge of PCSK9 and continued educational gaps: evaluating the impact of continuing medical education. <b>2015</b> , 14, 48-51	1
1088	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <b>2015</b> , 372, 2387-97	2371
1087	Comparison of treatment outcomes in patients with and without diabetes mellitus attending a multidisciplinary cardiovascular prevention programme (a retrospective analysis of the EUROACTION trial). <b>2015</b> , 15, 11	6
1086	Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis. <b>2015</b> , 763, 79-89	56
1085	Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS). <b>2015</b> , 9, 283-9	1
1084	Primary and secondary prevention of ischemic heart disease in women. <b>2015</b> , 17, 38	1
1083	A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State. <b>2015</b> , 20, 483-9	6
1082	Dyslipidemia and cardiovascular disease in women. <b>2015</b> , 17, 609	46
1081	Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice. <b>2015</b> , 22, 199-201	14
1080	To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. <b>2015</b> , 241, 450-4	15
1079	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials. <b>2015</b> , 763, 48-63	35
1078	PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. <b>2015</b> , 763, 38-47	26
1077	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet, The</i> , <b>2015</b> , 386, 452-60	40 140
1076	Las guías estadounidenses de dislipemia. Fortalezas y debilidades. <b>2015</b> , 15, 18-21	



1075	Cholesterol Absorption Inhibitor Ezetimibe: RiskâBenefits and Role in Treating Dyslipidemias. <b>2015</b> , 465-481	
1074	Twenty-five years of statins: where do we go from here?. <b>2015</b> , 10, 33-45	2
1073	Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. <b>2015</b> , 87, 1250-7	34
1072	Cholesterol metabolism and statin effectiveness in hemodialysis patients. <b>2015</b> , 65, 2299-301	4
1071	Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. <b>2015</b> , 18, 109-11	31
1070	Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia. <b>2015</b> , 9, 384-9	27
1069	We don't prescribe statins to lower cholesterol: we prescribe statins to reduce vascular risk. <b>2015</b> , 26, 1001-3	4
1068	Statins can delay insulin use and reduce diabetes-related diseases in Asian patients with type 2 diabetes. <b>2015</b> , 94, e735	1
1067	Global burden of CVD: focus on secondary prevention of cardiovascular disease. <b>2015</b> , 201 Suppl 1, S1-7	149
1066	Small Dense Low Density Lipoprotein Cholesterol, Paraoxonase 1 and Lipid Profile in Postmenopausal Women: Quality or Quantity?. <b>2015</b> , 46, 534-8	12
1065	Near-infrared spectroscopy for intracoronary detection of lipid-rich plaques to understand atherosclerotic plaque biology in man and guide clinical therapy. <b>2015</b> , 278, 110-25	19
1064	Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures. <b>2015</b> , 15, 245	40
1063	Sex and Age Differences in Global Pain Status Among Patients Using Opioids Long Term for Chronic Noncancer Pain. <b>2015</b> , 24, 629-35	34
1062	Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. <b>2015</b> , 132, 2424-47	168
1061	Smoke signals: urgent need for more successful interventions. <b>2015</b> , 8,	
1060	Lipids and Cerebrovascular Disease: Research and Practice. <b>2015</b> , 46, 3322-8	71
1059	Biochemistry laboratories should routinely report non-HDL-cholesterol. <b>2015</b> , 52, 629-31	3
1058	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. <b>2015</b> , 37, 2732-50	6

1057	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <b>2015</b> , 9, S1-122.e1	293
1056	Spécificité des accidents vasculaires cérébraux chez les diabétiques. <b>2015</b> , 9, 399-405	1
1055	Cardiovascular Disease Biomarkers in Clinical Use and Their Modulation by Functional Foods. <b>2015</b> , 1-24	
1054	Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. <b>2015</b> , 68, 1125.e1-1125.e64	20
1053	Is HPS2-THRIVE the death knell for niacin?. <b>2015</b> , 9, 343-50	8
1052	Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. <b>2015</b> , 25, 426-33	23
1051	Think Again About Cholesterol Survey. <b>2015</b> , 20, 1-5	5
1050	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <b>2015</b> , 169, 906-915.e13	251
1049	Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough. <b>2015</b> , 5, e008678	4
1048	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <b>2015</b> , 187, 174-180	41
1047	Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease. <b>2015</b> , 115, 441-6	15
1046	Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?. <b>2015</b> , 13, 1-21	21
1045	Statin-induced low low-density lipoprotein cholesterol level: is lower better?. <b>2015</b> , 65, 108-109	1
1044	More risk factors, less ischemia, and the relevance of MPI testing. <b>2015</b> , 22, 552-4	14
1043	Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use. <b>2015</b> , 22, 773-80	29
1042	Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014. <b>2015</b> , 68, 144.e1-144.e95	1
1041	Small-dense LDL/large-buoyant LDL ratio associates with the metabolic syndrome. <b>2015</b> , 48, 495-502	8
1040	Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. <b>2015</b> , 65, 402-404	31

1039	Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group. <b>2015</b> , 183, 63-75	13
1038	Gaps in guideline implementation: a cause for concern, time for action. <b>2015</b> , 65, 278-80	12
1037	Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. <b>2015</b> , 115, 447-53	33
1036	Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled Study. <b>2015</b> , 77, 1-6	32
1035	Puesta al d�a en estatinas. Nuevas recomendaciones. <b>2015</b> , 67, 304-311	1
1034	Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <b>2015</b> , 131, 927-64	226
1033	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. <b>2015</b> , 239, 93-100	54
1032	Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. <b>2015</b> , 183, 149-54	13
1031	Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(�)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. <b>2015</b> , 54, 133-46	115
1030	Advances in non-invasive drug delivery for atherosclerotic heart disease. <b>2015</b> , 12, 1135-47	17
1029	Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better?. <b>2015</b> , 65, 109	
1028	Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. <b>2015</b> , 16, 1-27	37
1027	[Dyslipidaemia and vascular risk. A new evidence based review]. <b>2015</b> , 41, 435-45	2
1026	Antisense oligonucleotides, microRNAs, and antibodies. <b>2015</b> , 224, 649-89	7
1025	High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. <b>2015</b> , 101, 356-62	33
1024	Cholesterol treatment and changes in guidelines in an academic medical practice. <b>2015</b> , 128, 403-9	20
1023	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. <b>2015</b> , 36, 1186-94	289
1022	Design and discovery of 2-oxochromene derivatives as liver X receptor �selective agonists. <b>2015</b> , 25, 1274-8	16

1021	The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?. <b>2015</b> , 17, 494	7
1020	Statins and Primary Prevention of Cardiovascular Disease in Women: A Critical Appraisal of the Evidence. <b>2015</b> , 9, 114-129	2
1019	Present status of statin therapy. <b>2015</b> , 25, 216-25	13
1018	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events Trial. <b>2015</b> , 4,	4
1017	Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma. <b>2015</b> , 191, 990-1000	47
1016	Statins and Incident Diabetes: Can Risk Outweigh Benefit?. <b>2015</b> , 9, 1	1
1015	Risikofaktoren für Schlaganfall und ihre therapeutische Beeinflussung. <b>2015</b> , 16, 32-44	
1014	Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. <b>2015</b> , 19, 223-38	457
1013	The new ACCF/AHA guidelines on the treatment of dyslipidemia: pros. <b>2015</b> , 10, 115-7	1
1012	The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study. <b>2015</b> , 169, 736-742.e1	53
1011	Lowering LDL cholesterol is good, but how and in whom?. <b>2015</b> , 372, 1564-5	15
1010	Primary prevention of atherosclerotic cardiovascular disease: controversies and clinical considerations. <b>2015</b> , 49, 484-93	8
1009	Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. <b>2015</b> , 240, 482-9	17
1008	Contemporary Cardiovascular Concerns after Spinal Cord Injury: Mechanisms, Maladaptations, and Management. <b>2015</b> , 32, 1927-42	95
1007	Statins: Risk-Benefits and Role in Treating Dyslipidemias. <b>2015</b> , 403-421	
1006	Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. <b>2015</b> , 36, 2975-83	55
1005	Blood Lipids and Type 2 Diabetes Risk: Can Genetics Help Untangle the Web?. <b>2015</b> , 64, 2344-5	6
1004	Statines et risque de diabète : quelles évidences ? <b>2015</b> , 9, 273-278	

1003	Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS). <b>2015</b> , 242, 155-60	3
1002	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. <b>2015</b> , 65, 2638-2651	123
1001	Statin desensitization in a patient with probable familial hypercholesterolemia. <b>2015</b> , 9, 597-601	2
1000	The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. <b>2015</b> , 9, 496-7	1
999	[Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target]. <b>2015</b> , 145, 67-9	2
998	Optimizing Placental Transfusion for Preterm Infants. <b>2015</b> , 136, 177-9	5
997	Fatty liver, inflamed blood and calcified coronary arteries: lessons and uncertainties from the multiethnic study of atherosclerosis -commentary on the study of Al Rifai et al. <b>2015</b> , 239, 634-6	1
996	Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes. <b>2015</b> , 184, 502-506	15
995	Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. <b>2015</b> , 9, 741-750	33
994	Nonalcoholic fatty liver disease and statins. <b>2015</b> , 64, 1215-23	47
993	Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis. <b>2015</b> , 242, 211-7	32
992	Combination Therapy In Dyslipidemia. <b>2015</b> ,	3
991	Ezetimibe and Plaque Regression: Cholesterol Lowering or Pleiotropic Effects?. <b>2015</b> , 66, 508-10	12
990	Familial hypercholesterolemia in children and adolescents: A clinical perspective. <b>2015</b> , 9, S11-9	13
989	Patterns of Lipid Lowering Therapy among Children Ages 8-20 Years. <b>2015</b> , 167, 113-9.e1	12
988	Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. <b>2015</b> , 241, 92-9	10
987	Butter increased total and LDL cholesterol compared with olive oil but resulted in higher HDL cholesterol compared with a habitual diet. <b>2015</b> , 102, 309-15	35
986	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. <b>2015</b> , 129, 63-79	19

985	Safety considerations with fenofibrate/simvastatin combination. <b>2015</b> , 14, 1481-93	18
984	Primary prevention of cardiovascular disease: global cardiovascular risk assessment and management in clinical practice. <b>2015</b> , 1, 31-36	5
983	Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. <b>2015</b> , 35, 1880-8	51
982	The new pooled cohort equations risk calculator. <b>2015</b> , 31, 613-9	52
981	Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. <b>2015</b> , 36, 1601-8	38
980	PON1 polymorphisms are predictors of ability to attain HDL-C goals in statin-treated patients. <b>2015</b> , 48, 1039-44	6
979	Cardiology patient page. Statin intolerance. <b>2015</b> , 131, e389-91	41
978	Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. <b>2015</b> , 4, e001937	57
977	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. <b>2015</b> , 100, 3140-8	176
976	A paradigm shift in the treatment of atherosclerosis. <b>2015</b> , 108, 337-9	0
975	Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: evaluación del riesgo cardiovascular. <b>2015</b> , 22, 263-269	3
974	Synthesis and biological evaluation of isoflavone amide derivatives with antihyperlipidemic and preadipocyte antiproliferative activities. <b>2015</b> , 23, 4428-4433	3
973	Ezetimibe-Statins Combination to Reduce Cardiovascular Events: The Evidence Base. <b>2015</b> , 13, 327-8	
972	Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS). <b>2015</b> , 37, 116-21	5
971	Hypercholesterolemia and Hypertension: Two Sides of the Same Coin. <b>2015</b> , 15, 403-14	36
970	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. <b>2015</b> , 241, 409-18	63
969	IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease. <b>2015</b> , 241, 498-501	21
968	Effect of the Mediterranean diet on the lipid-lipoprotein profile: is it influenced by the family history of dyslipidemia?. <b>2014</b> , 7, 177-87	1

967	Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement. <b>2015</b> , 353, 119-31	21
966	Sweetless'n low LDL-C targets for PCSK9 treatment. <b>2015</b> , 36, 1146-8	8
965	Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. <b>2015</b> , 75, 1187-99	20
964	The perils of surrogate endpoints. <b>2015</b> , 36, 2212-8	41
963	Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). <b>2015</b> , 241, 597-606	30
962	Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. <b>2015</b> , 107,	51
961	Statin intolerance: diagnosis and remedies. <b>2015</b> , 17, 27	28
960	Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012. <b>2015</b> , 4,	31
959	Clinical guidelines on hyperlipidaemia: recent developments, future challenges and the need for an Australian review. <b>2015</b> , 24, 495-502	0
958	Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. <b>2015</b> , 115, 1212-21	138
957	Situaci3n actual de la dislipemia en Espa1a: La visi3n del card3logo. <b>2015</b> , 15, 2-7	0
956	Del concepto de estatinas de alta potencia a los efectos extralip3dicos de las estatinas. <b>2015</b> , 15, 22-27	1
955	IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?. <b>2015</b> , 240, 161-2	41
954	The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study. <b>2015</b> , 2, 356-64	1
953	[Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets]. <b>2015</b> , 27, 138-43	6
952	Statin treatment: can genetics sharpen the focus?. <i>Lancet, The</i> , <b>2015</b> , 385, 2227-9	40 9
951	La gu1a europea de dislipemia. Fortalezas y debilidades. <b>2015</b> , 15, 14-17	
950	Risk identification and possible countermeasures for muscle adverse effects during statin therapy. <b>2015</b> , 26, 82-8	56

949	Implementation and evaluation of evidence-based patient care application during a primary care advanced practice experience. <b>2015</b> , 7, 324-331	2
948	Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation. <b>2015</b> , 67-69, 38-47	6
947	[Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines]. <b>2015</b> , 32, 83-91	1
946	2013 ACC/AHA cholesterol treatment guidelines. <b>2015</b> , 5, S15-S20	
945	Guidelines and guidance in lipid modification. <b>2015</b> , 25, 348-50	2
944	Optimizing statin treatment. <b>2015</b> , 25, 226-7	
943	Is it time to repair a Fairly Fast SAAB Convertible? Testing an evidence-based mnemonic for the secondary prevention of cardiovascular disease. <b>2015</b> , 24, 480-7	3
942	Does marital status contribute to the explanation of the hypercholesterolemia paradox in relation to long term mortality in myocardial infarction? Findings from the MONICA/KORA Myocardial Infarction Registry. <b>2015</b> , 75, 25-31	2
941	[Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines]. <b>2015</b> , 41, 149-57	0
940	Quality of buckwheat-enriched wheat bread and its antihyperlipidemic effect in statin treated patients. <b>2015</b> , 63, 556-561	25
939	Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?. <b>2015</b> , 128, 914.e1-4	9
938	Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly. <b>2015</b> , 29, 187-97	12
937	Genetic risk factors and Mendelian randomization in cardiovascular disease. <b>2015</b> , 17, 33	10
936	Role for combination therapy in diabetic dyslipidemia. <b>2015</b> , 17, 32	21
935	Prevention of Heart Failure in Patients with Chronic Kidney Disease. <b>2015</b> , 9, 1	1
934	Management of Coronary Artery Calcium and Coronary CTA Findings. <b>2015</b> , 8, 18	17
933	Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. <b>2015</b> , 240, 415-23	90
932	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <b>2015</b> , 14, 935-55	94



931	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. <b>2015</b> , 372, 1500-9		1081
930	Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: tratamiento farmacológico con estatinas. <b>2015</b> , 22, 14-21		5
929	Practical recommendations for the management of hyperlipidemia. <b>2015</b> , 18, 194-8		14
928	Chronic kidney disease: Statins in chronic kidney disease: time to move on?. <b>2015</b> , 11, 262-3		4
927	2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. <b>2015</b> , 21, 2		25
926	Cardiac Rehabilitation after an Acute Coronary Syndrome: The Impact in Elderly Patients. <b>2015</b> , 131, 177-85		18
925	Update of Clinical Trials of Anti-PCSK9 Antibodies. <b>2015</b> , 29, 159-69		7
924	Blood lipids and colorectal polyps: testing an etiologic hypothesis using phenotypic measurements and Mendelian randomization. <b>2015</b> , 26, 467-73		6
923	Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. <b>2015</b> , 65, 1552-61		228
922	Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet, The</i> , <b>2015</b> , 385, 2153-61	40	78
921	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. <i>Lancet, The</i> , <b>2015</b> , 385, 2264-2271	40	371
920	Lipidomic changes of LDL in overweight and moderately hypercholesterolemic subjects taking phytosterol- and omega-3-supplemented milk. <b>2015</b> , 56, 1043-56		17
919	Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. <b>2015</b> , 58, 1109-17		190
918	How effective are current dietary guidelines for cardiovascular disease prevention in healthy middle-aged and older men and women? A randomized controlled trial. <b>2015</b> , 101, 922-30		42
917	Mouse models of disturbed HDL metabolism. <b>2015</b> , 224, 301-36		13
916	Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. <b>2015</b> , 9, 226-33		17
915	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <b>2015</b> , 36, 1536-46		88
914	National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <b>2015</b> , 9, 129-69		478

913	Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. <b>2015</b> , 191, 138-48	33
912	Ezetimibe: rescued by randomization (clinical and mendelian). <b>2015</b> , 35, e13-5	15
911	Novel method for reducing plasma cholesterol: a ligand replacement therapy. <b>2015</b> , 10, 83-90	1
910	Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents. <b>2015</b> , 589-611	
909	Medical Management of Serum Lipids and Coronary Heart Disease. <b>2015</b> , 39-55	
908	PCSK9 inhibitors. <b>2015</b> , 145, w14094	12
907	Managing residual risk after myocardial infarction among individuals with low cholesterol levels. <b>2015</b> , 33, 299-308	3
906	Statins and diabetes. <b>2015</b> , 33, 233-43	12
905	Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal. <b>2015</b> , 18, 176-9	1
904	Statins and cognitive side effects: what cardiologists need to know. <b>2015</b> , 33, 245-56	6
903	New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia. <b>2015</b> , 33, 181-96	20
902	Statin use after acute myocardial infarction by patient complexity: are the rates right?. <b>2015</b> , 53, 324-31	8
901	Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals. <b>2015</b> , 262-274	
900	Lipid biomarkers and cardiovascular risk: which path to take at the fork in the road?. <b>2015</b> , 65, 1296-1297	2
899	Management of dyslipidaemia in statin-intolerant patients in light of AHA and NPA guidelines of 2013-2014. <b>2015</b> , 5, 119-122	1
898	Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. <b>2015</b> , 36, 39-48	51
897	Statin intolerance: reconciling clinical trials and clinical experience. <b>2015</b> , 313, 1011-2	40
896	Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. <b>2015</b> , 350, h1088	36

895	Impact of statins on serial coronary calcification during atheroma progression and regression. <b>2015</b> , 65, 1273-1282	319
894	Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. <b>2015</b> , 4, 25-38	43
893	Risk of Intracranial Hemorrhage From Statin Use in Asians: A Nationwide Cohort Study. <b>2015</b> , 131, 2070-8	27
892	Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study. <b>2015</b> , 67, 1718-28	42
891	Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. <b>2015</b> , 6, 6498	219
890	Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: a 50% reduction from baseline versus . <b>2015</b> , 187, 478-85	10
889	RETRACTED: The principles & practice of LDL lowering therapy. <b>2015</b> , 5, S54-S57	
888	Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. <b>2015</b> , 20, 299-312	4
887	Comparative Effectiveness of Statin Therapy in Chronic Kidney Disease and Acute Myocardial Infarction: A Retrospective Cohort Study. <b>2015</b> , 128, 1252.e1-1252.e11	6
886	The Role of Omega-3 Fatty Acids in Dyslipidemias. <b>2015</b> , 45-64	1
885	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. <b>2015</b> , 35, 2269-80	48
884	Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. <b>2015</b> , 3, e000132	8
883	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. <b>2015</b> , 56, 2085-93	26
882	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. <b>2015</b> , 17, 109	20
881	Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation. <b>2015</b> , 17, 121	8
880	Design and conduct of a large obstetric or neonatal randomized controlled trial. <b>2015</b> , 20, 389-402	14
879	Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. <b>2015</b> , 243, 124-30	14
878	A call for the better utilization of physical activity and exercise training in the defense against cardiovascular disease. <b>2015</b> , 43, 329-32	2

877	Statin Intolerance: the Clinician's Perspective. <b>2015</b> , 17, 69	38
876	Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?. <b>2015</b> , 17, 58	6
875	Augmentation du risque de diabète de type 2 sous statines : quel mécanisme ?. <b>2015</b> , 9, 37	
874	Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. <b>2015</b> , 17, 72	10
873	Cholesterol-lowering effects and potential mechanisms of different polar extracts from <i>Cyclocarya paliurus</i> leave in hyperlipidemic mice. <b>2015</b> , 176, 17-26	57
872	Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. <b>2015</b> , 22, 1331-9	6
871	Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study. <b>2015</b> , 117, 731-41	69
870	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. <b>2015</b> , 75, 1373-92	50
869	Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland. <b>2015</b> , 18, 896-905	37
868	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease: There Are Miles to Go Before We Sleep. <b>2015</b> , 66, 1873-5	4
867	Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. <b>2015</b> , 13, 123	154
866	Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative. <b>2015</b> , 5, e007075	4
865	Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. <b>2015</b> , 132, 1825-33	31
864	Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy. <b>2015</b> , 31, 2273-85	6
863	Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. <b>2015</b> , 37, 1945-1954.e6	21
862	Secondary prevention of stroke. <b>2015</b> , 76, C104-7	5
861	The effect of statins on average survival in randomised trials, an analysis of end point postponement. <b>2015</b> , 5, e007118	32
860	Prevalence and incidence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis protocol. <b>2015</b> , 5, e007404	9

859	Statins and CETP Inhibitors: Anacetrapib and Evacetrapib: The Last Hope?. <b>2015</b> , 65-71	1
858	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. <b>2015</b> , 170, 1061-9	63
857	Type 2 Diabetes Mellitus and Dyslipidemia. <b>2015</b> , 99-113	1
856	Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. <b>2015</b> , 201, 79-84	26
855	Synergistic effects of <i>Artemisia iwayomogi</i> and <i>Curcuma longa</i> radix on high-fat diet-induced hyperlipidemia in a mouse model. <b>2015</b> , 173, 217-24	16
854	Statins and Mipomersen: Mechanisms of Action and Patient Tolerability. <b>2015</b> , 73-86	1
853	Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses. <b>2015</b> , 15, 379-86	1
852	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <b>2015</b> , 19, 1-12	50
851	PCSK9 Inhibitors and Cardiovascular Events. <b>2015</b> , 373, 774	27
850	Lowering cholesterol in chronic kidney disease: is it safe and effective?. <b>2015</b> , 36, 2988-95	14
849	Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. <b>2015</b> , 11, 1505-15	8
848	Safety and efficacy of ezetimibe: A meta-analysis. <b>2015</b> , 201, 247-52	54
847	Prevention of Cardiovascular Diseases. <b>2015</b> ,	
846	Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials. <b>2015</b> , 47, 430-40	105
845	Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <b>2015</b> , 243, 60-4	28
844	A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). <b>2015</b> , 5, 282-290	3
843	Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. <b>2015</b> , 66, 1273-1285	79
842	The emergence of sedentary behaviour physiology and its effects on the cardiometabolic profile in young and older adults. <b>2015</b> , 37, 89	23

841	PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk: Great Expectations. <b>2015</b> , 116, 1643-5	4
840	LDL cholesterol, statins and PCSK 9 inhibitors. <b>2015</b> , 67, 419-24	10
839	Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. <b>2015</b> , 36, 566-75	96
838	Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. <b>2015</b> , 132, 1224-33	189
837	Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?. <b>2015</b> , 132, 1218-20	6
836	Antilipidemic Drug Therapy Today and in the Future. <b>2016</b> , 233, 373-435	3
835	Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke. <b>2015</b> , 243, 65-70	12
834	Five year trends in dyslipidaemia prevalence and management in Switzerland: the CoLaus study. <b>2015</b> , 25, 1007-15	8
833	Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia. <b>2015</b> , 9, 709-15	7
832	Statin use in prediabetic patients: rationale and results to date. <b>2015</b> , 6, 246-51	7
831	The link between lipids, statins and cancer: is there a role for cardio-oncology?. <b>2015</b> , 11, 389-93	1
830	Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. <b>2015</b> , 56, 2381-92	35
829	Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. <b>2015</b> , 242, 553-9	29
828	Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. <b>2015</b> , 243, 11-8	64
827	An evaluation of alirocumab for the treatment of hypercholesterolemia. <b>2015</b> , 13, 1307-23	15
826	Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?. <b>2015</b> , 37, 2716-31	23
825	Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective. <b>2015</b> , 67, 95-102	3
824	Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy. <b>2015</b> , 4,	30

823	Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention. <b>2015</b> , 243, 593-7	9
822	Sex-specific differential in risk of diabetes-related macrovascular outcomes. <b>2015</b> , 15, 85	12
821	Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. <b>2015</b> , 127, 655-63	12
820	Calcifediol improves lipid profile in osteopenic atorvastatin-treated postmenopausal women. <b>2015</b> , 45, 144-9	12
819	ApoA-I mimetics. <b>2015</b> , 224, 631-48	27
818	When compliance is an issue-how to enhance statin adherence and address adverse effects. <b>2015</b> , 17, 471	15
817	2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk. <b>2015</b> , 25, 340-7	17
816	[Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines]. <b>2015</b> , 27, 36-44	2
815	Aging and dyslipidemia: a review of potential mechanisms. <b>2015</b> , 19, 43-52	109
814	KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. <b>2015</b> , 65, 354-66	73
813	Cardiac rehabilitation in African Americans: evidence for poorer outcomes compared with whites, especially in women and diabetic participants. <b>2015</b> , 169, 102-7	10
812	Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: results from the multicenter CONFIRM registry. <b>2015</b> , 238, 119-25	8
811	Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. <b>2015</b> , 115, 21-6	96
810	Treating coronary disease and the impact of endothelial dysfunction. <b>2015</b> , 57, 431-42	42
809	Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?. <b>2015</b> , 17, 472	25
808	Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan. <b>2015</b> , 114, 1000-7	11
807	[LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis]. <b>2015</b> , 27, 1-8	4
806	Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. <b>2015</b> , 15, 27-34	12

805	Subclinical atherosclerosis measures for cardiovascular prediction in CKD. <b>2015</b> , 26, 439-47		81
804	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. <b>2015</b> , 29, 142-5		12
803	What the guidelines do not say: statin non-benefit groups. <b>2015</b> , 17, 468		4
802	Familial hypercholesterolaemia: PCSK9 inhibitors are coming. <i>Lancet, The</i> , <b>2015</b> , 385, 307-10	40	23
801	Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. <b>2015</b> , 36, 490-500		115
800	Evidence for the prevention and treatment of stroke in dialysis patients. <b>2015</b> , 28, 35-47		35
799	PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. <b>2015</b> , 145, 58-66		39
798	Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population. <b>2015</b> , 42, 283-9		8
797	Antiviral drug discovery: broad-spectrum drugs from nature. <b>2015</b> , 32, 29-48		112
796	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , <b>2015</b> , 385, 351-61	40	409
795	Are Patients with Low Non-HDL Cholesterol "Non-responders" to Statin Therapy on Coronary Plaque Regression?. <b>2016</b> , 23, 1030-2		
794	. <b>2016</b> ,		
793	Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. <b>2016</b> , 12, 421-433		7
792	AMCP Partnership Forum: Driving New Advances in Dyslipidemia Management. <b>2016</b> , 22, 426-33		
791	EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY. <b>2016</b> , 12, 351-358		
790	In Search of an Optimal Target Level of Low Density Lipoprotein Cholesterol for Secondary Prevention Among the Japanese Population. <b>2016</b> , 23, 397-8		1
789	[Diagnostic value of YRNA-derived small RNAs for coronary artery disease]. <b>2016</b> , 32, 248-51		4
788	Vascular Pathobiology. <b>2016</b> , 85-124		6



787	[Not Available]. <b>2016</b> , 33, 284	5
786	Cardiovascular risk factor control is insufficient in young patients with coronary artery disease. <b>2016</b> , 12, 219-27	5
785	Validity of a Novel Method for Estimation of Low-Density Lipoprotein Cholesterol Levels in Diabetic Patients. <b>2016</b> , 23, 1355-1364	30
784	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. <b>2016</b> , 12, 185-97	11
783	Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction. <b>2016</b> , 14,	28
782	Overview of guidelines for the management of dyslipidemia: EU perspectives. <b>2016</b> , 12, 357-369	11
781	Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases. <b>2016</b> , 159-176	
780	Statins Dose-Dependently Exert Significant Chemopreventive Effects Against Various Cancers in Chronic Obstructive Pulmonary Disease Patients: A Population-Based Cohort Study. <b>2016</b> , 7, 1892-1900	6
779	Prediction of Coronary Atherosclerotic Ostial Lesion with a Damping of the Pressure Tracing during Diagnostic Coronary Angiography. <b>2016</b> , 57, 58-63	1
778	Imaging of coronary atherosclerosis in various susceptible groups. <b>2016</b> , 6, 382-95	12
777	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. <b>2016</b> , 6, 282-303	10
776	Intracoronary near-infrared spectroscopy: an overview of the technology, histologic validation, and clinical applications. <b>2016</b> , 2016, e201618	1
775	Statin-induced diabetes: incidence, mechanisms, and implications. <b>2016</b> , 5,	17
774	The Different Effects of Atorvastatin and Pravastatin on Cell Death and PARP Activity in Pancreatic NIT-1 Cells. <b>2016</b> , 2016, 1828071	5
773	Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). <b>2016</b> , 23, 567-87	38
772	Disorders of Lipid Metabolism. <b>2016</b> , 1660-1700	4
771	High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities. <b>2016</b> , 71, 235-42	54
770	Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. <b>2016</b> , 12, 887-906	15

769	Introduction: The Role of Fats in Human Diet. <b>2016</b> , 1-20	4
768	Lipids in Coronary Heart Disease. <b>2016</b> , 67-80	
767	Modulation of microRNA Expression in Subjects with Metabolic Syndrome and Decrease of Cholesterol Efflux from Macrophages via microRNA-33-Mediated Attenuation of ATP-Binding Cassette Transporter A1 Expression by Statins. <b>2016</b> , 11, e0154672	20
766	Management of Familial Hypercholesterolemia in Hong Kong. <b>2016</b> , 23, 520-31	8
765	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. <b>2016</b> , 13, e1002007	35
764	Inflammatory Stress Sensitizes the Liver to Atorvastatin-Induced Injury in ApoE <sup>-/-</sup> Mice. <b>2016</b> , 11, e0159512	10
763	and Antioxidant, Anti-hyperlipidemic Properties and Chemical Characterization of (L.) Extract. <b>2016</b> , 7, 400	24
762	ACC/AHA Guidelines for Cardiovascular Disease Prevention and Cholesterol Management: Implications of New Therapeutic Agents. <b>2016</b> , 1, 399-408	1
761	Development of Antisense Drugs for Dyslipidemia. <b>2016</b> , 23, 1011-25	12
760	A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries. <b>2016</b> , 27, 388-97	15
759	Statin myopathy: over-rated and under-treated?. <b>2016</b> , 31, 417-25	6
758	Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. <b>2016</b> , 68, 252-260	103
757	Genetic insights into statin-associated diabetes risk. <b>2016</b> , 27, 125-30	6
756	The Management of LDL Cholesterol and Predictors of Goal Achievement in Stroke Patients in China: A Cross-Sectional Study. <b>2016</b> , 22, 577-83	5
755	High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. <b>2016</b> , 134, 22-8	34
754	Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction. <b>2016</b> , 64, 526-35	12
753	Regression of coronary atheroma with statin therapy. <b>2016</b> , 23, 131-7	9
752	Lifetime Risk for Sudden Cardiac Death in the Community. <b>2016</b> , 5,	42

751	Statin use and risk of disease recurrence and death after radical prostatectomy. <b>2016</b> , 76, 469-78	12
750	Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. <b>2016</b> , 30, 465-472	5
749	Favorable change of lipid profile after carbamazepine withdrawal. <b>2016</b> , 134, 219-23	3
748	General practitioners' insight into deprescribing for the multimorbid older individual: a qualitative study. <b>2016</b> , 70, 261-76	35
747	Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. <b>2016</b> , 10, 1109-18	43
746	Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects. <b>2016</b> , 36, 749-56	2
745	Deprescribing: An Application to Medication Management in Older Adults. <b>2016</b> , 36, 774-80	16
744	Dawn of a New Era - The Far Lower, the Far Better Low-Density Lipoprotein Cholesterol Story in Japan. <b>2016</b> , 80, 1903-4	
743	Cardiovascular complications of diabetes. <b>2016</b> , 9, 694-701	1
742	Cholesterol-lowering pattern affects the progression of atherosclerosis in apolipoprotein E deficient mice. <b>2016</b> , 132, 271-274	4
741	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. <b>2016</b> , 375, 2144-2153	418
740	Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. <b>2016</b> , 7, 13457	161
739	Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). <b>2016</b> , 87, 924-9	22
738	Influenza vaccine as a coronary intervention for prevention of myocardial infarction. <b>2016</b> , 102, 1953-1956	79
737	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. <b>2016</b> , 53, 835-845	28
736	Secondary prevention after coronary artery bypass graft surgery: a primer. <b>2016</b> , 31, 635-643	19
735	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. <b>2016</b> , 22, 84-113	333
734	HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. <b>2016</b> , 255, 128-139	62

733	Nationale Versorgungsleitlinie (NVL) Chronische KHK. <b>2016</b> , 13, 50-68	
732	Associations of genetic variants for adult lipid levels with lipid levels in children. The Generation R Study. <b>2016</b> , 57, 2185-2192	7
731	The future of lipid guidelines. <b>2016</b> , 27, 585-591	2
730	Comparison of the efficacy and safety of intensive-dose and standard-dose statin treatment for stroke prevention: A meta-analysis. <b>2016</b> , 95, e4950	9
729	Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2. <b>2016</b> , 4, e000275	15
728	Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. <b>2016</b> , 31, 644-653	4
727	Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis. <b>2016</b> , 14, 10	19
726	Trastornos del metabolismo lipídico. <b>2016</b> , 12, 1059-1071	
725	Is diabetes still a state of premature cardiovascular death?. <b>2016</b> , 33, 285-290	1
724	Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. <b>2016</b> , 17, 291	2
723	Diabetic Dyslipidemia Review: An Update on Current Concepts and Management Guidelines of Diabetic Dyslipidemia. <b>2016</b> , 351, 361-5	25
722	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <b>2016</b> , 374, 2021-31	440
721	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <b>2016</b> , 176, 83-92	32
720	Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea. <b>2016</b> , 37, 1357-9	5
719	Cholesterol metabolism: A review of how ageing disrupts the biological mechanisms responsible for its regulation. <b>2016</b> , 27, 108-124	77
718	Diabetic dyslipidaemia. <b>2016</b> , 27, 313-22	35
717	Emerging Risk Factors for Stroke: What Have We Learned From Mendelian Randomization Studies?. <b>2016</b> , 47, 1673-8	15
716	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. <b>2016</b> , 176, 135-44	48

715	Eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio as an associated factor of high risk plaque on coronary computed tomography in patients without coronary artery disease. <b>2016</b> , 250, 30-7	19
714	Cost-effectiveness of Screening for Abdominal Aortic Aneurysm in Combination with Medical Intervention in Patients with Small Aneurysms. <b>2016</b> , 51, 766-73	19
713	Reply: Primary Prevention With Statins or Increased Physical Activity. <b>2016</b> , 67, 1974-5	
712	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular	3919
711	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. <b>2016</b> , 10, 472-89	154
710	Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. <b>2016</b> , 10, 519-527.e4	27
709	Metabolic syndrome is associated with muscle symptoms among statin users. <b>2016</b> , 10, 1022-1029	12
708	The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. <b>2019</b> , 61, 20-27	1
707	?????????????????????????????????. <b>2019</b> , 57, 202-204	
706	[Possibilities of clinical use of ezetimibe Otrio (JSC "AKRIKHIN", Russia) in patients with high and very high cardiovascular risk who have not reached the target values of lipid metabolism. Conclusion of the Board of experts]. <b>2019</b> , 59, 47-57	1
705	[Possibilities of Computed Tomography of the Heart in Risk Stratification and Determination of Optimal Strategy of Primary Prevention of Cardiovascular Complications of Atherosclerosis]. <b>2019</b> , 59, 70-80	0
704	Lipid control and associated risk factors, before suffering from the first cardiovascular event. <b>2019</b> , 31, 141-151	
703	6. Update for the Management of Dyslipidemia. <b>2019</b> , 108, 1896-1901	
702	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <b>2019</b> , 66, 54-63	1
701	[Dyslipidemia management in geriatric patients: new guidelines 2017]. <b>2019</b> , 56, 417-426	
700	Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy. <b>2019</b> , 21-26	1
699	Hypercholesterolemia, Lipid-Lowering Strategies and Microcirculation. <b>2020</b> , 253-269	1
698	Arterial hypertension in elderly and senile patients: clinical characteristics and treatment quality (according to the national register of arterial hypertension). <b>2019</b> , 34, 73-86	

- 697 Hyperlipidemia management in Slovakia: observational study. **2019**, 65, 761-769
- 696 Chemoprevention of Esophageal Cancer. **2020**, 113-125
- 695 Myositis Mimics: The Differential Diagnosis of Myositis. **2020**, 209-223 1
- 694 LDL as a therapeutic objective. **2019**, 31 Suppl 2, 1-15 2
- 693 Novel Therapies for Dyslipidemia.
- 692 Stanovisko vĽboru ĽeskĽspoleĽ Ľosti pro aterosklerĽzu k doporuĽ ĽnĽm ESC/EAS pro diagnostiku a lĽ Bu dyslipidemiĽz roku 2019. **2019**, 65, 743-754 3
- 691 Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects?. **2019**, 57, 575-589 1
- 690 Pharmacogenomics in Cardiovascular Diseases. **2020**, 21-38
- 689 Bayesian flexible hierarchical skew heavy-tailed multivariate meta regression models for individual patient data with applications. **2020**, 13, 485-500 0
- 688 Lipidsenkende Mittel. **2020**, 601-614
- 687 Conservative Approach Might Be the Strategy by Default in Stable Angina Patients: A Case Report. **2020**, 10, 769-774
- 686 Evaluation of the effectiveness of lipid-lowering agents. **2020**, 26, 78-85
- 685 Lifetime risk assessment in cholesterol management among hypertensive patients: Observational cross-sectional study based on electronic health record data..
- 684 EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020). **2020**, 6-29 13
- 683 Stanovisko vĽboru ĽeskĽspoleĽ Ľosti pro aterosklerĽzu k doporuĽ ĽnĽm ESC/EAS pro diagnostiku a lĽ Bu dyslipidemiĽz roku 2019. **2020**, 62, 185-197 4
- 682 Combination therapy with perindopril and atorvastatin - an effective method to reduce cardiovascular risk in patients with hypertension and dyslipidaemia. **2020**, 17, 93-96
- 681 ANGPTL8 protein-truncating variant and the risk of coronary disease, type 2 diabetes and adverse effects. 2
- 680 Fixed combination of atorvastatin and ezetimibe in the dyslipidemia treatment. **2020**, 19, 122-124

679	Central directions for reducing cardiovascular mortality: what can be changed today?. <b>2020</b> , 25, 3983	6
678	Valid cardiac biomarkers. Part I. <b>2020</b> , 19, 2573	3
677	Assessment of Therapeutic Response to Statin Therapy in Patients With Intracranial or Extracranial Carotid Atherosclerosis by Vessel Wall MRI: A Systematic Review and Updated Meta-Analysis. <b>2021</b> , 8, 742935	1
676	Statin Intolerance and Noncompliance: An Empiric Approach. <b>2021</b> ,	1
675	High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. <b>2021</b> , 8, 760926	1
674	Effectiveness of Intensive Cardiac Rehabilitation in High-Risk Patients with Cardiovascular Disease in Real-World Practice. <b>2021</b> , 13,	2
673	New and emerging lipid-modifying drugs to lower LDL cholesterol. <b>2021</b> , 10,	1
672	Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications?. <b>2021</b> , 41, 2798-2801	1
671	The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: A Personalized Approach to Risk Reduction. <b>2021</b> , 179-200	
670	PCSK9-Inhibitoren - Erfahrungen im klinischen Alltag. <b>2020</b> , 20, 31-32	
669	The effect of switching from statin-monotherapy to statin/ezetimibe combination therapy on lipid profiles in patients with type 2 diabetes and dyslipidemia: a multicenter open-label study (EUCLID). <b>2020</b> , 4, 22-31	
668	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. <b>2021</b> , 139-158	0
667	European Society of Cardiology / European Atherosclerosis Society 2019 Dyslipidemia Treatment Guideline: What Has Changed?. <b>2020</b> , 9, 187-198	
666	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. <b>2021</b> , 615-636	
665	Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols. <b>2021</b> , 219-268	
664	HIV and Dyslipidemia. <b>2021</b> , 431-466	
663	Genetic Disorders of Lipoprotein Metabolism. <b>2021</b> , 35-80	
662	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. <b>2021</b> , 121-138	

- 661 Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. **2021**, 107-120
- 660 Cardiovascular Disease in Women: Focus on Lipid Management. **2021**, 467-487
- 659 How ApoB Measurements Could Improve Prevention of Cardiovascular Disease. **2021**, 545-563
- 658 Primary Prevention of Cardiovascular Disease Guidelines. **2021**, 653-672
- 657 Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. **2020**, 2020, e202039 1
- 656 Atherogenesis and Vascular Biology. **2021**, 11-34
- 655 Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. **2021**, 28, 114-121
- 654 Risikofaktoren und Primärprävention. **2020**, 21-31
- 653 Associations of the prevalence of atherogenic lipoprotein fractions and vital exhaustion in men of open population. **2020**, 34, 149-156
- 652 Origins of Cardiopulmonary Disease in Early Life. **2020**, 17-24
- 651 Polygenic modelling of treatment effect heterogeneity.
- 650 Introduction: Why Is Improving Use of Medicines and Medical Tests Important?. **2020**, 1-27
- 649 Secondary Prevention of Coronary Artery Disease. **2020**, 75-82
- 648 THE ROLE OF LIPOPROTEIN (A) AND PREGNANCY ASSOCIATED PLASMA PROTEIN A IN DIAGNOSTICS CORONARY HEART DISEASE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. **2020**, 73, 2489-2493
- 647 Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an observational study of treatment patterns and lipid control. **2020**, 59, 641-649 1
- 646 Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib. **2020**, 339-372
- 645 ERKRANKUNGEN DER GEFÄSSE. **2020**, E-1-E17-4
- 644 Current and Emerging Therapies for Atherosclerosis. **2020**, 71-88



- 643 Comparative analysis of the use of lipid modifying agents in the Republic of Serbia and Nordic countries in the period 2015-2017. **2020**, 7, 966-975
- 642 Statin prescription among patients with type 2 diabetes in Botswana: findings and implications.
- 641 Importance du cholestfol et de son traitement dans la prvention de lâAVC. **2020**, 204, 283-291
- 640 Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. **2020**, 32, 49-58 1
- 639 The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion). **2020**, 16, 147-155 1
- 638 Reader response: Lipid levels and the risk of hemorrhagic stroke among women. **2020**, 94, 549-550
- 637 Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. **2021**, 32, 223-229 2
- 636 Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. **2021**, 78, 1954-1964 2
- 635 Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study. **2021**, 11, 0
- 634 Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. **2021**, 0
- 633 Cost-utility analysis of evolocumab in patients with ASCVD in Italy. 8, 155-167
- 632 High-density Lipoprotein Cholesterol as a Risk Factor of Health-Related Quality of Life in 50-70-Year-Old Community-Dwelling Women. **2021**, 9, 1092-1096
- 631 Inflammation in Cardiovascular Disease: From Basic Concepts to Clinical Application. **2020**,
- 630 Role of Statins in the Primary Prevention of Atherosclerotic Cardiovascular Disease and Mortality in the Population with Mean Cholesterol in the Near-Optimal to Borderline High Range: A Systematic Review and Meta-Analysis.
- 629 Inferring Causal Direction Between Two Traits in the Presence of Horizontal Pleiotropy with GWAS Summary Data.
- 628 The role of sialic acids in the initiation of atherosclerosis. **2020**, 68, 359-364 2
- 627 High-Density Lipoproteins and Cardiovascular Disease.
- 626 HIGH-DENSITY LIPOPROTEINS AND CARDIOVASCULAR DISEASE.

- 625 Leserbrief zum Beitrag: Kappstein I. Mund-Nasen-Schutz in der Öffentlichkeit: Keine Hinweise für eine Wirksamkeit Krankenhaushygiene up2date 2020; 15: 279-297. **2020**, 15, 327-332 0
- 624 Adherence to statin therapy in patients with high and very high cardiovascular risk in real clinical practice. **2020**, 11, 38-48 1
- 623 COMPARISON OF PLASMA COAGULABILITY AFTER SHORT-TERM TREATMENT WITH ROSUVASTATIN VERSUS ATORVASTATIN IN UNSTABLE ANGINA PATIENTS. **2020**, 1
- 622 Features of using of a fixed combination of rosuvastatin and ezetimibe for effective hypolipidemic therapy. **2020**, 26-32 1
- 621 Effects of apolipoprotein B on the lifespan and risks of major disease including type 2 diabetes: a Mendelian randomization analysis using outcomes in first-degree relatives.
- 620 Primary Prevention of Coronary Artery Disease. **2021**, 81-123
- 619 Stable Ischemic Heart Disease. **2021**, 125-154
- 618 The impact of a run-in period on treatment effects in cardiovascular prevention randomised control trials: A protocol for a comprehensive review and meta-analysis. 3, 82 1
- 617 Impact of Endocrine Disorders on the Heart. **2021**, 59-95
- 616 Statin therapy in patients with high and very high cardiovascular risk: an optimal approach. **2020**, 19, 2696
- 615 Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?. **2020**, 16, 842-851
- 614 [Cardiovascular preventive recommendations. PAPPS 2020 update]. **2020**, 52 Suppl 2, 5-31 0
- 613 Prognóza pacienta s ischemickou chorobou srdeční a neb na čem závisí? **2020**, 66, 8-11
- 612 Association of small dense LDL-cholesterol with disease severity, hypertension status and clinical outcome in patients with coronary artery disease. **2021**, 39, 511-518 4
- 611 The impact of normal range estimated glomerular filtration rate on mortality in selected patients undergoing coronary angiography - a long-term follow-up. **2021**, 32, 302-308 2
- 610 Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?. **2011**, 122, 256-89 33
- 609 Implications of a newer Framingham model. **2012**, 58, 378-9; author reply 379-80
- 608 Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011. **2012**, 6, e17-23

607	Cholesterol and cardiovascular disease in the elderly. Facts and gaps. <b>2013</b> , 4, 154-69	33
606	Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. <b>2013</b> , 40, 288-9	3
605	Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy. <b>2013</b> , 18, e32-6	2
604	Monitoring in clinical biochemistry. <b>2013</b> , 34, 85-92	2
603	Prevention & control of CVD in women & children in India. <b>2013</b> , 138, 281-4	5
602	Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. <b>2013</b> , 59, 1169-80	35
601	Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer. <b>2013</b> , 4, 183-92	1
600	Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. <b>2013</b> , 138, 461-91	13
599	Chemoprevention for hepatocellular carcinoma: the role of statins. <b>2013</b> , 2, 1-3	
598	Statins: emerging role in chemoprevention for hepatocellular carcinoma?. <b>2013</b> , 2, 117-20	1
597	American academy of dermatology and american college of cardiology. <b>2014</b> , 39, 370-4	1
596	The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. <b>2014</b> , 10, 298-304	5
595	Does ezetimibe modify clinical outcomes?. <b>2015</b> , 61, 251	1
594	Trends in high LDL cholesterol, cholesterol-lowering medication use, and dietary saturated-fat intake: United States, 1976-2010. <b>2013</b> , 1-8	20
593	The Interaction Between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy. <b>2015</b> , 15, 429-37	16
592	Differences of prevalence of dyslipidemia and risk factors related to LDL-c in the patients with abnormal fasting glucose between Uygur and Han in Xinjiang. <b>2015</b> , 8, 22403-10	3
591	Factors Associated with Lipid Goal Attainment among Patients with Deployed Drug Eluting Stent. <b>2014</b> , 30, 325-32	1
590	Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. <b>2016</b> , 9, 123-6	7

- 589 Medical Management of Metabolic Complications of Liver Transplant Recipients. **2016**, 12, 601-608 8
- 588 Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use. **2016**, 9, 434-444 8
- 587 ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. **2017**, 19, D163-D189
- 586 Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges. **2017**, 9, 80-87 18
- 585 Complications of HIV disease and antiretroviral therapy. **2012**, 20, 48-60 8
- 584 Cardiovascular risk and dyslipidemia management in HIV-infected patients. **2012**, 20, 129-33; quiz 123-4 12
- 583 HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial. **2015**, 23, 146-9 65
- 582 Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?. **2016**, 23, 169-73 3
- 581 Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. **2018**, 34, 371-378 5
- 580 Will routine use of statins after age 50 become as common as fluoridating drinking water? It should!. **2013**, 110, 342-3
- 579 Improving adherence to cardiovascular disease medications with information technology. **2014**, 20, SP502-10 37
- 578 [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease]. **2017**, 37, 938-942
- 577 A Bridge Still Too Far. **2019**, 35, 615-617
- 576 PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?. **2020**, 131, 42-47
- 575 Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. **2020**, 10, e036769 1
- 574 Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study). **2021**, 18, 261-270
- 573 Associations of subclinical cerebral small vessel disease and processing speed in non-demented subjects: A 7-year study.. **2021**, 32, 102884 2
- 572 Role of cereal bioactive compounds in the prevention of age-related diseases. **2022**, 247-286

571	Probiotics in the prevention and management of cardiovascular diseases with focus on dyslipidemia. <b>2022</b> , 337-351	
570	The relationship of socioeconomic factors to the use of preventative cardiovascular disease medications: A prospective Australian cohort study. <b>2021</b> , 154, 106884	
569	The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. <b>2021</b> , 175, 105986	3
568	A genome-wide association study of childhood adiposity and blood lipids. 6, 303	1
567	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus.. <b>2021</b> , 11,	2
566	Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. <b>2021</b> ,	0
565	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. <b>2021</b> , 57, 1-99	
564	An update on emerging drugs for the treatment of hypercholesterolemia. <b>2021</b> , 1-7	1
563	Are Statins Indicated in Senior Citizens? A Review of Statin Therapy in the Elderly. <b>2021</b> ,	
562	CETP-inhibitors: from HDL-C to LDL-C lowering agents?. <b>2021</b> ,	3
561	Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis.. <b>2021</b> ,	1
560	Statins mediate anti- and pro-tumourigenic functions in lung adenocarcinoma development by remodelling the tumour microenvironment. <b>2021</b> ,	4
559	Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia.. <b>2021</b> , 9,	0
558	Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. <b>2021</b> , 1	1
557	[Cardiovascular risk management in type-2 diabetes: Is the patients' cardiovascular risk adequately considered in type-2 specialist diabetes care?]. <b>2021</b> , 167, 6-14	
556	Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. <b>2021</b> , 2, 100446	3
555	Statins for secondary prevention and major adverse events after coronary artery bypass grafting. <b>2021</b> ,	3
554	Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy.. <b>2021</b> , 7, e15	

553	Associations Between Intake of Fermented Dairy Products and Blood Lipid Concentrations Are Affected by Fat Content and Dairy Matrix - The Tromsø Study: Tromsø. <b>2021</b> , 8, 773468	0
552	The 2021 ESC guidelines on cardiovascular prevention: Whether the ends justify the means. <b>2021</b> ,	0
551	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). <b>2021</b> , 6-59	1
550	Crosstalk between Statins and Cancer Prevention and Therapy: An Update.. <b>2021</b> , 14,	2
549	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.. <b>2021</b> , 17, 1447-1547	8
548	Effect of Omega-3 Fatty Acids on Coronary Plaque Morphology - A Serial Computed Tomography Angiography Study. <b>2021</b> ,	2
547	Active Annotation in Evaluating the Credibility of Web-Based Medical Information: Guidelines for Creating Training Data Sets for Machine Learning. <b>2021</b> , 9, e26065	0
546	Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. <b>2021</b> , 16, e0260839	0
545	ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis.. <b>2022</b> , 148, 197-203	4
544	Welche Risikofaktoren gibt es und was kann man dagegen tun?. <b>2021</b> , 9-81	
543	Lipidsenkende Mittel. <b>2021</b> , 509-521	
542	Principles of Diabetes Care and Lifestyle Modification. <b>2021</b> , 83-107	
541	Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease. <b>2021</b> ,	0
540	Screening of asymptomatic patients with elevated lipoprotein(a) levels by coronary computed tomography angiography.. <b>2022</b> ,	
539	Encyclopedia of Molecular Pharmacology. <b>2021</b> , 929-936	
538	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis.. <b>2021</b> , 74, 484-490	0
537	Deep Sea Water-Dissolved Organic Matter Intake Improves Hyperlipidemia and Inhibits Thrombus Formation and Vascular Inflammation in High-Fat Diet Hamsters.. <b>2022</b> , 12,	1
536	Atherosclerotic plaque-targeted nanotherapeutics ameliorates atherogenesis by blocking macrophage-driven inflammation. <b>2022</b> , 42, 101351	2

535 Stellenwert der Statine: Nach wie vor die erste Wahl.

534 Coronary artery stenosis regression by long-term standard dose statin therapy in middle-aged and elderly patients: Report and analysis of 31 cases. **2020**, 2, 162-165

533 Clinical Outcomes of Olmesartan/Rosuvastatin Combination Therapy in Acute Coronary Syndrome Patients With Essential Hypertension. **2020**,

532 Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. **2020**, 10, e036769

531 Lipoprotein(a). **2021**, 201

530 Evaluating membrane structure by Laurdan imaging: Disruption of lipid packing by oxidized lipids. **2021**, 88, 235-256

529 The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. **2021**, 12, 1857-1871

528 An Overview on the Role of Statins in Dyslipidemia Management in Primary Health Care. **2021**, 10, 33-37

527 Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly. **2021**,

526 Rationale and Design of a Randomized Controlled Trial on Intensive Management of Blood PRESSure and Cholesterol in Elderly Chinese with Hypertension and Atrial Fibrillation (IMPRESSION). **2021**, 1, 173-178

525 A Prognostic Merit of Statins in Patients with Chronic Hemodialysis after Percutaneous Coronary Intervention-A 10-Year Follow-Up Study.. **2022**, 11,

524 Health Effects of Metabolic Risks in the United States From 1990 to 2019.. **2022**, 10, 751126

523 Comparative Effect of Bergamot Polyphenolic Fraction and Red Yeast Rice Extract in Rats Fed a Hyperlipidemic Diet: Role of Antioxidant Properties and PCSK9 Expression.. **2022**, 14,

522 Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.. **2022**, 15,

521 Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea.. **2021**, 8, 812416

520 JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. **2022**, 86,

519 Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease.. **2022**,

518 Attenuates Atherosclerosis by Regulating Cholesterol Metabolism and Inducing M2 Macrophage Polarization.. **2022**, 12,

517	Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis.. <b>2022</b> ,	0
516	The Impact of the COVID-19 Outbreak on Patients' Adherence to PCSK9 Inhibitors Therapy.. <b>2022</b> , 11,	1
515	Where the Action Is-Leukocyte Recruitment in Atherosclerosis.. <b>2021</b> , 8, 813984	4
514	The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern?. <b>2022</b> , 11,	1
513	Quality care in ST-segment elevation myocardial infarction.. <b>2022</b> , 85,	
512	Traitement médical de l'arthropathie athéromateuse des membres inférieurs. <b>2022</b> , 2022, 9-13	
511	Should a Statin be Given to All Hypertensive Patients?. <b>2022</b> , 24, 21	
510	Paradoxical Association Between Baseline Apolipoprotein B and Prognosis in Coronary Artery Disease: A 36,460 Chinese Cohort Study.. <b>2022</b> , 9, 822626	0
509	Effectiveness of lipid-lowering therapy in outpatients with coronary artery disease living in a large industrial center of Eastern Siberia. <b>2022</b> , 20, 3135	1
508	PCSK9 inhibitor recatimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study.. <b>2022</b> , 20, 13	
507	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology.. <b>2022</b> , 37, 61-72	
506	Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention.. <b>2022</b> , 29, 137	
505	Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review.. <b>2022</b> , 1	0
504	Application of the very high risk criterion and evaluation of cholesterol guideline adherence in acute myocardial infarction patients at an urban academic medical center. <b>2022</b> , 13, 100082	
503	New targets for treating hypertriglyceridemia.. <b>2022</b> , 29,	0
502	SLCO1B1*5 allele is associated with atorvastatin discontinuation and adverse muscle symptoms in the context of routine care.. <b>2022</b> ,	1
501	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.. <b>2021</b> , 343, 28-50	4
500	Intracranial Hemorrhage in the TST Trial.. <b>2021</b> , STROKEAHA121035846	1



- 499 Childhood Hypertriglyceridemia: Is It Time for a New Approach?. **2022,**
- 498 Variabilité du cholestérol plasmatique. **2022,** 16, 48-53 0
- 497 What is the Optimal Low-Density Lipoprotein Cholesterol?. **2022,** 106, 285-298
- 496 Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and older.. **2022,** 100, 104644
- 495 Effect of Eicosapentaenoic Acid/ Docosahexaenoic Acid on Coronary High-Intensity Plaques Detected Using Non-Contrast T1-Weighted Imaging: A Randomized&nbsp;Trial. 0
- 494 Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults.. **2022,** 1
- 493 Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease.. **2021,** 0
- 492 Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.. **2022,** 0
- 491 The Returns to Preventing Chronic Disease in Europe and the United States. 000-000
- 490 Comparison of a Machine Learning Method and Various Equations for Estimating Low-Density Lipoprotein Cholesterol in Korean Populations.. **2022,** 9, 824574 2
- 489 Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus.. **2022,** 21, 19 2
- 488 Long-term clinical impact of low-density lipoprotein cholesterol target attainment according to lesion complexity after percutaneous coronary intervention.. **2022,**
- 487 Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis.. **2022,** 0
- 486 Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study.. **2022,** 22, 228 0
- 485 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. **2022,** 45, S144-S174 46
- 484 Statin therapy prescribing for patients with type 2 diabetes mellitus: A review of current evidence and challenges. **2017,** 9, 80 14
- 483 Treatment of Dyslipidemia in the Elderly. **2021,** 735-746
- 482 Estimated Cardiovascular Benefits of Bempedoic Acid in Patients with Established Cardiovascular Disease.

- 481 Statin Prescription Patterns and Associated Factors Among Patients with Type 2 Diabetes Mellitus Attending Diabetic Clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania.. **2022**, 15, 633-646 3
- 480 Using a Systems Approach to Explore the Mechanisms of Interaction Between Severe Covid-19 and Its Coronary Heart Disease Complications.. **2022**, 9, 737592
- 479 Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L.. **2022**, 33197221075861
- 478 Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia.. **2022**, 15, 119-130
- 477 Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.. **2022**, 27, e935604 1
- 476 Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte. **2022**, 25, 19-30
- 475 Low-Density Lipoprotein Cholesterol Level After a Stroke-Reducing It by Any Means.. **2022**,
- 474 Using Genomic data to Investigate the Anti-Depressive Effects of Statins.
- 473 JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease.. **2022**, 2
- 472 Pyrroloquinoline Quinone inhibits PCSK9, augments LDLR recycling and enhances the effect of atorvastatin.
- 471 Predictive value of ACEF II score for adverse prognosis in patients with coronary heart disease after percutaneous coronary intervention.. **2022**, 1
- 470 Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.. **2022**, 4
- 469 Causal relationship of excess body weight on cardiovascular events through risk factors.. **2022**, 12, 5269
- 468 Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. **2022**, 9, 812294 2
- 467 The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries: A Review.. **2022**, 17, 18 0
- 466 Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities.. **2022**, 11, 2
- 465 Variation in Statin Prescription among Veterans with HIV and Known Atherosclerotic Cardiovascular Disease.. **2022**,
- 464 The microsomal triglyceride transfer protein inhibitor lomitapide improves vascular function in mice with obesity.. **2022**, 0

463	Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications.. <b>2022,</b>	4
462	Identification of Potential Diagnostic Biomarkers From Circulating Cells During the Course of Sleep Deprivation-Related Myocardial Infarction Based on Bioinformatics Analyses.. <b>2022, 9, 843426</b>	0
461	Aggressive lipid-lowering therapy after percutaneous coronary intervention - for whom and how?: Aggressive lipid-lowering therapy after PCI.. <b>2022, 8, 24-31</b>	
460	Achieving lipid targets within 12 months of an acute coronary syndrome: an observational analysis.. <b>2022,</b>	1
459	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.. <b>2022,</b>	11
458	Achievement of LDL-Cholesterol Goals after Acute Myocardial Infarction: Real-World Data from the City of Curitiba Public Health System.. <b>2022,</b>	0
457	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.. <b>2022, 23,</b>	0
456	The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis. <b>2022, 1, 253-262</b>	2
455	Cardiovascular event rate and death in high-risk secondary prevention patient cohort in Finland: A registry study.. <b>2022,</b>	0
454	Does the ISCHEMIA Trial Apply to My Patients?. <b>2022, 1</b>	
453	Impact of lipoprotein (a) on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents.. <b>2022,</b>	
452	Targeting triglycerides to lower residual cardiovascular risk.. <b>2022,</b>	1
451	Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China.. <b>2022, 9, 839571</b>	0
450	Genetically predicted on-statin LDL response is associated with higher intracerebral hemorrhage risk.	
449	Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India.. <b>2022,</b>	0
448	The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients.. <b>2022, 11,</b>	0
447	LDL como objetivo terapêutico. <b>2022,</b>	
446	Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.. <b>2021,</b>	

- 445 Impact of a cardiology pharmacist-led intervention on high-intensity statin prescribing upon discharge after acute myocardial infarction.
- 444 Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data.. **2022**, 10, e369-e379 6
- 443 Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning.. **2022**, 104029
- 442 Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019.. **2022**, 14, 189-203 1
- 441 Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications.. **2022**, 0
- 440 A comparison of regression discontinuity and propensity score matching to estimate the causal effects of statins using electronic health records.
- 439 Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors.. **2022**, 9, 0
- 438 Dihydroflavonoids as Bioactive Components of *Penthorum chinense*, a Miao Ethnomedicine, against NAFLD through Bile Acid Metabolism Pathway.. **2022**, 0
- 437 Primary and Secondary Prevention of CAD: A Review.. **2022**, 31, 16-26
- 436 The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke.. **2021**, 10, 0
- 435 Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans.. **2021**, 16, e0261194 0
- 434 Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK.. **2021**, 11, e052884
- 433 Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam. **2021**, 1
- 432 Sustained low-density lipoprotein-cholesterol . **2021**, e13732 0
- 431 Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. **2021**, 0
- 430 Modifiable Risk Factors and Residual Risk Following Coronary Revascularization: Insights From a Regionalized Dedicated Follow-Up Clinic.. **2021**, 5, 1138-1152 1
- 429 How cold waves influence LDL cholesterol levels? A regional study for Campinas, S<sup>o</sup> Paulo, Brazil. **2021**,
- 428 Risk of remnants and remnant risk in peripheral artery disease. **2021**, 0

- 427 Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia.. **2021**, 16, e54 0
- 426 The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods.. **2021**, 11,
- 425 Pharmacotherapy in Familial Hypercholesterolemia- Current State and Emerging Paradigms.. **2021**,
- 424 Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis.. **2021**, 2
- 423 Kardiovaskulær Risikofaktor Dyslipidämie. **2022**, 1-14
- 422 Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study.. **2022**, 13, 865863 1
- 421 Stroke Risk Factors of Stroke Patients in China: A Nationwide Community-Based Cross-Sectional Study.. **2022**, 19, 1
- 420 Approach to patients with elevated low-density lipoprotein cholesterol levels.. **2022**, 101658
- 419 Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.. **2022**, 1-10 0
- 418 HDL particle subclasses in statin treated patients with peripheral artery disease predict long-term survival.. **2022**,
- 417 Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. **2022**, 1
- 416 Performance of Radiomics Models Based on Coronary Computed Tomography Angiography in Predicting The Risk of Major Adverse Cardiovascular Events Within 3 Years: A Comparison Between the Pericoronary Adipose Tissue Model and the Epicardial Adipose Tissue Model.. **2022**,
- 415 Defining the role of the hypothalamic-pituitary-adrenal axis in the relationship between fetal growth and adult cardiometabolic outcomes.. **2022**, 1-12
- 414 The RAGE/DIAPH1 Signaling Axis & Implications for the Pathogenesis of Diabetic Complications.. **2022**, 23, 1
- 413 A Systematic Review of Cost-Effectiveness of Non-Statins Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.. **2022**, 101211 1
- 412 fdata-01-00004-g0001.tif. **2018**,
- 411 fdata-01-00004-g0002.tif. **2018**,
- 410 fdata-01-00004-g0003.tif. **2018**,

409 fdata-01-00004-g0004.tif. **2018**,

408 fdata-01-00004-g0005.tif. **2018**,

407 fdata-01-00004-g0006.tif. **2018**,

406 Data\_Sheet\_1.PDF. **2019**,

405 Data\_Sheet\_1.docx. **2018**,

404 DataSheet\_1.pdf. **2020**,

403 [Cost-benefit analysis of new lipid-lowering agents].. **2022**, 1

402 Statins are associated with a large reduction in all-cause mortality in women from a cardiac outpatient population.. **2022**, 9, 1

401 Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment.. **2022**, 9, 1

400 Dietary fibre in hypertension and cardiovascular disease management: systematic review and meta-analyses.. **2022**, 20, 139 1

399 Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.. **2022**, 0

398 Correlation Between Atherosclerotic Cardiovascular Disease Risk Factors and Statin Prescribing Patterns.. **2021**, 14, 140-146

397 OUP accepted manuscript.

396 Patient Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media.

395 Clinical strategies for reducing cholesterol levels. **2022**, 853-901

394 Acute coronary syndrome without persistent elevation of the ST segment: New recommendations. **2022**, 1, 105-110

393 Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis.. **2022**, 2022, 8729003 1

392 Prevalence and predictors of clinically significant statin-drug interactions among Yemeni patients taking statins for primary and secondary prevention of cardiovascular disease.. **2022**, 1-27

391	New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. <b>2022</b> , 10, 970	1
390	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. <b>2022</b> , 21, 3235	11
389	Macrovascular Complications. <b>2022</b> ,	0
388	Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK.. <b>2022</b> , 12, e055015	
387	[Novel options to maximize oral lipid lowering treatment : Role of bempedoic acid in combination treatment].. <b>2022</b> , 1	
386	European Stroke Organisation (ESO) Guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. 239698732211000	5
385	Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice. 1,	
384	PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.. <b>2022</b> , 377, e069116	3
383	The problem of choice: original drug or generic? Emphasis on rosuvastatin. <b>2022</b> , 18, 225-230	
382	Secondary Prevention of Atherosclerotic Cardiovascular Disease. <b>2022</b> , 475-482	
381	Determination of Characteristics and Data Elements requirements in National Acute Coronary Syndrome Registries for Post-discharge Follow-up.. <b>2022</b> , 101244	
380	The LEPIS-HuR-TMOD4 axis regulates hepatic cholesterol homeostasis and accelerates atherosclerosis.	
379	Current status of low-density lipoprotein cholesterol for primary prevention of coronary artery disease in late-stage elderly persons with type 2 diabetes mellitus: A retrospective, single-center study.. <b>2022</b> ,	1
378	Commentary: Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.. <b>2022</b> , 12, 891352	
377	Albuminuria, estimated glomerular filtration rate, and traditional predictors for composite cardiovascular and kidney outcome: a population-based cohort study in Korea.. <b>2022</b> ,	
376	Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—evidence from ApoE <sup>-/-</sup> Mice. <b>2022</b> , 23, 5415	0
375	Target Low-Density Lipoprotein-Cholesterol and Secondary Prevention for Patients with Acute Myocardial Infarction: A Korean Nationwide Cohort Study.. <b>2022</b> , 11,	
374	Remnant Cholesterol Predicts Risk of Cardiovascular Events in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries.. <b>2022</b> , 11, e024366	2

- 373 Statin Therapy for Primary Prevention in Women: What is the Role for Coronary Artery Calcium?. **2022**, 0
- 372 Chitin oligosaccharides alleviate atherosclerosis progress in ApoE<sup>-/-</sup> mice by regulating lipid metabolism and inhibiting inflammation. **2022**, 11, 999-1009 0
- 371 Serum Lipid Profiles and All-Cause Mortality: A Retrospective Single Center Study on Chinese Inpatient Centenarians. **2022**, 10,
- 370 Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.. **2022**, 0
- 369 Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management.. **2022**, 21, 74 1
- 368 Lipid-Modifying Therapies and Stroke Prevention.. **2022**, 1
- 367 Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.. **2022**, 0
- 366 Lipid-modifying and antiatherosclerotic drugs. **2013**, 398-435 3
- 365 Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage: A Danish Nationwide Case-Control Study.. **2022**, 1
- 364 Hypercholesterolemia. **2022**, 61-71
- 363 European Guidelines for Risk Assessment in the Primary Prevention of Cardiovascular Disease. **2022**, 35-58
- 362 Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. **2022**, 122, 7 0
- 361 Attainment of Lipid Targets Following Coronary Artery Bypass Graft Surgery: Can We Do Better?. **2022**, 11, 187 0
- 360 Familial Resemblance in Low-Density Lipoprotein Cholesterol Response to Statins in the Danish Population.
- 359 Longitudinal effects of lipid indices on incident cardiovascular diseases adjusting for time-varying confounding using marginal structural models: 25 years follow-up of two US cohort studies. **2022**, 4, 100075 0
- 358 Mendelian Randomization: Principles and its usage in Lp(a) research. **2022**, 349, 36-41 7
- 357 Genetic Architecture And Clinical Outcomes Of The Fredrickson-Levy-Lees Dyslipoproteinemias.
- 356 Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease. **2022**, 251, 78-78 0



355	Mediation roles of neutrophils and high-density lipoprotein (HDL) on the relationship between HLA-DQB1 and rosacea. <b>2022</b> , 54, 1530-1537	
354	Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.	0
353	Discordance of Apolipoprotein B, Non-HDL-Cholesterol, and LDL-Cholesterol Predicts Risk of Increased Arterial Stiffness and Elevated Carotid Intima-Media Thickness in Middle-Aged and Elderly Chinese Adults. <b>2022</b> , 9,	0
352	Revealing the Critical Regulators of Modulated Smooth Muscle Cells in Atherosclerosis in Mice. 13,	1
351	Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada.	0
350	Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. <b>2022</b> ,	0
349	Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention. <b>2022</b> , 12, e050266	
348	Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature. 13,	4
347	Significance of superficial macrophage cluster in coronary atherosclerotic plaque. <b>2022</b> ,	
346	Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study. <b>2022</b> , 2022, 1-9	
345	Genetically predicted on-statin LDL response is associated with higher intracerebral haemorrhage risk.	2
344	ApoB and non-HDL cholesterol versus LDL cholesterol for ischemic stroke risk.	0
343	Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019. Volume 14, 737-748	
342	Towards more personalized low-density lipoprotein-cholesterol lowering strategies in patients with atherosclerotic cardiovascular disease.	
341	Utilisations des statines chez le sujet âgé selon le type de prise en charge : un exemple de l'impact des groupements hospitaliers de territoire. <b>2022</b> ,	
340	Demographics and Characteristics of Patients Admitted With Acute Coronary Syndrome to the Coronary Care Unit at King Abdulaziz University. <b>2022</b> ,	0
339	Comparação das Novas Equações de Martin/Hopkins e Sampson para o Cálculo do Colesterol de Lipoproteína de Baixa Densidade em Pacientes Diabéticos. <b>2022</b> ,	
338	Clinical impact of statin intensity according to age in patients with acute myocardial infarction. <b>2022</b> , 17, e0269301	0

337	Statins and statin intensity in peripheral artery disease.	2
336	Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease. <b>2022</b> , 22,	0
335	The Effect of Curcumin on Lipid Profile and Glycemic Status of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <b>2022</b> , 2022, 1-13	1
334	Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. <b>2022</b> ,	0
333	Rationale, Criteria, and Impact of Identifying Extreme Risk in Patients with Atherosclerotic Cardiovascular Disease. <b>2022</b> , 2, 114-123	
332	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.	1
331	NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. <b>2022</b> ,	3
330	Trends and Risk Factors Associated With Stroke Recurrence in China, 2007-2018. <b>2022</b> , 5, e2216341	0
329	Impact of clonal hematopoiesis on atherosclerotic cardiovascular disease according to low-density lipoprotein cholesterol levels.	
328	Early statin use and cardiovascular outcomes after myocardial infarction: A population-based case-control study. <b>2022</b> ,	1
327	Preadmission Statin Treatment and Outcome in Patients Hospitalized With COVID-19. <b>2022</b> ,	2
326	Sintomatologã muscular asociada a estatinas: ¿mito o realidad?. <b>2022</b> ,	
325	Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis. <i>ejhpharm-2022-00333</i>	
324	Mobile app and digital system for patients after myocardial infarction (afterAMI): study protocol for a randomized controlled trial. <b>2022</b> , 23,	1
323	Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care. <b>2022</b> , 15,	0
322	Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know.	0
321	Extra-Cranial Carotid Artery Stenosis: An Objective Analysis of the Available Evidence. 13,	1
320	Plasma Homocysteine Level Is Independently Associated With Conventional Atherogenic Lipid Profile and Remnant Cholesterol in Adults. 9,	0

- 319 Beneficial effects of probiotic and synbiotic supplementation on some cardiovascular risk factors among individuals with prediabetes and type 2 diabetes mellitus: A grade-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials. **2022**, 182, 106288 ○
- 318 Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study. **2022**, ○
- 317 Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaque—Provided by the Society for the Prevention of Symptomatic Heart Disease. **2022**, 12, 320-341 ○
- 316 Vascular Pathobiology: Atherosclerosis and Large Vessel Disease. **2022**, 265-306
- 315 Excessive Visit-to-Visit Small and Dense Low-Density Lipoproteins Elevate Cerebral Small Vessel Disease Progression Risk in the Elderly. 13,
- 314 Sex Difference in Control of Low-Density Lipoprotein Cholesterol in Older Patients after Acute Coronary Syndrome. **2022**, 7, 71
- 313 Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk. **2022**, 29, 327-336 ○
- 312 Inclisiran — a new era in lipid-lowering therapy. **2022**, 62, 57-62
- 311 New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention. ○
- 310 Emphasizing Study Selection in a Review of Statin Treatment Effects and Low-Density Lipoprotein Cholesterol—Reply. 1
- 309 Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies. ○
- 308 Testosterone in men with hypogonadism and transgender males: a systematic review comparing 3 different preparations. **2022**, ○
- 307 Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. 174077452211055
- 306 Remnant Cholesterol and the Risk of Coronary Artery Calcium Progression: Insights From the CARDIA and MESA Study. ○
- 305 Safety of Statins and Nonstatins for Treatment of Dyslipidemia. **2022**, ○
- 304 Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review. **2022**,
- 303 Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease. 1
- 302 Potentially inappropriate prescribing for adults living with diabetes mellitus: a scoping review. ○

301	Development and characterization of a camelid derived antibody targeting a linear epitope in the hinge domain of human PCSK9 protein. <b>2022</b> , 12,			0
300	Rationale and Design of a Pragmatic Trial Aimed at Improving Treatment of Hyperlipidemia in Outpatients with Very High Risk Atherosclerotic Cardiovascular Disease: A PRagmatic Trial Of Messaging to Providers about Treatment of HyperLIPIDemia (PROMPT-LIPID). <b>2022</b> ,			0
299	ER-Stress and Senescence Coordinately Promote Endothelial Barrier Dysfunction in Diabetes-Induced Atherosclerosis. <b>2022</b> , 14, 2786			0
298	The Role of Colchicine in Atherosclerosis: From Bench to Bedside. <b>2022</b> , 14, 1395			1
297	LDL CholesterolâHow Low Can We Go?. <b>2022</b> ,			0
296	Dyslipidemia in Diabetes. <b>2022</b> ,			0
295	Secular Trends in Risk Profiles Among Adults With Cardiovascular Disease in the United States. <b>2022</b> , 80, 126-137			0
294	Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , <b>2022</b> ,	40		5
293	Progression of precision statin prescribing for reduction of statin-associated muscle symptoms.			1
292	Cardiovascular Disease Risk in Rural Adults. Publish Ahead of Print,			
291	Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging. <b>2022</b> , 11, 100366			1
290	Activation of circulating monocytes by low-density lipoproteinârisk factor for osteoarthritis?.			
289	Olfactory receptor 2 activation in macrophages: novel mediator of atherosclerosis progression. <b>2022</b> , 7,			0
288	Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality. <b>2022</b> , 15, 919			0
287	Cardiovascular Risk Prediction Models and Scores in the Era of Personalized Medicine. <b>2022</b> , 12, 1180			0
286	Prevalence and prognosis of molecularly defined familial hypercholesterolemia in patients with acute coronary syndrome. 9,			
285	New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. <b>2022</b> , 46, 517-532			0
284	Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review. <b>2022</b> ,			

- 283 Polygenic risk score and statin relative risk reduction for primary prevention of myocardial infarction in a real-world population. 0
- 282 Inclisiran: How Widely and When Should We Use It?. 4
- 281 Statin-associated muscle symptoms: Myth or reality?. **2022**,
- 280 A microRNA Signature for the Diagnosis of Statins Intolerance. **2022**, 23, 8146
- 279 Evaluation of the Therapeutic Pattern and Pharmaco-Utilization in Hypercholesterolemic Patients Treated with Statins: A Retrospective Study on Italian Real-World Data. Volume 15, 1483-1489 0
- 278 Rhabdomyolysis-Induced AKI (RIAKI) Including the Role of COVID-19. **2022**, 23, 8215 1
- 277 Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy. **2022**, 11, 4344
- 276 Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies: Combination therapy in the guideline. **2022**, 1, 25-29 0
- 275 Lipid-lowering for the prevention of cardiovascular disease in the new era: A practical approach to combination therapy: Lipid-lowering and combination therapy. **2022**, 1, 30-36 0
- 274 Effekter av helfete meieriprodukter pLDL-kolesterol:. **2016**, 14, 6-11
- 273 The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. **2022**, 1, 2-13
- 272 Atherosclerosis risk factor management - what's new for the neurologist?. **2022**, 80, 88-93
- 271 Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention. 1
- 270 Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond. **2022**, 0
- 269 Statin Use Reduces the Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis and Systematic Review. **2022**, 0
- 268 2022 Consensus statement on the management of familial hypercholesterolemia in Korea.
- 267 Management of Dyslipidemia after Stroke. **2022**, 40, 217-227 1
- 266 Low-Density Lipoprotein Cholesterol and Mortality in Peritoneal Dialysis. 9,

265	Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome. <b>2022,</b>	0
264	Cascade screening for familial hypercholesterolemia should be organized at a national level. Publish Ahead of Print,	0
263	Bempedoic Acid: for Whom and When.	1
262	Hypoxia truncates and constitutively activates the key cholesterol synthesis enzyme squalene monooxygenase.	
261	Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study. 9,	1
260	Pharmacoepidemiological analysis of the effect of lipid-lowering therapy on cardiovascular mortality in the regions of the Russian Federation. <b>2022,</b> 45-54	
259	Control of dyslipidemia in the prevention of recurrent ischemic cerebrovascular accidents (expert opinion). <b>2022,</b> 14, 108-113	
258	Statin use and the risk of CVD events, stroke, and all-cause mortality in patients with diabetes: a systematic review and meta-analysis. <b>2022,</b>	0
257	Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk. <b>2022,</b> 11, 4611	1
256	Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?. <b>2022,</b> 23, 9326	0
255	Hypertension and Hypercholesterolemia: Letâ Make Therapy Easy and Efficient. <b>2022,</b> 111, 558-563	
254	Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials. 9,	
253	Effect of atorvastatin on skeletal muscles of patients with knee osteoarthritis: Post-hoc analysis of a randomised controlled trial. 9,	
252	2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <b>2022,</b>	4
251	The association between low-density and non-high-density lipoprotein cholesterol with incident cardiovascular disease among low-risk Iranians during 2 decades follow-up. <b>2022,</b>	0
250	Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. <b>2022,</b> 23, 9417	0
249	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ2022 Update. <b>2022,</b>	8
248	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. <b>2022,</b> 7,	4

247	Adherence to lifestyle advice and its related cardiovascular disease risk among US adults with high cholesterol. <b>2022</b> ,	
246	The Global Burden of Diseases attributed to high low-density lipoprotein cholesterol from 1990 to 2019. <b>10</b> ,	
245	Statin Recommendations for Primary Prevention. <b>2022</b> , 328, 716	
244	Extent of LDL-cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: a Systematic Review and Meta-analysis. <b>2022</b> , Publish Ahead of Print,	
243	Association of Low-Density Lipoprotein Cholesterol Levels with More than 20-Year Risk of Cardiovascular and All-Cause Mortality in the General Population. <b>2022</b> , 11,	2
242	Revisiting "intensive" blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials.	0
241	Identifying patient perceptions and attitudes regarding statin-associated diabetes mellitus: a mixed-methods study.	1
240	LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals.	0
239	Comorbidities Associated With Residual Cardiovascular Risk in Patients With Chronic Coronary Syndrome Receiving Statin Therapy "Subanalysis of the REAL-CAD Trial " <b>2022</b> ,	
238	Impact of Low Baseline Low-Density Lipoprotein Cholesterol on Long-Term Postdischarge Cardiovascular Outcomes in Patients With Acute Myocardial Infarction.	1
237	A biomathematical model of atherosclerosis in mice. <b>2022</b> , 17, e0272079	
236	Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media. <b>2022</b> , 45, 971-981	0
235	Statin therapy for the primary prevention of cardiovascular disease: Cons. <b>2022</b> , 356, 46-49	
234	HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism. <b>2022</b> , 150, 81-89	2
233	Blood lipid levels and treatment following an acute coronary syndrome or coronary intervention " Journey from hospital to cardiac rehabilitation. <b>2022</b> , 15, 200145	
232	Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease. <b>2022</b> , 7, 955	1
231	Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach. <b>2022</b> , 42, 1207-1216	1
230	Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study. <b>2022</b> , 358, 34-40	0

229	Functions and therapeutic interventions of non-coding RNAs associated with TLR signaling pathway in atherosclerosis. <b>2022</b> , 100, 110471	0
228	Intuitive Modification of the Friedewald Formula for Calculation of LDL-Cholesterol. <b>2023</b> , 43, 29-37	1
227	2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea. <b>2022</b> , 11, 213	0
226	Opposing View: A Blind Faith in Meta-Analyses in Academia Could Be a Threat to Public Health. <b>2022</b> , 11, 308	0
225	Evaluaci3n econ3mica de evolocumab en pacientes con enfermedad cardiovascular de alto riesgo con hipercolesterolemia primaria y dislipidemia mixta no controlados. <b>2022</b> , 33, 52-63	0
224	What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline myths. <b>2022</b> , 33, 219-226	0
223	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <b>2022</b> ,	2
222	Effects of statin response on cardiovascular outcomes in patients with ST-segment elevation myocardial infarction. <b>2022</b> , 68, 1053-1058	0
221	Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease.	11
220	Macronutrient Ratio Modification in a Semi-Purified Diet Composition: Effects on Growth and Body Composition of Juvenile Zebrafish <i>Danio rerio</i> .	0
219	Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial.	0
218	LDL as a therapeutic target. <b>2022</b> , 34, 271-284	0
217	Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the United Kingdom. <b>2022</b> , 23,	2
216	Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease – An Observation From the REAL-CAD Study – <b>2022</b> ,	0
215	Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape.	0
214	How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology.	2
213	The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran.	0
212	Part I: Interactive case: Hyperlipidemia management for special populations. <b>2022</b> , 5, 1011-1015	0



211	Meta-analysis of the Placebo and Nocebo Effects Associated with Placebo Treatment in Randomized Trials of Lipid Lowering Therapy.	3
210	Adenosine-rich extract of <i>Ganoderma lucidum</i> : a safe and effective lipid-lowering substance via regulating expression and modulation of PPAR signaling pathway. <b>2022</b> , 105214	0
209	PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection.	3
208	Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study. <b>2022</b> , 23, 10418	1
207	Effects of Simvastatin on Plasma Amyloid- $\beta$ Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. <b>2022</b> , 1-14	0
206	Lp(a): a New Pathway to Target?. <b>2022</b> , 24, 831-838	0
205	Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. <b>2022</b> , 400, 832-845	1
204	Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. <b>2022</b> , 11,	3
203	Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis. 13,	0
202	Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline. <b>2022</b> , 21, 100201	0
201	Lipidic profiles of patients starting peritoneal dialysis suggest an increased cardiovascular risk beyond classical dyslipidemia biomarkers. <b>2022</b> , 12,	0
200	Association Between Statin Exposure and Diabetes Incidence among Privately-Insured Patients Before and After Applying a Novel Technique to Control for Selection Bias. <b>2022</b> ,	0
199	Association of follicle stimulating hormone and serum lipid profiles in postmenopausal women. <b>2022</b> , 101, e30920	0
198	Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty.	1
197	The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials.	0
196	Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017. heartjnl-2022-321452	0
195	Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: a post hoc analysis of the CAPTURE study.	0
194	Cholesterol: how to measure and how to treat. <b>2022</b> , 33, 402-410	0

193	Abordagem atual das dislipidemias. <b>2022</b> , 20-31	0
192	Long-Term Association between Intensive Medical Treatment and the Incidence of Cardiovascular Outcomes in Patients with Dyslipidemia: an Observational Study.	0
191	Therapeutic Effects of Lipid Lowering Medications on Myocardial Blood Flow, Inflammation, and Sympathetic Nerve Activity Using Nuclear Techniques.	0
190	Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk. <b>2022</b> , 17, e0276898	0
189	Lipoprotein (a) and long-term outcome in patients with peripheral artery disease undergoing revascularization. <b>2022</b> ,	0
188	Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.	0
187	Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2).	1
186	Magnitude of low-density lipoprotein reduction and impact on major cardiovascular outcomes. Publish Ahead of Print,	0
185	Patients with high cardiovascular risk as candidates to bempedoic acid after treatment with statins, ezetimibe and PCSK9 inhibitors. An estimation and cost-effectiveness analysis.. <b>2022</b> , Publish Ahead of Print,	0
184	Statistical methods for cis -Mendelian randomization with two-sample summary-level data.	0
183	A New Marker for Determining Cardiovascular Risk: Salusin Alpha. <b>2022</b> ,	0
182	Influence of acute and chronic intermittent hypoxic-hyperoxic exposure prior to aerobic exercise on cardiovascular risk factors in geriatric patientsâ randomized controlled trial. 13,	0
181	Reply. <b>2022</b> , 80, e127	0
180	European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction.	0
179	Effect of a Run-In Period on Estimated Treatment Effects in Cardiovascular Randomized Clinical Trials: A Meta-Analytic Review. <b>2022</b> , 11,	0
178	Prognostic Impact of Statins on Patients With Peripheral Artery Disease With Elevated C-Reactive Protein Levels. <b>2022</b> ,	0
177	Management of patients with statin intolerance. <b>2022</b> , 101714	1
176	Mortality Analysis of Endovascular Aneurysm Sealing versus Endovascular Aneurysm Repair. <b>2022</b> ,	0

175	Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance. Publish Ahead of Print,	0
174	SmartLab 2.0 en prevenciã cardiovascular de dislipemia aterogflica. <b>2022,</b>	0
173	Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters. <b>2022,</b>	0
172	2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. <b>2022,</b>	3
171	2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.	12
170	Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study.	2
169	The Complexity of Physiology in the Evaluation of the Effect of Medication for Cardiovascular Disease. <b>2022,</b>	0
168	Comparability of calculated LDL-C with directly measured LDL-C in selected paediatric and adult cohorts. <b>2022,</b> 537, 158-166	0
167	Healthcare resource utilization and costs of cardiovascular events in patients with atherosclerotic cardiovascular disease in Germany - results of a claims database study. 1-20	0
166	Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults.	1
165	LDL-C-Zielwerterreichung ist nur durch konsequente lipidsenkende Stufen-/Kombinationstherapie sicher erreichbar. <b>2022,</b> 26, 394-397	0
164	Effect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part 1. Analysis of patients with fatal outcome during hospitalization. <b>2022,</b> 21, 58-66	1
163	Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective.	0
162	Guidelines for the management of hyperlipidemia: How can clinicians effectively implement them?. <b>2022,</b>	0
161	Study Protocol and Baseline Characteristics of Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid: RESPECT-EPA, The Combination of a Randomized Control Trial and an Observational Biomarker Study. <b>2022,</b>	0
160	Closing gaps in medication taking for secondary prevention of coronary heart disease patients among US adults. <b>2022,</b> 8, e11530	0
159	Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy. <b>2022,</b> 14, 4769	1
158	Initial statin dose after myocardial infarction and long-term cardiovascular outcomes.	0

- 157 Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. **2022**, 20, 0
- 156 Pre-Stroke Statin Use Is Associated with Mild Neurological Deficits at the Onset of Acute Ischemic Stroke. **2022**, 9, 396 1
- 155 Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins. 9, 0
- 154 PCSK9 Inhibition and Risk of Diabetes: Should We Worry?. 0
- 153 Effects of Vitamin D Supplementation in Patients with Statin-Associated Muscle Symptoms and Low Vitamin D Levels. 0
- 152 Effects of statins on fat oxidation improvements after aerobic exercise training. 1
- 151 Development of Machine Learning Tools for Predicting Coronary Artery Disease in the Chinese Population. **2022**, 2022, 1-18 0
- 150 Secondary Diseases of the Kidney. **2022**, 366-399 0
- 149 Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence. **2022**, 27, 107424842211463 1
- 148 Effect of dietary patterns on cardiovascular risk factors in people with type 2 diabetes. A systematic review and network meta-analysis. **2023**, 195, 110207 0
- 147 Sex disparities and dyslipidemic control in a coronary rehabilitation program. **2023**, 370, 72-74 0
- 146 Ten-Year Evolution of Statin Eligibility and Use in a Population-Based Cohort. **2023**, 187, 138-147 0
- 145 Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology. **2023**, 148, 107137 0
- 144 The modifiable effect of vitamin D in the association between long-term exposure to ambient air pollution and glycosylated hemoglobin in patients with hypertension. **2023**, 107, 111920 0
- 143 Hypolipidemic agents in the secondary prevention of the stroke. **2022**, 1, 96-102 0
- 142 Serum 25-hydroxyvitamin D3 is associated with homocysteine more than with apolipoprotein B. **2022**, 16, 745 0
- 141 Economic evaluation of PCSK9 inhibitors inclusion in the list of medicines for outpatient preferential drug provision («23 INNs» list) for secondary prevention of cardiovascular events. **2022**, 51 0
- 140 Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation. **2022**, 1, 41-47 0

- 139 Recomendaciones preventivas cardiovasculares. Actualizaci3n PAPPS 2022. **2022**, 54, 102444 ○
- 138 Percutaneous coronary intervention from COURAGE to ISCHEMIA and beyond. **2022**, ○
- 137 To Explore the Key Active Compounds and Therapeutic Mechanism of Guizhi Gancao Decoction in Coronary Heart Disease by Network Pharmacology and Molecular Docking. **2022**, 2022, 1-15 ○
- 136 Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing. 1
- 135 Combined individual participant data: highest level evidence on obesity and colorectal cancer molecular subtypes. ○
- 134 Gender discrepancies in predictors for newly onset cardiovascular events and metabolic syndrome in elderly patients from rural China. 9, ○
- 133 Statin therapy for primary prevention in men: What is the role for coronary artery calcium?. **2022**, ○
- 132 Analysis of drug prescriptions of patients with atrial fibrillation in combination with chronic kidney disease for compliance with STOPP/START criteria. **2022**, 12-18 ○
- 131 Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. **2022** , 65, 15513-15539 1
- 130 Association of statin therapy with progression of carotid arterial stiffness: the Multi-Ethnic Study of Atherosclerosis (MESA). ○
- 129 Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. ○
- 128 Lost therapeutic benefit of delayed LDL-C control in statin treated patients and cost-effectiveness analysis of lipid-lowering intensification. **2022**, ○
- 127 Time trends of cardiovascular risk management in type 1 diabetes' nationwide analyses of real-life data. **2022**, 21, ○
- 126 CETP Inhibitors: Should We Continue to Pursue This Pathway?. **2022**, 24, 915-923 ○
- 125 Secondary Prevention in Lower Extremity Artery Disease Patients: Lipid-Lowering Therapy and Long-Term Guideline Adherence. **2022**, 11, 6838 ○
- 124 Evaluation the effects of red yeast rice in combination with statin on lipid profile and inflammatory indices; a randomized clinical trial. **2022**, 8, ○
- 123 Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection. ○
- 122 Avocado consumption and cardiometabolic disease risk factors: a systematic review and meta-analysis. **2022**, ○

121	Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience. <b>2022</b> ,	0
120	Immunomodulatory effects of atorvastatin on MRL/lpr mice. <b>2022</b> , 62,	0
119	Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden.	0
118	Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.	0
117	A single-center pilot randomized controlled trial of atorvastatin loading for preventing ischemic brain damage after carotid artery stenting. 14,	0
116	Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle?. Publish Ahead of Print,	0
115	Repeated lipoprotein apheresis and immune response: Effects on different immune cell populations.	0
114	Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery. <b>2022</b> , 136, 1731-1758	0
113	Undertreatment and Underachievement of LDL-C Target among Individuals with High and Very High Cardiovascular Risk in the Malaysian Community. <b>2022</b> , 10, 2448	0
112	2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea. <b>2022</b> , 97, 339-352	0
111	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. 9,	0
110	Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial&nbsp;; <b>2022</b> , 18, e888-e896	0
109	Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat. 9,	0
108	Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease.	1
107	Effect of 4-Week Consumption of Soy Kori-tofu on Cardiometabolic Health Markers: A Double-Blind Randomized Controlled Cross-Over Trial in Adults with Mildly Elevated Cholesterol Levels. <b>2023</b> , 15, 49	0
106	Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol.	0
105	Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. <b>2022</b> , 2022, 1-5	1
104	Russian consensus statement on the diagnosis and treatment of patients with carotid stenosis. <b>2022</b> , 27, 5284	1

103	Effect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part II. Analysis of patients discharged from the infectious diseases hospital. <b>2022</b> , 21, 58-68	○
102	Current Understanding of Diabetic Dyslipidemia: A Review.	○
101	Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the ExpertsâCommittee Of National Society Of Cardiometabolic Medicine. 13,	○
100	Small dense LDL cholesterol and ischemic stroke.	○
99	Risk Stratification for Cardiovascular Disease Based on Prior Coronary Artery Disease, Cerebrovascular Disease and Diabetes Mellitus.	○
98	Discovery of drugâomics associations in type 2 diabetes with generative deep-learning models.	○
97	The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes.	○
96	The frequency of rs2231142 in ABCG2âamong Asian subgroups: implications for personalized rosuvastatin dosing.	○
95	Dyslipidemia and the preventive potential in the Greenlandic population. <b>2023</b> , 51, 22-27	○
94	Is There a Role for Coronary Calcium in Patients With Diabetes?. <b>2023</b> , 190, 98-101	○
93	Primary prevention statin therapy in older adults. <b>2023</b> , 38, 11-20	○
92	Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology (ESC). <b>2023</b> , 11, 200-213	3
91	The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study). 10,	○
90	Association between lipid level and atherosclerotic CVD in community-dwelling older people: the longitudinal observation of SONIC study.	○
89	Physicians and pharmacistsâclinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice. <b>2023</b> , 18, e0280432	○
88	Hypoxia truncates and constitutively activates the key cholesterol synthesis enzyme squalene monooxygenase. 12,	○
87	Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. <b>2023</b> , 12, 12	○
86	Consensus Recommendations of the Asia Pacific Cardiometabolic Consortium on Secondary Prevention Strategies in Myocardial Infarction: Recommendations on Pharmacotherapy, Lifestyle Modification and Cardiac Rehabilitation. <b>2023</b> ,	○

- 85 Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study. **2023**, 47, 59-71 ○
- 84 Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i. ○
- 83 Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. **2023**, 47, 1-9 ○
- 82 Effects of Nut Consumption on Blood Lipids and Lipoproteins: A Comprehensive Literature Update. **2023**, 15, 596 1
- 81 Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. **2023**, 22, ○
- 80 Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here. **2023**, 15, 459 1
- 79 Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study. **2023**, 64, 175 ○
- 78 Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial. **2023**, ○
- 77 Residual risks and evolving atherosclerotic plaques. ○
- 76 Association of Remnant-like Particle Cholesterol with Major Adverse Cardiovascular Events in Subjects with Different Levels of Proprotein Convertase Subtilisin/Kexin 9: A 9.5-year Follow-up Study in a Beijing Community Population. Publish Ahead of Print, ○
- 75 Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis. **2023**, 81, 1339-1349 ○
- 74 Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis. **2023**, 371, 21-31 ○
- 73 Bempedoic Acid and the Prevention of Cardiovascular Disease. **2023**, 388, 1427-1430 1
- 72 Index. 252-254 ○
- 71 Glossary. 226-231 ○
- 70 Impact of lipid lowering on coronary atherosclerosis moving from the lumen to the artery wall. **2023**, 367, 8-14 ○
- 69 Statin Use and the Risk of All-cause Mortality. **2023**, 98, 4-10 ○
- 68 Lipidstoffwechselstörungen. **2022**, 287-302 ○



67	Longitudinal association of remnant cholesterol with joint arteriosclerosis and atherosclerosis progression beyond LDL cholesterol. <b>2023</b> , 21,	0
66	Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease. Publish Ahead of Print,	0
65	Individual and combined contributions of non-high-density lipoprotein cholesterol and brachial-ankle pulse wave velocity to cardiovascular disease risk: Results of a prospective study using the Kailuan cohort. 10,	0
64	Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis. <b>2023</b> , 377, 104-111	0
63	Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery.	0
62	Prognostic value of low-density lipoprotein cholesterol in IgA nephropathy and establishment of nomogram model. 14,	0
61	Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial. <b>2023</b> , 25, 85-93	1
60	Trends in LDL-C following coronary angiography involving assessment by fractional flow reserve in obstructive vs non-obstructive coronary artery disease. <b>2023</b> , 13, 100473	0
59	Exploring the Active Compounds of Traditional Mongolian Medicine Baolier Capsule (BLEC) in Patients with Coronary Artery Disease (CAD) Based on Network Pharmacology Analysis, Molecular Docking and Experimental Validation. Volume 17, 459-476	0
58	High triglyceride-glucose index is associated with poor cardiovascular outcomes in Chinese acute coronary syndrome patients without diabetes mellitus who underwent emergency percutaneous coronary intervention with drug-eluting stents. 14,	0
57	Remnant cholesterol is independently associated with an increased risk of peripheral artery disease in type 2 diabetic patients. 14,	0
56	Low-density lipoprotein cholesterol to apolipoprotein B ratio predicts mortality and cardiovascular events in peritoneal dialysis patients.	0
55	The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. <b>2023</b> , 29,	0
54	Association of clinical and genetic risk factors with management of dyslipidaemia: analysis of repeated cross-sectional studies in the general population of Lausanne, Switzerland. <b>2023</b> , 13, e065409	0
53	Robust Mendelian Randomization Analysis by Automatically Selecting Valid Genetic Instruments for Inferring Causal Relationships between Complex Traits and Diseases.	0
52	The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology. <b>2023</b> , 13, 100472	0
51	The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. <b>2023</b> , 17, 208-218	0
50	Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk. <b>2023</b> , 6, e231047	1

- 49 Intrapartum Factors Affecting Abnormal Lipid Profiles in Early Postpartum Period. **2023**, 13, 444 ○
- 48 Inclisiran: new era of lipid-lowering therapy?. **2023**, 65, 69-75 ○
- 47 A Review of Low-Density Lipoprotein-Lowering Diets in the Age of Anti-Sense Technology. **2023**, 15, 1249 ○
- 46 Long-term outcomes and predictors of patients with ST elevated versus non-ST elevated myocardial infarctions in non-obstructive coronary arteries: a retrospective study in Northern China. 11, e14958 ○
- 45 Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function. **2023**, 148, 104513 1
- 44 Therapy of Elevated Lipoprotein(a). **2023**, 347-357 ○
- 43 Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. **2023**, 388, 1353-1364 4
- 42 Baseline inflammatory status affects the prognostic impact of statins in patients with peripheral arterial disease. ○
- 41 Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. **2023**, 329, 1078 ○
- 40 Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis. **2023**, ○
- 39 Medical Therapy After CABG: the Known Knowns, the Known Unknowns, and the Unknown Unknowns. ○
- 38 Association between Lipid Level and Revascularization at Routine Coronary Angiography Follow-up among Patients with Acute Coronary Syndrome: A Case-control Study. **2022**, 48, 113-120 ○
- 37 Analysis of The Use of PCSK9 Inhibitors in Clinical Practice. **2023**, 19, 43-49 ○
- 36 Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation. 10, ○
- 35 Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. **2023**, 12, 2161 ○
- 34 Identification of putative causal relationship between stroke and 1504 complex traits using large-scale phenome-wide screening. ○
- 33 Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease. **2023**, 3, 211-225 ○
- 32 Plaque volume, composition, and fraction versus ischemia and outcomes in patients with coronary artery disease. **2023**, ○

- 31 Role of plaque imaging for identification of vulnerable patients beyond the stage of myocardial ischemia. 10, ○
- 30 Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. **2023**, 190, 106738 ○
- 29 The Disposition and Metabolism of Bempedoic Acid, A Potent Inhibitor of ATP Citrate Lyase, In Healthy Human Subjects. DMD-AR-2022-001142 ○
- 28 Low-density lipoprotein cholesterol levels are associated with first-phase insulin release. **2023**, 199, 110633 ○
- 27 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167 ○
- 26 A genome-wide association study of childhood adiposity and blood lipids. 6, 303 ○
- 25 Regression discontinuity design to evaluate the effect of statins on myocardial infarction in electronic health records. **2023**, 38, 393-402 ○
- 24 The Correlation of Apolipoprotein B with Alterations in Specific Fat Depots Content in Adults. **2023**, 24, 6310 ○
- 23 Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics. **2023**, 97-135 ○
- 22 Exploring the Association between Low-Density Lipoprotein Subfractions and Major Adverse Cardiovascular Outcomes—A Comprehensive Review. **2023**, 24, 6669 ○
- 21 Evaluation of low-density lipoprotein cholesterol equations by cross-platform assessment of accuracy-based EQA data against SI-traceable reference value. **2023**, ○
- 20 Servindo a Dois Mestres: Resolvendo o Dilema entre Metanálise de Dados Individuais e Metanálise de Dados Agregados de Estudos com Estatinas. **2023**, 120, ○
- 19 Assessing the impact of single or short-term administration on a therapy—cost-effectiveness: a hypothetical disease-agnostic model. 1-43 ○
- 18 Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review. **2023**, 13, 168-175 ○
- 17 A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease. **2023**, ○
- 16 Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial. ○
- 15 Hyperlipidemia and Cardiovascular Disease in People with Type 1 Diabetes: Review of Current Guidelines and Evidence. ○
- 14 Person-Centered Cardiology. **2023**, 501-538 ○

- 13 Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology. **2023**, 24, e86-e94 ○
- 12 Prevention of Coronary Atherosclerosis. **2023**, 39-57 ○
- 11 Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. **2023**, 59, 776 ○
- 10 Short-Term Effect of Nutraceutical Fruit Juices on Lipid Metabolism in Patients with Acquired Hypercholesterolemia. **2023**, 24, 7358 ○
- 9 PCSK9 Inhibitors and Coronary Atherosclerosis: Insights From Recent Intravascular Imaging Clinical Trials. 3, ○
- 8 Understanding the molecular mechanisms of statin pleiotropic effects. ○
- 7 Pragmatic evaluation of events and benefits of lipid lowering in older adults ( PREVENTABLE ): Trial design and rationale. ○
- 6 Statin therapy and sex hormones. **2023**, 551-571 ○
- 5 Lipid treatment status and goal attainment among patients with premature acute coronary syndrome in Israel. **2023**, ○
- 4 Bempedoic acid: what prospective uses?. **2023**, 25, C109-C111 ○
- 3 Current status and time trends of lipid and use of statins among older adults in China—Real world data from primary community health institutions. 11, ○
- 2 Do blood metals influence lipid profiles? Findings of a cross-sectional population-based survey. **2023**, 116107 ○
- 1 A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates. ○